<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>GRADE: ì¦ê±° íŒë‹¨ì˜ ê¸°ìˆ </title>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Cormorant+Garamond:ital,wght@0,400;0,600;0,700;1,400;1,600&amp;family=Source+Sans+Pro:wght@300;400;600;700&amp;display=swap" rel="stylesheet"/>
<style>
    :root {
      --navy: #1E2761;
      --deep-navy: #141B3D;
      --gold: #D4AF37;
      --cream: #FAF8F5;
      --light-cream: #FFFFFF;
      --text: #2D3748;
      --light-text: #718096;
      --red: #C53030;
      --green: #22c55e;
      --teal: #0f766e;
      --purple: #7c3aed;
      --orange: #f59e0b;
      --transition: 0.5s cubic-bezier(0.4, 0, 0.2, 1);
    }

    * { margin: 0; padding: 0; box-sizing: border-box; }
    html, body {
      height: 100%;
      font-family: 'Source Sans Pro', sans-serif;
      background: var(--deep-navy);
      color: var(--cream);
    }

    .course-container { display: flex; height: 100vh; overflow: hidden; }

    /* Skip Link for Accessibility */
    .skip-link {
      position: absolute;
      top: -40px;
      left: 0;
      background: var(--gold);
      color: var(--navy);
      padding: 8px 16px;
      z-index: 10000;
      text-decoration: none;
      font-weight: 600;
    }
    .skip-link:focus { top: 0; }

    /* ====== SIDEBAR ====== */
    .sidebar {
      width: 300px;
      background: linear-gradient(180deg, var(--deep-navy) 0%, #0a0f1a 100%);
      border-right: 1px solid rgba(212,175,55,0.2);
      display: flex;
      flex-direction: column;
      flex-shrink: 0;
    }

    .sidebar-header {
      padding: 1.25rem;
      border-bottom: 1px solid rgba(212,175,55,0.2);
      text-align: center;
    }
    .sidebar-header h1 {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: 1.3rem;
      font-weight: 700;
      color: var(--gold);
    }
    .sidebar-header p {
      font-size: 0.75rem;
      color: rgba(255,255,255,0.6);
    }

    /* Gamification Stats Panel */
    .stats-panel {
      padding: 1rem;
      background: rgba(212,175,55,0.1);
      border-bottom: 1px solid rgba(212,175,55,0.2);
    }
    .level-display {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 0.75rem;
    }
    .level-badge {
      width: 48px;
      height: 48px;
      background: linear-gradient(135deg, var(--gold), #f0c040);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.5rem;
      box-shadow: 0 2px 8px rgba(212,175,55,0.4);
    }
    .level-info { flex: 1; }
    .level-title { font-weight: 700; font-size: 0.9rem; color: var(--gold); }
    .level-subtitle { font-size: 0.7rem; color: rgba(255,255,255,0.6); }
    .xp-bar {
      height: 8px;
      background: rgba(255,255,255,0.1);
      border-radius: 4px;
      overflow: hidden;
      margin-top: 0.5rem;
    }
    .xp-fill {
      height: 100%;
      background: linear-gradient(90deg, var(--gold), var(--orange));
      border-radius: 4px;
      transition: width 0.5s ease;
    }
    .xp-text {
      font-size: 0.65rem;
      color: rgba(255,255,255,0.5);
      text-align: right;
      margin-top: 0.25rem;
    }
    .quick-stats {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 0.5rem;
      margin-top: 0.75rem;
    }
    .quick-stat {
      background: rgba(0,0,0,0.2);
      padding: 0.5rem;
      border-radius: 6px;
      text-align: center;
    }
    .quick-stat-value {
      font-size: 1.1rem;
      font-weight: 700;
      color: var(--gold);
    }
    .quick-stat-label {
      font-size: 0.6rem;
      color: rgba(255,255,255,0.5);
    }

    /* Course Progress */
    .course-progress {
      padding: 0.75rem 1rem;
      border-bottom: 1px solid rgba(212,175,55,0.2);
      background: rgba(0,0,0,0.2);
    }
    .course-progress-label {
      display: flex;
      justify-content: space-between;
      font-size: 0.7rem;
      color: rgba(255,255,255,0.6);
      margin-bottom: 0.35rem;
    }
    .course-progress-bar {
      height: 6px;
      background: rgba(255,255,255,0.1);
      border-radius: 3px;
      overflow: hidden;
    }
    .course-progress-fill {
      height: 100%;
      background: linear-gradient(90deg, var(--green), #22d3ee);
      border-radius: 3px;
      transition: width 0.5s ease;
    }

    .module-list { flex: 1; overflow-y: auto; padding: 0.5rem 0; }
    .module-item {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      padding: 0.6rem 1rem;
      cursor: pointer;
      transition: all 0.2s;
      border-left: 3px solid transparent;
    }
    .module-item:hover { background: rgba(212,175,55,0.1); }
    .module-item.active { background: rgba(212,175,55,0.15); border-left-color: var(--gold); }
    .module-item.completed .module-number { background: var(--green); color: white; }
    .module-item.locked { opacity: 0.5; cursor: not-allowed; }
    .module-number {
      width: 26px;
      height: 26px;
      border-radius: 50%;
      background: rgba(255,255,255,0.1);
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 0.7rem;
      font-weight: 700;
      flex-shrink: 0;
    }
    .module-item.active .module-number { background: var(--gold); color: var(--navy); }
    .module-info { flex: 1; min-width: 0; }
    .module-title { font-size: 0.8rem; font-weight: 600; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; }
    .module-subtitle { font-size: 0.65rem; color: rgba(255,255,255,0.5); }
    .module-xp { font-size: 0.6rem; color: var(--gold); }
    .module-time { font-size: 0.55rem; color: rgba(255,255,255,0.4); display: flex; align-items: center; gap: 0.25rem; margin-top: 0.15rem; }

    /* Badges Panel */
    .badges-panel {
      padding: 1rem;
      border-top: 1px solid rgba(212,175,55,0.2);
    }
    .badges-title { font-size: 0.75rem; font-weight: 600; color: var(--gold); margin-bottom: 0.5rem; }
    .badges-grid { display: flex; flex-wrap: wrap; gap: 0.35rem; }
    .badge-item {
      width: 32px;
      height: 32px;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.1);
      border-radius: 6px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 0.9rem;
      opacity: 0.3;
      transition: all 0.3s;
      cursor: help;
      position: relative;
      padding: 0;
      color: inherit;
    }
    .badge-item.earned { opacity: 1; background: rgba(212,175,55,0.2); border-color: var(--gold); }
    .badge-item:hover::after {
      content: attr(title);
      position: absolute;
      bottom: 100%;
      left: 50%;
      transform: translateX(-50%);
      background: var(--navy);
      color: white;
      padding: 0.25rem 0.5rem;
      border-radius: 4px;
      font-size: 0.6rem;
      white-space: nowrap;
      z-index: 100;
    }

    /* ====== MAIN CONTENT ====== */
    .main-content { flex: 1; display: flex; flex-direction: column; overflow: hidden; }
    .content-header {
      padding: 0.75rem 1.5rem;
      background: rgba(0,0,0,0.3);
      border-bottom: 1px solid rgba(212,175,55,0.2);
      display: flex;
      align-items: center;
      justify-content: space-between;
    }
    .breadcrumb { font-size: 0.85rem; color: rgba(255,255,255,0.6); }
    .breadcrumb span { color: var(--gold); }
    .header-actions { display: flex; gap: 0.5rem; align-items: center; }
    .streak-display {
      display: flex;
      align-items: center;
      gap: 0.35rem;
      background: rgba(239,68,68,0.2);
      border: 1px solid rgba(239,68,68,0.4);
      padding: 0.35rem 0.75rem;
      border-radius: 20px;
      font-size: 0.8rem;
    }
    .streak-display.active { background: rgba(249,115,22,0.2); border-color: var(--orange); }
    .streak-flame { font-size: 1rem; }
    .streak-count { font-weight: 700; color: var(--orange); }

    .btn {
      padding: 0.5rem 1rem;
      border: 1px solid rgba(212,175,55,0.3);
      border-radius: 6px;
      background: rgba(255,255,255,0.05);
      color: var(--cream);
      font-size: 0.8rem;
      cursor: pointer;
      transition: all 0.2s;
    }
    .btn:hover { background: rgba(212,175,55,0.2); border-color: var(--gold); }
    .btn.primary { background: var(--gold); color: var(--navy); border-color: var(--gold); font-weight: 600; }

    .content-body { flex: 1; overflow: hidden; display: flex; }

    /* ====== SLIDES ====== */
    .slides-container { flex: 1; position: relative; overflow: hidden; }
    .module-slides { display: none; width: 100%; height: 100%; }
    .module-slides.active { display: block; }

    .slide {
      position: absolute;
      top: 0; left: 0;
      width: 100%; height: 100%;
      display: flex;
      flex-direction: column;
      justify-content: flex-start;
      align-items: center;
      padding: 2rem 2rem 4rem;
      opacity: 0;
      visibility: hidden;
      transition: opacity var(--transition), visibility var(--transition);
      overflow-y: auto;
    }
    .slide.active { opacity: 1; visibility: visible; }
    .slide.dark { background: var(--deep-navy); }
    .slide.light { background: var(--cream); color: var(--text); }
    .slide.black { background: #000; }
    .slide.red-bg { background: linear-gradient(135deg, #7f1d1d, #450a0a); }
    .slide.green-bg { background: linear-gradient(135deg, #14532d, #052e16); }
    .slide.purple-bg { background: linear-gradient(135deg, #4c1d95, #2e1065); }
    .slide.orange-bg { background: linear-gradient(135deg, #9a3412, #431407); }

    .slide-progress-bar {
      position: absolute;
      top: 0;
      left: 0;
      height: 3px;
      background: linear-gradient(90deg, var(--gold), var(--orange));
      transition: width 0.3s ease;
      z-index: 50;
    }

    .serif { font-family: 'Cormorant Garamond', Georgia, serif; }
    .title {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(1.8rem, 4vw, 3rem);
      font-weight: 700;
      margin-bottom: 1rem;
      line-height: 1.2;
      text-align: center;
    }
    .title.gold { color: var(--gold); }
    .title.navy { color: var(--navy); }
    .subtitle {
      font-size: clamp(0.9rem, 2vw, 1.3rem);
      color: rgba(255,255,255,0.7);
      margin-bottom: 1.5rem;
      text-align: center;
    }
    .slide.light .subtitle { color: var(--light-text); }

    .big-number {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(4rem, 12vw, 8rem);
      font-weight: 700;
      line-height: 1;
    }
    .big-number.gold { color: var(--gold); }
    .big-number.red { color: var(--red); }

    .refrain {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(1.3rem, 3vw, 2rem);
      font-style: italic;
      color: var(--gold);
      text-align: center;
      max-width: 700px;
    }

    .content { display: flex; flex-direction: column; align-items: center; width: 100%; max-width: 850px; }

    /* Cards */
    .card {
      background: var(--light-cream);
      border: 1px solid var(--gold);
      padding: 1.25rem 1.5rem;
      margin: 0.5rem 0;
      max-width: 750px;
      width: 100%;
      border-radius: 8px;
    }
    .card.navy-bg { background: var(--navy); color: var(--cream); }
    .card.red-border { border: 2px solid var(--red); }
    .card.green-border { border: 2px solid var(--green); }
    .card-label {
      font-size: 0.7rem;
      font-weight: 700;
      color: var(--gold);
      letter-spacing: 0.05em;
      margin-bottom: 0.4rem;
      text-transform: uppercase;
    }
    .card-text { font-size: 0.95rem; line-height: 1.6; }
    .card.navy-bg .card-text { color: var(--cream); }

    /* Story box */
    .story-box {
      background: linear-gradient(135deg, rgba(197,48,48,0.15), rgba(30,39,97,0.2));
      border-left: 4px solid var(--red);
      padding: 1.25rem;
      margin: 0.75rem 0;
      max-width: 750px;
      width: 100%;
      border-radius: 0 8px 8px 0;
    }
    .story-box.success { background: linear-gradient(135deg, rgba(34,197,94,0.15), rgba(30,39,97,0.2)); border-left-color: var(--green); }
    .story-box.warning { background: linear-gradient(135deg, rgba(245,158,11,0.15), rgba(30,39,97,0.2)); border-left-color: var(--orange); }
    .story-label {
      font-size: 0.7rem;
      font-weight: 700;
      letter-spacing: 0.1em;
      color: var(--red);
      margin-bottom: 0.4rem;
      text-transform: uppercase;
    }
    .story-box.success .story-label { color: var(--green); }
    .story-box.warning .story-label { color: var(--orange); }
    .story-text { font-size: 0.95rem; line-height: 1.6; }

    /* Epic Story Box */
    .story-box.epic {
      background: linear-gradient(135deg, rgba(20,27,61,0.95), rgba(0,0,0,0.9));
      border-left: 4px solid var(--gold);
      border-top: 1px solid rgba(212,175,55,0.3);
      border-right: 1px solid rgba(212,175,55,0.2);
      border-bottom: 1px solid rgba(212,175,55,0.2);
      padding: 1.5rem;
      position: relative;
    }
    .story-box.epic::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      right: 0;
      height: 2px;
      background: linear-gradient(90deg, var(--gold), transparent);
    }
    .story-box.epic .story-label { color: var(--gold); font-size: 0.65rem; letter-spacing: 0.15em; }
    .story-box.epic .story-text { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.05rem; line-height: 1.7; }

    /* GRADE Certainty Colors */
    .grade-high { background: linear-gradient(135deg, rgba(34,197,94,0.2), rgba(30,39,97,0.2)); border-color: var(--green); }
    .grade-moderate { background: linear-gradient(135deg, rgba(59,130,246,0.2), rgba(30,39,97,0.2)); border-color: #3b82f6; }
    .grade-low { background: linear-gradient(135deg, rgba(245,158,11,0.2), rgba(30,39,97,0.2)); border-color: var(--orange); }
    .grade-very-low { background: linear-gradient(135deg, rgba(197,48,48,0.2), rgba(30,39,97,0.2)); border-color: var(--red); }

    .grade-badge {
      display: inline-block;
      padding: 0.25rem 0.75rem;
      border-radius: 4px;
      font-size: 0.75rem;
      font-weight: 700;
      text-transform: uppercase;
      letter-spacing: 0.05em;
    }
    .grade-badge.high { background: var(--green); color: white; }
    .grade-badge.moderate { background: #3b82f6; color: white; }
    .grade-badge.low { background: var(--orange); color: white; }
    .grade-badge.very-low { background: var(--red); color: white; }

    /* Stats */
    .stats-grid {
      display: flex;
      gap: 0.75rem;
      margin: 1rem 0;
      flex-wrap: wrap;
      justify-content: center;
    }
    .stat-box {
      background: var(--navy);
      color: var(--cream);
      padding: 1rem 1.25rem;
      text-align: center;
      min-width: 120px;
      border-radius: 8px;
    }
    .stat-box.light { background: var(--light-cream); color: var(--navy); border: 1px solid var(--gold); }
    .stat-value {
      font-family: 'Cormorant Garamond', serif;
      font-size: clamp(1.3rem, 2.5vw, 2rem);
      font-weight: 700;
    }
    .stat-value.gold { color: var(--gold); }
    .stat-value.red { color: var(--red); }
    .stat-value.green { color: var(--green); }
    .stat-label { font-size: 0.75rem; opacity: 0.8; margin-top: 0.2rem; }

    /* Timeline */
    .timeline { display: flex; flex-direction: column; gap: 0.4rem; width: 100%; max-width: 650px; }
    .timeline-item {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      padding: 0.6rem 0.75rem;
      background: rgba(255,255,255,0.05);
      border-radius: 6px;
      border-left: 4px solid var(--gold);
    }
    .timeline-days { font-weight: 700; font-size: 0.8rem; min-width: 70px; color: var(--gold); }
    .timeline-content { flex: 1; }
    .timeline-title { font-weight: 600; font-size: 0.9rem; }
    .timeline-desc { font-size: 0.75rem; opacity: 0.7; }

    /* Checklist */
    .checklist { display: flex; flex-direction: column; gap: 0.4rem; width: 100%; max-width: 650px; }
    .checklist-item {
      display: flex;
      align-items: flex-start;
      gap: 0.6rem;
      padding: 0.6rem 0.75rem;
      background: rgba(255,255,255,0.05);
      border-radius: 6px;
      border: 1px solid rgba(255,255,255,0.1);
    }
    .check-icon {
      width: 22px;
      height: 22px;
      background: var(--gold);
      color: var(--navy);
      border-radius: 4px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.75rem;
      flex-shrink: 0;
    }
    .checklist-text { font-size: 0.9rem; line-height: 1.4; }

    /* Lessons */
    .lesson-item { display: flex; align-items: flex-start; gap: 0.75rem; margin: 0.5rem 0; max-width: 700px; }
    .lesson-number {
      background: var(--gold);
      color: var(--navy);
      width: 28px;
      height: 28px;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.85rem;
      flex-shrink: 0;
    }
    .lesson-content h4 { font-size: 1rem; font-weight: 700; margin-bottom: 0.2rem; }
    .lesson-content p { font-size: 0.85rem; opacity: 0.8; }

    /* ====== DECISION TREE ====== */
    .decision-tree {
      width: 100%;
      max-width: 700px;
      background: linear-gradient(135deg, rgba(124,58,237,0.15), rgba(30,39,97,0.25));
      border: 2px solid var(--purple);
      border-radius: 12px;
      padding: 1.5rem;
      margin: 0.75rem 0;
    }
    .decision-header {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 1rem;
    }
    .decision-icon {
      width: 40px;
      height: 40px;
      background: var(--purple);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.25rem;
    }
    .decision-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.2rem;
      font-weight: 700;
    }
    .decision-xp {
      margin-left: auto;
      background: rgba(212,175,55,0.2);
      padding: 0.25rem 0.75rem;
      border-radius: 12px;
      font-size: 0.75rem;
      color: var(--gold);
      font-weight: 600;
    }
    .decision-scenario {
      background: rgba(0,0,0,0.2);
      padding: 1rem;
      border-radius: 8px;
      margin-bottom: 1rem;
      font-size: 0.95rem;
      line-height: 1.6;
    }
    .decision-question {
      font-weight: 600;
      color: var(--gold);
      margin-bottom: 0.75rem;
      font-size: 1rem;
    }
    .decision-options { display: flex; flex-direction: column; gap: 0.5rem; }
    .decision-option {
      display: flex;
      align-items: flex-start;
      gap: 0.75rem;
      padding: 0.75rem 1rem;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.15);
      border-radius: 8px;
      cursor: pointer;
      transition: all 0.2s;
    }
    .decision-option:hover { background: rgba(124,58,237,0.2); border-color: var(--purple); }
    .decision-option.selected { background: rgba(124,58,237,0.3); border-color: var(--purple); }
    .decision-option.correct { background: rgba(34,197,94,0.2); border-color: var(--green); }
    .decision-option.incorrect { background: rgba(239,68,68,0.15); border-color: var(--red); }
    .decision-option.disabled { pointer-events: none; opacity: 0.7; }
    .decision-option:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .option-letter {
      width: 24px;
      height: 24px;
      background: rgba(255,255,255,0.1);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.8rem;
      flex-shrink: 0;
    }
    .decision-option.correct .option-letter { background: var(--green); color: white; }
    .decision-option.incorrect .option-letter { background: var(--red); color: white; }
    .option-text { font-size: 0.9rem; }
    .decision-feedback {
      margin-top: 1rem;
      padding: 1rem;
      border-radius: 8px;
      display: none;
    }
    .decision-feedback.show { display: block; }
    .decision-feedback.correct { background: rgba(34,197,94,0.2); border: 1px solid var(--green); }
    .decision-feedback.incorrect { background: rgba(239,68,68,0.15); border: 1px solid var(--red); }
    .feedback-title { font-weight: 700; margin-bottom: 0.5rem; display: flex; align-items: center; gap: 0.5rem; }
    .feedback-text { font-size: 0.9rem; line-height: 1.5; }

    /* ====== QUIZ ====== */
    .quiz-container { width: 100%; max-width: 650px; }
    .quiz-question {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.2rem;
      margin-bottom: 1.25rem;
      text-align: center;
    }
    .quiz-options { display: flex; flex-direction: column; gap: 0.5rem; }
    .quiz-option {
      padding: 0.75rem 1rem;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.2);
      border-radius: 8px;
      cursor: pointer;
      transition: all 0.2s;
      text-align: left;
      font-size: 0.9rem;
    }
    .quiz-option:hover { background: rgba(212,175,55,0.15); border-color: var(--gold); }
    .quiz-option.correct { background: rgba(34,197,94,0.2); border-color: var(--green); }
    .quiz-option.incorrect { background: rgba(239,68,68,0.15); border-color: var(--red); }
    .quiz-option.disabled { pointer-events: none; }
    .quiz-option:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .quiz-feedback {
      margin-top: 1rem;
      padding: 1rem;
      border-radius: 8px;
      display: none;
      font-size: 0.9rem;
    }
    .quiz-feedback.show { display: block; }
    .quiz-feedback.correct { background: rgba(34,197,94,0.2); border: 1px solid var(--green); }
    .quiz-feedback.incorrect { background: rgba(239,68,68,0.15); border: 1px solid var(--red); }

    /* Learning Objectives */
    .objectives-box {
      background: linear-gradient(135deg, rgba(59,130,246,0.15), rgba(30,39,97,0.25));
      border: 2px solid #3b82f6;
      border-radius: 12px;
      padding: 1.25rem;
      margin: 0.75rem 0;
      max-width: 700px;
      width: 100%;
    }
    .objectives-header {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 0.75rem;
    }
    .objectives-icon {
      width: 36px;
      height: 36px;
      background: #3b82f6;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.1rem;
    }
    .objectives-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.1rem;
      font-weight: 700;
      color: #60a5fa;
    }
    .objectives-list { list-style: none; padding: 0; }
    .objectives-list li {
      display: flex;
      align-items: flex-start;
      gap: 0.5rem;
      padding: 0.4rem 0;
      font-size: 0.9rem;
    }
    .objectives-list li::before { content: 'â—‹'; color: #3b82f6; font-weight: bold; }

    /* Animation */
    .slide.active .animate { animation: fadeUp 0.5s ease-out forwards; }
    .slide.active .animate.delay-1 { animation-delay: 0.1s; }
    .slide.active .animate.delay-2 { animation-delay: 0.2s; }
    .slide.active .animate.delay-3 { animation-delay: 0.3s; }
    @keyframes fadeUp {
      from { opacity: 0; transform: translateY(15px); }
      to { opacity: 1; transform: translateY(0); }
    }
    .animate { opacity: 0; }

    /* XP Popup */
    .xp-popup {
      position: fixed;
      top: 50%;
      left: 50%;
      transform: translate(-50%, -50%) scale(0);
      background: linear-gradient(135deg, var(--gold), #f0c040);
      color: var(--navy);
      padding: 1.5rem 2.5rem;
      border-radius: 12px;
      font-family: 'Cormorant Garamond', serif;
      font-size: 2rem;
      font-weight: 700;
      z-index: 1000;
      box-shadow: 0 10px 40px rgba(0,0,0,0.5);
      transition: transform 0.3s ease;
    }
    .xp-popup.show { transform: translate(-50%, -50%) scale(1); }
    .xp-popup .xp-amount { font-size: 3rem; display: block; }

    /* Badge Earned Modal */
    .badge-modal {
      position: fixed;
      top: 0; left: 0; right: 0; bottom: 0;
      background: rgba(0,0,0,0.85);
      display: none;
      justify-content: center;
      align-items: center;
      z-index: 1001;
    }
    .badge-modal.show { display: flex; }
    .badge-modal-content {
      background: linear-gradient(135deg, var(--deep-navy), #0a0f1a);
      border: 2px solid var(--gold);
      border-radius: 16px;
      padding: 2rem;
      text-align: center;
      max-width: 350px;
    }
    .badge-modal-icon { font-size: 4rem; margin-bottom: 1rem; }
    .badge-modal-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.5rem;
      color: var(--gold);
      margin-bottom: 0.5rem;
    }
    .badge-modal-desc { font-size: 0.9rem; opacity: 0.8; margin-bottom: 1rem; }
    .badge-modal-close {
      padding: 0.5rem 1.5rem;
      background: var(--gold);
      color: var(--navy);
      border: none;
      border-radius: 6px;
      font-weight: 600;
      cursor: pointer;
    }

    /* Confetti */
    .confetti-container {
      position: fixed;
      top: 0; left: 0;
      width: 100%; height: 100%;
      pointer-events: none;
      z-index: 999;
      overflow: hidden;
    }
    .confetti {
      position: absolute;
      width: 10px; height: 10px;
      opacity: 0;
      animation: confetti-fall 3s ease-out forwards;
    }
    @keyframes confetti-fall {
      0% { transform: translateY(-100px) rotate(0deg); opacity: 1; }
      100% { transform: translateY(100vh) rotate(720deg); opacity: 0; }
    }
    @media (prefers-reduced-motion: reduce) {
      .confetti { animation: none; display: none; }
      .xp-popup { transition: none; }
      .slide { transition: none; }
    }

    /* Nav */
    .slide-nav {
      position: absolute;
      bottom: 0; left: 0; right: 0;
      display: flex;
      justify-content: space-between;
      align-items: flex-end;
      padding: 0.75rem 1rem 1.25rem;
      z-index: 100;
      pointer-events: none;
    }
    .nav-btn {
      background: rgba(0,0,0,0.5);
      border: 1px solid rgba(255,255,255,0.2);
      color: white;
      font-size: 1.1rem;
      cursor: pointer;
      opacity: 0.6;
      transition: all 0.2s;
      padding: 0.4rem 0.6rem;
      border-radius: 6px;
      pointer-events: auto;
    }
    .nav-btn:hover { opacity: 1; background: rgba(0,0,0,0.7); border-color: var(--gold); }
    .nav-btn:disabled { opacity: 0.2; cursor: not-allowed; }
    .nav-btn:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .nav-center { display: flex; flex-direction: column; align-items: center; gap: 0.2rem; pointer-events: auto; }
    .slide-counter { font-size: 0.7rem; opacity: 0.5; }
    .progress-dots { display: flex; gap: 3px; flex-wrap: wrap; max-width: 220px; justify-content: center; }
    .progress-dot {
      width: 44px;
      height: 44px;
      display: flex;
      align-items: center;
      justify-content: center;
      cursor: pointer;
      background: none;
      border: none;
      padding: 0;
    }
    .progress-dot::after {
      content: '';
      width: 12px;
      height: 12px;
      border-radius: 50%;
      background: var(--text-muted, rgba(255,255,255,0.25));
      transition: all 0.2s ease;
    }
    .progress-dot.active::after,
    .progress-dot.completed::after {
      background: var(--gold);
      width: 14px;
      height: 14px;
    }

    /* Mobile */
    @media (max-width: 768px) {
      .sidebar {
        position: fixed;
        left: -300px;
        top: 0;
        bottom: 0;
        z-index: 1000;
        transition: left 0.3s ease;
      }
      .sidebar.open { left: 0; }
      .sidebar-toggle {
        display: flex;
        position: fixed;
        top: 10px;
        left: 10px;
        z-index: 1001;
        width: 40px;
        height: 40px;
        background: var(--gold);
        color: var(--navy);
        border: none;
        border-radius: 8px;
        align-items: center;
        justify-content: center;
        font-size: 1.2rem;
        cursor: pointer;
      }
      .sidebar-overlay {
        display: none;
        position: fixed;
        top: 0; left: 0; right: 0; bottom: 0;
        background: rgba(0,0,0,0.5);
        z-index: 999;
      }
      .sidebar-overlay.show { display: block; }
    }
    @media (min-width: 769px) {
      .sidebar-toggle { display: none; }
      .sidebar-overlay { display: none !important; }
    }

    /* Combo Counter */
    .combo-display {
      position: fixed;
      top: 80px;
      right: 20px;
      background: linear-gradient(135deg, var(--orange), #ef4444);
      color: white;
      padding: 0.5rem 1rem;
      border-radius: 20px;
      font-weight: 700;
      font-size: 0.9rem;
      z-index: 500;
      transform: scale(0);
      transition: transform 0.3s ease;
      box-shadow: 0 4px 15px rgba(239,68,68,0.4);
    }
    .combo-display.show { transform: scale(1); }
  </style>
</head>
<body>
<a class="skip-link" href="#main-content">Skip to main content</a>
<div class="course-container">
<!-- Sidebar -->
<nav aria-label="ì½”ìŠ¤ íƒìƒ‰" class="sidebar" role="navigation">
<div class="sidebar-header">
<a href="index.html" onmouseout="this.style.color='rgba(212,175,55,0.7)'" onmouseover="this.style.color='#D4AF37'" style="display:block;font-size:0.7rem;color:rgba(212,175,55,0.7);text-decoration:none;margin-bottom:0.5rem;">â† Course Library</a>
<h1>GRADE Mastery</h1>
<p>ì¦ê±° íŒë‹¨ì˜ ê¸°ìˆ </p>
</div>
<div class="stats-panel">
<div class="level-display">
<div class="level-badge" id="levelIcon">ğŸ“Š</div>
<div class="level-info">
<div class="level-title" id="levelTitle">Novice Appraiser</div>
<div class="level-subtitle">Level <span id="levelNum">1</span></div>
</div>
</div>
<div class="xp-bar"><div class="xp-fill" id="xpFill" style="width: 0%"></div></div>
<div class="xp-text"><span id="xpCurrent">0</span> / <span id="xpNeeded">100</span> XP</div>
<div class="quick-stats">
<div class="quick-stat">
<div class="quick-stat-value" id="correctCount">0</div>
<div class="quick-stat-label">Correct</div>
</div>
<div class="quick-stat">
<div class="quick-stat-value" id="decisionCount">0</div>
<div class="quick-stat-label">Decisions</div>
</div>
<div class="quick-stat">
<div class="quick-stat-value" id="gradesCount">0</div>
<div class="quick-stat-label">Graded</div>
</div>
</div>
</div>
<div class="course-progress">
<div class="course-progress-label">
<span>Course Progress</span>
<span id="courseProgressPct">0%</span>
</div>
<div class="course-progress-bar">
<div class="course-progress-fill" id="courseProgressFill" style="width: 0%"></div>
</div>
</div>
<div class="module-list" id="moduleList"></div>
<div class="badges-panel">
<div class="badges-title">Achievements</div>
<div class="badges-grid" id="badgesGrid"></div>
</div>
</nav>
<!-- Main Content -->
<main class="main-content" id="main-content">
<header class="content-header">
<div class="breadcrumb">GRADE Mastery / <span id="currentModule">Module 1</span></div>
<div class="header-actions">
<div class="streak-display" id="streakDisplay">
<span class="streak-flame">ğŸ”¥</span>
<span class="streak-count" id="streakCount">0</span>
<span>day streak</span>
</div>
<button class="btn" onclick="resetProgress()">Reset</button>
</div>
</header>
<div class="content-body">
<div class="slides-container" id="slidesContainer"></div>
</div>
</main>
</div>
<!-- XP Popup -->
<div aria-atomic="true" aria-live="polite" class="xp-popup" id="xpPopup" role="status">
<span class="xp-amount" id="xpAmount">+25</span>
    XP
  </div>
<!-- Badge Modal -->
<div aria-labelledby="badgeModalTitle" aria-modal="true" class="badge-modal" id="badgeModal" role="dialog">
<div class="badge-modal-content">
<div class="badge-modal-icon" id="badgeModalIcon">ğŸ†</div>
<div class="badge-modal-title" id="badgeModalTitle">Badge Earned!</div>
<div class="badge-modal-desc" id="badgeModalDesc">ìƒˆë¡œìš´ ì—…ì ì„ ë‹¬ì„±í•˜ì…¨ìŠµë‹ˆë‹¤.</div>
<button class="badge-modal-close" onclick="closeBadgeModal()">Awesome!</button>
</div>
</div>
<!-- Confetti Container -->
<div class="confetti-container" id="confettiContainer"></div>
<!-- Combo Counter -->
<div aria-live="polite" class="combo-display" id="comboDisplay" role="status">ğŸ”¥ <span id="comboCount">0</span>x Combo!</div>
<!-- Mobile Sidebar Toggle -->
<button aria-expanded="false" aria-label="Toggle menu" class="sidebar-toggle" onclick="toggleSidebar()">â˜°</button>
<div class="sidebar-overlay" id="sidebarOverlay" onclick="toggleSidebar()"></div>
<script>
// ===== GAMIFICATION STATE =====
const DEFAULT_STATE = {
  xp: 0,
  level: 1,
  streak: 0,
  lastActive: null,
  correctAnswers: 0,
  decisionsCompleted: 0,
  gradesAssigned: 0,
  badges: [],
  completedModules: [],
  answeredQuestions: {},
  consecutiveCorrect: 0
};

function safeGetStorage(key, fallback) {
  try {
    const item = localStorage.getItem(key);
    return item ? JSON.parse(item) : fallback;
  } catch (e) {
    return fallback;
  }
}

function safeSetStorage(key, value) {
  try {
    localStorage.setItem(key, JSON.stringify(value));
  } catch (e) {}
}

// Migration from old storage key to versioned key
(function migrateStorage() {
  try {
    const oldData = localStorage.getItem('gradeGame');
    if (oldData && !localStorage.getItem('gradeGame_v1')) {
      localStorage.setItem('gradeGame_v1', oldData);
      localStorage.removeItem('gradeGame');
    }
  } catch (e) {}
})();

let gameState = safeGetStorage('gradeGame_v1', DEFAULT_STATE);

const LEVELS = [
  { level: 1, title: "Novice Appraiser", icon: "ğŸ“Š", xp: 0 },
  { level: 2, title: "Bias Spotter", icon: "ğŸ”", xp: 100 },
  { level: 3, title: "Certainty Seeker", icon: "âš–ï¸", xp: 250 },
  { level: 4, title: "Evidence Evaluator", icon: "ğŸ“‹", xp: 450 },
  { level: 5, title: "GRADE Apprentice", icon: "ğŸ“", xp: 700 },
  { level: 6, title: "Certainty Guardian", icon: "ğŸ›¡ï¸", xp: 1000 },
  { level: 7, title: "Evidence Master", icon: "ğŸ†", xp: 1400 },
  { level: 8, title: "GRADE Sage", icon: "ğŸ‘‘", xp: 1900 }
];

const BADGES = [
  { id: "first_grade", icon: "ğŸ“Š", name: "First Rating", desc: "Assign your first GRADE rating" },
  { id: "bias_hunter", icon: "ğŸ”", name: "Bias Hunter", desc: "í¸ê²¬ ìœ„í—˜ ëª¨ë“ˆ ì™„ë£Œ" },
  { id: "precision_master", icon: "ğŸ¯", name: "Precision Master", desc: "ë¶ˆì •ë°€ ëª¨ë“ˆ ì™„ë£Œ" },
  { id: "consistency_king", icon: "ğŸ”—", name: "Consistency King", desc: "ë¶ˆì¼ì¹˜ ëª¨ë“ˆ ì™„ë£Œ" },
  { id: "directness_detective", icon: "ğŸª", name: "Directness Detective", desc: "ê°„ì ‘ì„± ëª¨ë“ˆ ì™„ë£Œ" },
  { id: "publication_sleuth", icon: "ğŸ“°", name: "Publication Sleuth", desc: "ì¶œíŒ í¸ê²¬ ì™„ë£Œ ëª¨ë“ˆ" },
  { id: "upgrader", icon: "â¬†ï¸", name: "The Upgrader", desc: "Learn all upgrading factors" },
  { id: "perfect_5", icon: "â­", name: "Five Star", desc: "Get 5 correct answers in a row" },
  { id: "decision_maker", icon: "âš–ï¸", name: "Decision Maker", desc: "15ê°œì˜ ì˜ì‚¬ê²°ì • íŠ¸ë¦¬ ì™„ë£Œ" },
  { id: "finisher", icon: "ğŸ", name: "Course Complete", desc: "ì „ì²´ ê³¼ì • ì™„ë£Œ" },
  { id: "streak_3", icon: "ğŸ”¥", name: "On Fire", desc: "Maintain a 3-day streak" },
  { id: "streak_7", icon: "ğŸ’«", name: "Weekly Warrior", desc: "Maintain a 7-day streak" },
  { id: "grade_master", icon: "ğŸ‘‘", name: "GRADE Master", desc: "ìµœì¢… í‰ê°€ ì™„ë£Œ" }
];

// ===== MODULES DATA =====
const MODULES = [
  {
    id: 1, title: "Why Certainty Matters", subtitle: "When confidence kills", xp: 150,
    slides: [
      { type: "title", theme: "dark", content: { title: "Why Certainty Matters", subtitle: "When overconfidence in evidence kills patients" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand why evidence certainty determines patient outcomes",
          "í™•ì‹¤ì„±ì´ ì˜ëª» íŒë‹¨ë˜ì–´ ì¤‘ë‹¨ëœ ì§€ì¹¨ì—ì„œ ë°°ìš°ê¸°",
          "'ì¦ê±° ì¡´ì¬'ì™€ 'ì¦ê±°ëŠ” ì‹ ë¢°í•  ìˆ˜ ìˆë‹¤'ì˜ ì°¨ì´",
          "Understand what GRADE provides that traditional reviews don't"
        ],
        tip: "ì´ ëª¨ë“ˆì—ì„œëŠ” í™•ì‹ ì´ ì˜ëª»ë˜ë©´ ì‹¤ì œ ê²°ê³¼ê°€ ì´ˆë˜ë˜ëŠ” ì´ìœ ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "ë² íƒ€ ì°¨ë‹¨ì œ ì¬ì•™", title: "Guidelines Based on a Liar",
        text: "For two decades, clinical guidelines worldwide recommended <strong>beta-blockers before non-cardiac surgery</strong> to prevent heart attacks. The recommendation was rated 'strong'â€”high certainty of benefit. Millions of patients received the drugs before operations. The evidence came largely from one man: <strong>Don Poldermans</strong>, who contributed 15 studies showing dramatic benefits.",
        followup: "In 2011, Poldermans was found guilty of research misconduct. His data was fabricated. When his studies were removed from meta-analyses, the math reversed: beta-blockers didn't prevent heart attacksâ€”they caused them. Researchers calculated the cost: following guidelines based on this fraudulent 'high certainty' evidence may have <strong>killed 800,000 patients</strong> over a decade. The certainty rating was wrong. The patients paid with their lives."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "âš ï¸", title: "ì‹œë‚˜ë¦¬ì˜¤: ê°•ë ¥í•œ ê¶Œì¥ ì‚¬í•­",
        xp: 25,
        scenario: "ì§€ì¹¨ íŒ¨ë„ì€ ì¦ê±°ë¥¼ 'ë†’ì€ í™•ì‹¤ì„±'ìœ¼ë¡œ í‰ê°€í•˜ê³  ì˜ˆë°©ì  ì¹˜ë£Œì— ëŒ€í•´ 'ê°•ë ¥í•œ ê¶Œê³ 'ë¥¼ ë‚´ë¦½ë‹ˆë‹¤. ì¦ê±°ì˜ 60%ê°€ ì—°êµ¬ ê²°ê³¼ê°€ ë…ë¦½ì ìœ¼ë¡œ ë³µì œëœ ì ì´ ì—†ëŠ” ë‹¨ì¼ ì—°êµ¬ ê·¸ë£¹ì—ì„œ ë‚˜ì˜¨ ê²ƒì„ ë°œê²¬í–ˆìŠµë‹ˆë‹¤.",
        question: "í™•ì‹¤ì„± ë“±ê¸‰ì— ëŒ€í•´ ì–´ë–¤ ìš°ë ¤ë¥¼ ì œê¸°í•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "ì—†ìŒâ€”ë™ë£Œ ê²€í†  ì—°êµ¬ëŠ” ì‹ ë¢°í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.", correct: false },
          { letter: "B", text: "í¸í–¥ ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ìœ¼ë¡œ ì¸í•´ í™•ì‹¤ì„±ì€ ë‚®ì•„ì ¸ì•¼ í•©ë‹ˆë‹¤. ë³µì œ", correct: true },
          { letter: "C", text: "í™•ì¸ì„ ìœ„í•´ ë™ì¼í•œ ê·¸ë£¹ì— ì¶”ê°€ ì—°êµ¬ ìš”ì²­", correct: false },
          { letter: "D", text: "ê°•ë ¥í•œ ê¶Œì¥ ì‚¬í•­ì€ ëª¨ë“  ë¶ˆí™•ì‹¤ì„±ì„ ë³´ìƒí•©ë‹ˆë‹¤", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! Poldermansì˜ ë³µì œë˜ì§€ ì•Šì€ ì—°êµ¬ ê²°ê³¼ëŠ” í•œ ì¶œì²˜ì— ì˜ì¡´í–ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  'ë†’ì€ í™•ì‹¤ì„±'ìœ¼ë¡œ í‰ê°€ë˜ì—ˆìŠµë‹ˆë‹¤. GRADEëŠ” ì¦ê±°ê°€ ë…ë¦½ì  í™•ì¸ì´ ë¶€ì¡±í•œ ì ì¬ì ìœ¼ë¡œ í¸í–¥ëœ ì†ŒìŠ¤ì— í¬ê²Œ ì˜ì¡´í•˜ëŠ” ê²½ìš° ë‹¤ìš´ê·¸ë ˆì´ë“œë¥¼ ìš”êµ¬í•©ë‹ˆë‹¤.",
          incorrect: "ë‹¨ì¼ ì†ŒìŠ¤ì˜ ë³µì œë˜ì§€ ì•Šì€ ì¦ê±°ë¥¼ ì‹ ë¢°í•œ ê²°ê³¼ 800,000ëª…ì´ ì‚¬ë§í–ˆìŠµë‹ˆë‹¤. ë†’ì€ í™•ì‹¤ì„±ì„ ìœ„í•´ì„œëŠ” ë…ë¦½ì ì¸ ë³µì œê°€ í•„ìš”í•©ë‹ˆë‹¤. í•œ ì—°êµ¬ ê·¸ë£¹ì— ì§‘ì¤‘í•˜ëŠ” ê²ƒì€ í¸í–¥ì˜ ì¤‘ìš”í•œ ìœ„í—˜ì…ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "í˜¸ë¥´ëª¬ ì—­ì „", title: "Two Million Women Betrayed",
        text: "For forty years, doctors prescribed <strong>hormone replacement therapy (HRT)</strong> to prevent heart disease in menopausal women. The evidence seemed overwhelming: observational studies showed <strong>50% fewer heart attacks</strong>. Experts were certain. Guidelines were strong. Two million American women took HRT specifically for heart protection.",
        followup: "In 2002, the Women's Health Initiative RCT delivered a verdict that shattered decades of certainty. HRT didn't prevent heart diseaseâ€”it <strong>increased heart attacks by 29%</strong>, strokes by 41%, and breast cancer by 26%. The observational evidence had been confounded: healthy women chose HRT, creating an illusion of benefit. The certainty had been based on the wrong type of evidence. Two million women had taken a drug that harmed them, prescribed by doctors who were certain they were helping."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“Š", title: "Scenario: Observational vs. RCT",
        xp: 25,
        scenario: "20ê°œì˜ ëŒ€ê·œëª¨ ê´€ì°° ì—°êµ¬ì— ë”°ë¥´ë©´ ì¹˜ë£Œë²•ì´ ì‹¬í˜ˆê´€ ì‚¬ë§ì„ 45% ê°ì†Œì‹œí‚¤ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ë‘ ê°œì˜ ì‘ì€ RCTëŠ” íš¨ê³¼ë¥¼ ë‚˜íƒ€ë‚´ì§€ ì•ŠìŠµë‹ˆë‹¤. ê°€ì´ë“œë¼ì¸ íŒ¨ë„ì€ ì´ì ì— ëŒ€í•œ ì¦ê±°ì˜ í™•ì‹¤ì„±ì„ í‰ê°€í•´ì•¼ í•©ë‹ˆë‹¤.",
        question: "What certainty rating is appropriate?",
        options: [
          { letter: "A", text: "ë†’ìŒâ€”20ê°œì˜ ì—°êµ¬ê°€ 2ê°œì˜ ì—°êµ¬ë³´ë‹¤ ì¤‘ìš”í•©ë‹ˆë‹¤", correct: false },
          { letter: "B", text: "Moderateâ€”mixed evidence requires caution", correct: false },
          { letter: "C", text: "Lowâ€”RCTs trump observational studies; confounding likely explains the discrepancy", correct: true },
          { letter: "D", text: "Very Lowâ€”no conclusion is possible", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! HRT ì¬ë‚œì€ ìš°ë¦¬ì—ê²Œ ì´ ì •í™•í•œ êµí›ˆì„ ê°€ë¥´ì³ì£¼ì—ˆìŠµë‹ˆë‹¤. 50%ì˜ ì´ìµì„ ë³´ì—¬ì£¼ëŠ” ê´€ì°° ì—°êµ¬ëŠ” í•´ë¡œì›€ì„ ë³´ì—¬ì£¼ëŠ” RCTì— ì˜í•´ ì••ë„ë˜ì—ˆìŠµë‹ˆë‹¤. RCTê°€ ê´€ì°° ë°ì´í„°ì™€ ëª¨ìˆœë˜ëŠ” ê²½ìš° í˜¼ë€ìŠ¤ëŸ¬ìš´ ì„¤ëª…ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. GRADEëŠ” ë†’ì€ ìˆ˜ì¤€ì—ì„œ RCTë¥¼ ì‹œì‘í•˜ê³  ë‚®ì€ ìˆ˜ì¤€ì—ì„œ ê´€ì°°ì„ ì‹œì‘í•©ë‹ˆë‹¤.",
          incorrect: "HRT observational studies showed 50% benefit; the RCT showed 29% harm. The discrepancy was confoundingâ€”healthy women chose HRT. RCT evidence, even from smaller studies, provides higher certainty than observational evidence for causal questions."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "ì˜ëª»ëœ í™•ì‹¤ì„±ìœ¼ë¡œ ì¸í•œ ë¹„ìš©",
        stats: [
          { value: "800K", label: "í´ë”ë§ŒìŠ¤ ì‚¬ê¸°ë¡œ ì¸í•œ ì‚¬ë§" },
          { value: "2M", label: "Women harmed by HRT" },
          { value: "50K", label: "CAST drug deaths" },
          { value: "83K", label: "Avandia heart attacks" }
        ],
        caption: "ê° ì¬í•´ì—ëŠ” ê²°í•¨ì´ ìˆëŠ” ì¦ê±° í‰ê°€ë¥¼ ê¸°ë°˜ìœ¼ë¡œ 'í™•ì‹¤í•œ' ì§€ì¹¨ì´ í¬í•¨ë˜ì—ˆìŠµë‹ˆë‹¤."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "ì§‘ì¤‘ í¬ë„ë‹¹ ì¬í•´", title: "ACCORD: When Tight Control Killed",
        text: "Diabetes doctors were certain: if high blood sugar caused complications, then tighter glucose control must prevent them. The logic seemed irrefutable. Guidelines recommended <strong>aggressive targets</strong>. The ACCORD trial enrolled 10,251 patients to prove what everyone already 'knew'â€”intensive glucose control saves lives.",
        followup: "In February 2008, the trial was stopped early. Not for benefitâ€”<strong>for harm</strong>. Intensive glucose control increased deaths by 22%. The certainty had been based on biological plausibility, not actual outcome data. The surrogate outcome (glucose levels) improved while the patient-important outcome (survival) worsened. 257 excess deaths occurred in the intensive group. The guidelines had been confident. The confidence was misplaced."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ¯", title: "ì‹œë‚˜ë¦¬ì˜¤: ë…¼ë¦¬ì  ì¹˜ë£Œ",
        xp: 25,
        scenario: "ì¹˜ë£ŒëŠ” ì§ˆë³‘ì„ ìœ ë°œí•˜ëŠ” ê²ƒìœ¼ë¡œ ì•Œë ¤ì§„ ë°”ì´ì˜¤ë§ˆì»¤(ì‹¤í—˜ì‹¤ ê°’)ë¥¼ ê·¹ì ìœ¼ë¡œ í–¥ìƒì‹œí‚µë‹ˆë‹¤. ì‚¬ë§ì´ë‚˜ ì…ì›ê³¼ ê°™ì€ ì‹¤ì œ ì„ìƒ ê²°ê³¼ë¥¼ ì¸¡ì •í•œ ì„ìƒì‹œí—˜ì€ ì•„ì§ ì—†ìŠµë‹ˆë‹¤. ë™ë£ŒëŠ” ë©”ì»¤ë‹ˆì¦˜ì´ ì˜ ì´í•´ë˜ì–´ ìˆê¸° ë•Œë¬¸ì— ì´ì ì˜ í™•ì‹¤ì„±ì´ 'ë†’ë‹¤'ê³  ì£¼ì¥í•©ë‹ˆë‹¤.",
        question: "What certainty rating should apply?",
        options: [
          { letter: "A", text: "Highâ€”clear mechanism implies clear benefit", correct: false },
          { letter: "B", text: "Moderateâ€”mechanism is supportive but not definitive", correct: false },
          { letter: "C", text: "Low or Very Lowâ€”surrogate outcomes don't guarantee patient-important benefits", correct: true },
          { letter: "D", text: "ì‹œí—˜ì´ ì™„ë£Œë  ë•Œê¹Œì§€ í‰ê°€í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! ACCORD, CAST ë° ê¸°íƒ€ ìˆ˜ë§ì€ ì¬ë‚œì´ 'ë…¼ë¦¬ì  ë©”ì»¤ë‹ˆì¦˜'ì˜ ì˜¤ë¥˜ë¥¼ ë”°ëìŠµë‹ˆë‹¤. ëŒ€ë¦¬ìë¥¼ ê°œì„ í•˜ë©´ ê²°ê³¼ê°€ ì•…í™”ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. GRADEì—ì„œëŠ” ëŒ€ë¦¬ ê²°ê³¼ë§Œ ì¸¡ì •í•  ë•Œ ê°„ì ‘ì ì¸ ì´ìœ ë¡œ í•˜í–¥ ì¡°ì •ì´ í•„ìš”í•©ë‹ˆë‹¤.",
          incorrect: "ACCORD ì§‘ì¤‘ ìš”ë²•ì€ í™˜ìë¥¼ ì£½ì´ë©´ì„œ í˜ˆë‹¹ì„ ì™„ë²½í•˜ê²Œ ê°œì„ í–ˆìŠµë‹ˆë‹¤. CAST ì•½ë¬¼ì€ ì‹¬ì „ë„ë¥¼ ê³ ì •í•˜ê³  ì‚¬ë§ìë¥¼ 3ë°° ëŠ˜ë ¸ìŠµë‹ˆë‹¤. ìƒë¬¼í•™ì  íƒ€ë‹¹ì„±ì€ ì„ìƒì  ì¦ê±°ê°€ ì•„ë‹™ë‹ˆë‹¤. ë†’ì€ í™•ì‹¤ì„±ì„ ìœ„í•´ì„œëŠ” í™˜ìì—ê²Œ ì¤‘ìš”í•œ ê²°ê³¼ê°€ í•„ìš”í•©ë‹ˆë‹¤."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "What GRADE Provides",
        subtitle: "í™•ì‹¤ì„±ì„ ìœ„í•œ ì²´ê³„ì ì¸ í”„ë ˆì„ì›Œí¬",
        text: "GRADE(Grading of Recommendations Assessment, Development and Evaluation)ëŠ” ê·¼ê±°ì— ì–´ëŠ ì •ë„ì˜ ì‹ ë¢°ë„ë¥¼ ë‘ì–´ì•¼ í•˜ëŠ”ì§€ í‰ê°€í•˜ê¸° ìœ„í•œ ì²´ê³„ì ì´ê³  íˆ¬ëª…í•œ ë°©ë²•ì„ ì œê³µí•©ë‹ˆë‹¤. ì´ëŠ” 'ì¦ê±°ê°€ ì¡´ì¬í•œë‹¤'ì™€ 'ì¦ê±°ê°€ ì‹ ë¢°í•  ìˆ˜ ìˆë‹¤'ë¥¼ êµ¬ë¶„í•©ë‹ˆë‹¤.",
        highlight: "GRADEëŠ” ë‹¤ìŒê³¼ ê°™ì´ ë¬»ìŠµë‹ˆë‹¤. 'ì‹¤ì œ íš¨ê³¼ê°€ ì˜ˆìƒ íš¨ê³¼ì— ê°€ê¹ë‹¤ê³  í™•ì‹ í•˜ëŠ”ê°€?'"
      }},
      { type: "story", theme: "dark", content: {
        label: "ê´€ì ˆê²½ ê³„ì‹œ", title: "A Billion-Dollar Placebo",
        text: "Knee arthroscopy for osteoarthritis was one of the most common orthopedic procedures in the world. <strong>700,000 Americans</strong> underwent it annually at a cost of $3 billion. Surgeons were certain it workedâ€”they saw patients improve. Insurance covered it. Guidelines recommended it.",
        followup: "Then came the sham surgery trials. Patients were randomized to real arthroscopy or fake surgery (incisions but no actual procedure). The result: <strong>no difference</strong>. Patients improved equally whether they received real surgery or placebo. Decades of certainty, billions of dollars, millions of surgeriesâ€”all based on the placebo effect that surgeons couldn't see. The certainty had been based on uncontrolled observations. Controlled trials revealed the truth."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ”¬", title: "ì‹œë‚˜ë¦¬ì˜¤: ê²½í—˜ì´ í’ë¶€í•œ ì™¸ê³¼ì˜ì‚¬",
        xp: 25,
        scenario: "í•œ ì„ ì„ ì™¸ê³¼ ì˜ì‚¬ê°€ ì´ ì‹œìˆ ì„ 2,000íšŒ ìˆ˜í–‰í–ˆê³  'í™˜ìë¥¼ ë³´ì•˜ê¸° ë•Œë¬¸ì— í™•ì‹¤íˆ íš¨ê³¼ê°€ ìˆë‹¤'ê³  ì£¼ì¥í•©ë‹ˆë‹¤. ê°œì„ í•˜ì„¸ìš”.' ë¬´ì‘ìœ„ ì‹œí—˜ì€ ì¡´ì¬í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ë…€ëŠ” ì„ìƒ ê²½í—˜ì„ ë°”íƒ•ìœ¼ë¡œ í™•ì‹¤ì„±ì„ 'ë³´í†µ'ìœ¼ë¡œ í‰ê°€í•˜ëŠ” ì§€ì¹¨ì„ ì›í•©ë‹ˆë‹¤.",
        question: "What certainty rating is appropriate?",
        options: [
          { letter: "A", text: "Moderateâ€”2,000 cases is substantial experience", correct: false },
          { letter: "B", text: "Lowâ€”uncontrolled observations can't distinguish treatment effect from placebo", correct: true },
          { letter: "C", text: "ë†’ìŒ - ì „ë¬¸ê°€ ê²½í—˜ì´ ê°€ì¥ ë†’ì€ í˜•íƒœì˜ ì¦ê±°", correct: false },
          { letter: "D", text: "ë§¤ìš° ë‚®ìŒ - ì¼í™”ëŠ” ì¦ê±°ê°€ ì•„ë‹˜", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! ë¬´ë¦ ê´€ì ˆê²½ ì™¸ê³¼ ì˜ì‚¬ë“¤ì€ í™˜ìë“¤ì´ ìˆ˜ì‹­ ë…„ ë™ì•ˆ í˜¸ì „ë˜ëŠ” ê²ƒì„ 'ë´¤ìŠµë‹ˆë‹¤'. ê·¸ëŸ° ë‹¤ìŒ ê°€ì§œ ìˆ˜ìˆ  ì‹¤í—˜ì—ì„œëŠ” ê·¸ê²ƒì´ ìœ„ì•½ì´ë¼ëŠ” ê²ƒì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ì „ë¬¸ê°€ì˜ ê²½í—˜ìœ¼ë¡œëŠ” ìœ„ì•½ íš¨ê³¼ë¥¼ ê°ì§€í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. GRADEëŠ” í†µì œë˜ì§€ ì•Šì€ ê´€ì°°ì„ ë§¤ìš° ë‚®ì€ í™•ì‹¤ì„±ìœ¼ë¡œ í‰ê°€í•©ë‹ˆë‹¤.",
          incorrect: "ì™¸ê³¼ì˜ì‚¬ëŠ” ë§¤ë…„ 700,000ê±´ì˜ ê´€ì ˆê²½ ê²€ì‚¬ë¥¼ ìˆ˜í–‰í–ˆëŠ”ë°, ì´ëŠ” ì™„ì „íˆ ìœ„ì•½ì— ë¶ˆê³¼í•œ 'ì‹œê°' ì´ì ì´ì—ˆìŠµë‹ˆë‹¤. ì•„ë¬´ë¦¬ ê´‘ë²”ìœ„í•œ ì„ìƒ ê²½í—˜ì´ë¼ë„ ì¹˜ë£Œ íš¨ê³¼ì™€ ìì—°ì  ê°œì„  ë˜ëŠ” ìœ„ì•½ì„ êµ¬ë³„í•  ìˆ˜ëŠ” ì—†ìŠµë‹ˆë‹¤. RCTëŠ” í•„ìˆ˜ì ì…ë‹ˆë‹¤."
        }
      }},
      { type: "refrain", theme: "black", content: { text: "í™•ì‹¤ì„±ì€ ì–¼ë§ˆë‚˜ ë§ì€ ì¦ê±°ê°€ ì¡´ì¬í•˜ëŠ”ì§€ì— ê´€í•œ ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ì–¼ë§ˆë‚˜ ì‹ ë¢°í•´ì•¼ í•˜ëŠ”ê°€ì˜ ë¬¸ì œì…ë‹ˆë‹¤." }},
      { type: "quiz", theme: "dark", content: {
        question: "HRT ê´€ì°° ì—°êµ¬ê°€ ì™œ 40ë…„ê°„ ì˜ì‚¬ë“¤ì„ ì˜¤ë„í–ˆì„ê¹Œìš”?",
        options: [
          { text: "ê·¸ ì—°êµ¬ëŠ” ì¡°ì‘ë˜ì—ˆìŠµë‹ˆë‹¤", correct: false },
          { text: "Healthy women were more likely to choose HRT, creating confounding", correct: true },
          { text: "The RCTs used different doses", correct: false },
          { text: "Heart disease definitions changed over time", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "ì •í™•íˆ ê·¸ë ‡ìŠµë‹ˆë‹¤. ê±´ê°•í•œ ì—¬ì„±ì´ HRTë¥¼ ì„ íƒí–ˆë‹¤ëŠ” ì§•í›„ë¡œ ì¸í•œ í˜¼ë€ì€ í˜œíƒì— ëŒ€í•œ ì°©ê°ì„ ë¶ˆëŸ¬ì¼ìœ¼ì¼°ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì¸ê³¼ê´€ê³„ ì§ˆë¬¸ì— ëŒ€í•œ GRADEì˜ ê´€ì°° ì—°êµ¬ í‰ê°€ê°€ RCTë³´ë‹¤ ë‚®ì€ ì´ìœ ì…ë‹ˆë‹¤.",
          incorrect: "ì—°êµ¬ëŠ” ì‹¤ì œì˜€ì§€ë§Œ í˜¼ë€ìŠ¤ëŸ¬ì› ìŠµë‹ˆë‹¤. ê±´ê°•í•œ ì—¬ì„±ì€ HRTë¥¼ ë°›ì„ ê°€ëŠ¥ì„±ì´ ë” ë†’ì•„ ìœ ìµí•´ ë³´ì˜€ìŠµë‹ˆë‹¤. RCTëŠ” ì´ëŸ¬í•œ í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì†Œë¥¼ ë¬´ì‘ìœ„ë¡œ ì œê±°í•˜ì—¬ ì‹¤ì œ íš¨ê³¼ë¥¼ ë“œëŸ¬ëƒ…ë‹ˆë‹¤."
        }
      }}
    ]
  },
  {
    id: 2, title: "GRADE í”„ë ˆì„ì›Œí¬", subtitle: "ë†’ì€ ìˆ˜ì¤€ì—ì„œ ë§¤ìš° ë‚®ì€ ìˆ˜ì¤€ê¹Œì§€", xp: 120,
    slides: [
      { type: "title", theme: "dark", content: { title: "GRADE í”„ë ˆì„ì›Œí¬", subtitle: "Four levels of certainty, five reasons to doubt" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "4ê°€ì§€ GRADE í™•ì‹¤ì„± ìˆ˜ì¤€ê³¼ ê·¸ ì˜ë¯¸ì— ëŒ€í•´ ì•Œì•„ë³´ì„¸ìš”",
          "Understand starting points: RCTs vs observational studies",
          "ë‹¤ìš´ê·¸ë ˆì´ë“œë¥¼ ìœ„í•œ 5ê°€ì§€ ì˜ì—­ ì•Œì•„ë³´ê¸° í™•ì‹¤ì„±",
          "ê´€ì°° ì¦ê±°ë¥¼ ì—…ê·¸ë ˆì´ë“œí•˜ê¸° ìœ„í•œ ì„¸ ê°€ì§€ ìš”ì†Œë¥¼ ì•Œì•„ë³´ì„¸ìš”"
        ],
        tip: "ì´ ëª¨ë“ˆì€ ê³¼ì • ì „ë°˜ì— ê±¸ì³ ì ìš©í•  í”„ë ˆì„ì›Œí¬ë¥¼ ì œê³µí•©ë‹ˆë‹¤."
      }},
      { type: "stats", theme: "dark", content: {
        title: "4ê°€ì§€ í™•ì‹¤ì„± ìˆ˜ì¤€",
        stats: [
          { value: "âŠ•âŠ•âŠ•âŠ•", label: "HIGH" },
          { value: "âŠ•âŠ•âŠ•â—‹", label: "MODERATE" },
          { value: "âŠ•âŠ•â—‹â—‹", label: "LOW" },
          { value: "âŠ•â—‹â—‹â—‹", label: "VERY LOW" }
        ],
        caption: "ê° ìˆ˜ì¤€ì€ ì˜ì‚¬ ê²°ì •ìê°€ ì¦ê±°."
      }},
      { type: "concept", theme: "dark", content: {
        title: "What Each Level Means",
        subtitle: "Practical interpretation",
        checkpoints: [
          { day: "HIGH", event: "ì‹¤ì œ íš¨ê³¼ê°€ ì¶”ì •ì¹˜ì— ê°€ê¹ë‹¤ê³  ë§¤ìš° í™•ì‹ í•©ë‹ˆë‹¤" },
          { day: "MODERATE", event: "Moderately confident; true effect likely close but may differ" },
          { day: "LOW", event: "Limited confidence; true effect may be substantially different" },
          { day: "VERY LOW", event: "Very little confidence; true effect likely substantially different" }
        ]
      }},
      { type: "story", theme: "dark", content: {
        label: "ì‹œì‘ì  ì›ì¹™", title: "Why RCTs Begin Higher",
        text: "In 1747, James Lind conducted what many consider the first controlled trial. Twelve sailors with scurvy were divided into six pairs, each receiving a different treatment. <strong>Only the two who received citrus fruits recovered.</strong> This simple comparisonâ€”treated vs. untreated under similar conditionsâ€”revealed truth that centuries of observation had missed.",
        followup: "Randomization is the great equalizer. It balances known and unknown confounders between groups. When patients are randomized, differences in outcomes can be attributed to the treatment, not to differences between patients. This is why GRADE starts RCT evidence at <strong>HIGH</strong> certainty and observational evidence at <strong>LOW</strong>â€”the study design itself determines how much confounding might distort results."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ²", title: "ì‹œë‚˜ë¦¬ì˜¤: ì‹œì‘ì ",
        xp: 25,
        scenario: "You're rating evidence for a new drug. You have three RCTs (total n=1,200) and five cohort studies (total n=45,000). A colleague argues the cohort studies should start at the same certainty level because they have more patients.",
        question: "ê° ì¦ê±° ìœ í˜•ì˜ ì˜¬ë°”ë¥¸ ì‹œì‘ì ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Both start at HIGHâ€”sample size determines certainty", correct: false },
          { letter: "B", text: "RCTs start HIGH, cohorts start LOWâ€”design determines starting point", correct: true },
          { letter: "C", text: "Cohorts start MODERATE because of large sample size", correct: false },
          { letter: "D", text: "ë‘ ê°€ì§€ ëª¨ë‘ ì‹œì‘ë©ë‹ˆë‹¤. MODERATEì—ì„œ ì¡°ì •í•˜ê³ ", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! GRADE ì‹œì‘ì ì€ í‘œë³¸ í¬ê¸°ê°€ ì•„ë‹Œ ì—°êµ¬ ì„¤ê³„ë¥¼ ê¸°ë°˜ìœ¼ë¡œ í•©ë‹ˆë‹¤. ë¬´ì‘ìœ„í™”ê°€ êµë€ì„ ì œì–´í•˜ê¸° ë•Œë¬¸ì— RCTëŠ” HIGHë¡œ ì‹œì‘í•©ë‹ˆë‹¤. ê´€ì°° ì—°êµ¬ëŠ” ê·œëª¨ì— ê´€ê³„ì—†ì´ êµë€ì„ ì œê±°í•  ìˆ˜ ì—†ê¸° ë•Œë¬¸ì— ë‚®ì€ ìˆ˜ì¤€ìœ¼ë¡œ ì‹œì‘í•©ë‹ˆë‹¤.",
          incorrect: "Sample size affects precision, not confounding. The HRT cohort studies had millions of patients but were still wrong because of confounding. RCTs start HIGH; observational studies start LOW."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "ë‹¤ìš´ê·¸ë ˆì´ë“œë¥¼ ìœ„í•œ 5ê°œ ì˜ì—­",
        items: [
          "í¸í–¥ ìœ„í—˜ â€” ì—°êµ¬ê°€ í¸í–¥ ìœ„í—˜ì´ ë†’ìŠµë‹ˆê¹Œ?",
          "ë¶ˆì¼ê´€ì„± â€” ê²°ê³¼ê°€ ì„¤ëª…í•  ìˆ˜ ì—†ì„ ì •ë„ë¡œ ë‹¤ì–‘í•©ë‹ˆê¹Œ? ì—°êµ¬?",
          "ê°„ì ‘ì„± â€” ì¦ê±°ê°€ ìš°ë¦¬ì˜ ì§ˆë¬¸ì„ ì§ì ‘ì ìœ¼ë¡œ í•´ê²°í•©ë‹ˆê¹Œ?",
          "Imprecision â€” Is the effect estimate precise enough?",
          "ì¶œíŒ í¸í–¥ â€” ì—°êµ¬ê°€ ì¦ê±° ê¸°ë°˜ì—ì„œ ëˆ„ë½ë˜ì—ˆìŠµë‹ˆê¹Œ?"
        ]
      }},
      { type: "story", theme: "red-bg", content: {
        label: "íƒ€ë¯¸í”Œë£¨ ì‚¬ê°€", title: "When All Five Domains Failed",
        text: "In 2009, governments stockpiled Tamiflu for pandemic flu. The UK spent <strong>Â£473 million</strong>. The evidence looked solid: published trials showed reduced complications. But Cochrane reviewers noticed problems in every GRADE domain.",
        followup: "<strong>Risk of bias:</strong> Trials were industry-funded with unclear methods. <strong>Inconsistency:</strong> Results varied between published and unpublished studies. <strong>Indirectness:</strong> 'Complications' were poorly defined. <strong>Imprecision:</strong> Confidence intervals were wide. <strong>Publication bias:</strong> 60% of patient data was never published. When Roche finally released the raw data after five years, the truth emerged: Tamiflu reduced symptom duration by less than a day and had no proven effect on hospitalizations or complications. Half a billion pounds spent on evidence that should have been rated VERY LOW."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“‰", title: "ì‹œë‚˜ë¦¬ì˜¤: ë‹¤ì¤‘ ë„ë©”ì¸ ë¬¸ì œ",
        xp: 25,
        scenario: "You're rating evidence from 5 RCTs. You find: unclear allocation concealment (risk of bias), IÂ² = 75% with no explanation (inconsistency), and half the trials never published (publication bias). The trials themselves are precise and direct.",
        question: "HIGHì—ì„œ ëª‡ ë‹¨ê³„ê¹Œì§€ ë‹¤ìš´ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "One levelâ€”multiple minor concerns equal one downgrade", correct: false },
          { letter: "B", text: "Two levelsâ€”serious concerns in two domains", correct: false },
          { letter: "C", text: "Three levelsâ€”serious concerns in three domains (to VERY LOW)", correct: true },
          { letter: "D", text: "Cannot downgrade RCTsâ€”they're always HIGH", correct: false }
        ],
        feedback: {
          correct: "Correct! Serious concerns in each domain typically warrant one downgrade each. Risk of bias (âˆ’1), inconsistency (âˆ’1), and publication bias (âˆ’1) would take HIGH to VERY LOW. Multiple domains can compound.",
          incorrect: "Each domain with serious concerns typically warrants one downgrade. Three serious domain concerns = three downgrades. HIGH âˆ’ 3 = VERY LOW. GRADE is cumulative."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Three Factors for Upgrading (Observational Only)",
        items: [
          "Large Effect â€” Very large magnitude of effect (RR > 2 or < 0.5)",
          "Dose-Response â€” Clear gradient between exposure and outcome",
          "Confounding â€” All plausible confounding would reduce the effect"
        ]
      }},
      { type: "story", theme: "green-bg", content: {
        label: "í¡ì—° ì¦ê±°", title: "When Observation Earned Certainty",
        text: "In the 1950s, Richard Doll and Austin Bradford Hill published observational studies linking cigarettes to lung cancer. No RCTs existedâ€”you cannot randomize people to smoke. Yet the evidence became <strong>HIGH certainty</strong>. Why?",
        followup: "Every upgrading criterion was met. <strong>Large effect:</strong> Smokers had 10-30x higher lung cancer ratesâ€”an effect size that confounding alone cannot explain. <strong>Dose-response:</strong> More cigarettes = more cancer in a clear gradient. <strong>Confounding direction:</strong> Any unmeasured confounder that caused both smoking and cancer would have to be implausibly powerful to explain the effect. When observational evidence meets all three upgrading criteria, it can achieve certainty that rivals RCTs."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "â¬†ï¸", title: "ì‹œë‚˜ë¦¬ì˜¤: ì—…ê·¸ë ˆì´ë“œ ì§ˆë¬¸",
        xp: 25,
        scenario: "An observational study shows a treatment increases survival with RR = 1.3 (30% relative increase). The association is statistically significant with narrow confidence intervals. The authors argue this should be upgraded from LOW to MODERATE.",
        question: "ì´ ì¦ê±°ë¥¼ ì—…ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Yesâ€”statistical significance warrants upgrading", correct: false },
          { letter: "B", text: "Yesâ€”narrow confidence intervals warrant upgrading", correct: false },
          { letter: "C", text: "Noâ€”RR 1.3 is not large enough; confounding could easily explain it", correct: true },
          { letter: "D", text: "Noâ€”observational evidence can never be upgraded", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 1.3 is well within the range that confounding can produce. Large effect upgrading typically requires RR > 2 or < 0.5â€”effects so large that confounding alone is an implausible explanation. Statistical significance and precision are not upgrading criteria.",
          incorrect: "A 30% relative increase (RR 1.3) can easily result from modest confounding. The HRT studies showed RR 0.5 for heart protectionâ€”entirely due to confounding. Large effect upgrading requires effects that confounding cannot plausibly explain (typically RR > 2 or < 0.5)."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "GRADE ë‹ˆëª¨ë‹‰: RIIPP",
        subtitle: "ë‹¤ìš´ê·¸ë ˆì´ë“œ ë„ë©”ì¸ 5ê°œ ê¸°ì–µ",
        text: "<strong style='color:var(--gold);font-size:1.5rem'>R</strong>isk of bias â€” Can we trust the studies?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>nconsistency â€” Do studies agree?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>ndirectness â€” Does evidence match our question?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>mprecision â€” Is the estimate precise?<br><br><strong style='color:var(--gold);font-size:1.5rem'>P</strong>ublication bias â€” Is evidence missing?",
        highlight: "RIIPP â€” ê¸°ì–µí•˜ì„¸ìš”: 'ì´ëŸ¬í•œ ë„ë©”ì¸ì— ì‹¬ê°í•œ ë¬¸ì œê°€ ìˆëŠ” ê²½ìš° RCT ì¦ê±°ê°€ RIIPPë¡œ ë¶„ë¦¬ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤.'"
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why do observational studies start at LOW certainty in GRADE?",
        options: [
          { text: "They usually have smaller sample sizes", correct: false },
          { text: "They cannot control for unmeasured confounding", correct: true },
          { text: "They are more often industry-funded", correct: false },
          { text: "ì™„ë£Œí•˜ëŠ” ë° ì‹œê°„ì´ ë” ì˜¤ë˜ ê±¸ë¦½ë‹ˆë‹¤", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "ì •í™•í•©ë‹ˆë‹¤. ë¬´ì‘ìœ„í™”ëŠ” ê·¸ë£¹ ê°„ì˜ í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì†Œì˜ ê· í˜•ì„ ìœ ì§€í•©ë‹ˆë‹¤. ê·¸ê²ƒì´ ì—†ìœ¼ë©´ ê²°ê³¼ì˜ ì°¨ì´ëŠ” ì¹˜ë£Œ íš¨ê³¼ê°€ ì•„ë‹Œ í™˜ìì˜ ì°¨ì´ë¥¼ ë°˜ì˜í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìˆ˜ë°±ë§Œ ëª…ì˜ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ HRT ì—°êµ¬ëŠ” í˜¼ë€ìœ¼ë¡œ ì¸í•´ ì—¬ì „íˆ ì˜ëª»ëœ ê²°ê³¼ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤.",
          incorrect: "ë¬¸ì œëŠ” í‘œë³¸ í¬ê¸°ê°€ ì•„ë‹ˆë¼ í˜¼ë€ì…ë‹ˆë‹¤. ê´€ì°° ì—°êµ¬ëŠ” ë¬´ì‘ìœ„ ë°°ì •ì²˜ëŸ¼ ì•Œë ¤ì§€ì§€ ì•Šì€ í˜¼ë€ ìš”ì¸ì˜ ê· í˜•ì„ ë§ì¶œ ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì´ ê·¼ë³¸ì ì¸ í•œê³„ê°€ ì¶œë°œì ì„ ê²°ì •í•©ë‹ˆë‹¤."
        }
      }}
    ]
  },
  {
    id: 3, title: "Risk of Bias", subtitle: "ì—°êµ¬ê°€ ê±°ì§“ë§ì„ í•  ë•Œ", xp: 180,
    slides: [
      { type: "title", theme: "purple-bg", content: { title: "Risk of Bias", subtitle: "ì²« ë²ˆì§¸ ì˜ì—­: ì´ ì—°êµ¬ë¥¼ ì‹ ë¢°í•  ìˆ˜ ìˆìŠµë‹ˆê¹Œ?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "RCT ë° ê´€ì°° ì—°êµ¬ì—ì„œ ì£¼ìš” í¸í–¥ ì˜ì—­ì„ ì‹ë³„",
          "Recognize how bias inflates or deflates treatment effects",
          "Apply risk of bias assessment to real examples",
          "Decide when to downgrade certainty for bias"
        ],
        tip: "í¸í–¥ ì‚¬ëƒ¥ê¾¼ì„ íšë“í•˜ë ¤ë©´ ëª¨ë“  ê²°ì • ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ì™„ë£Œí•˜ì„¸ìš”. ë°°ì§€!"
      }},
      { type: "story", theme: "red-bg", content: {
        label: "VIGOR ì†ì„ìˆ˜", title: "When Merck Chose the Cutoff",
        text: "In 2000, Merck published the VIGOR trial comparing Vioxx to naproxen. The New England Journal of Medicine reported a 4-fold increase in heart attacks with Vioxx. But the published paper hid something: <strong>three additional heart attacks</strong> occurred in the Vioxx group after the data cutoff date. Merck scientists knew about them.",
        followup: "Those three heart attacks mattered. Including them would have changed the risk ratio from 'concerning' to 'alarming.' Instead, Merck's chosen cutoff dateâ€”a methodological decision made after seeing the dataâ€”obscured the true risk. The NEJM later published an 'expression of concern,' calling the paper 'inaccurate and incomplete.' By then, tens of thousands had suffered heart attacks from a drug whose danger had been hidden by selective reporting. The bias wasn't in the trial designâ€”it was in how the data was analyzed and presented."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "âœ‚ï¸", title: "ì‹œë‚˜ë¦¬ì˜¤: ì´ë™ ë‹¨ì ˆ",
        xp: 30,
        scenario: "ì—°êµ¬ ì‹œì‘ í›„ 1ì°¨ ë¶„ì„ ì‹œì ì„ 12ê°œì›”ì—ì„œ 6ê°œì›”ë¡œ ë³€ê²½í•œ ì„ìƒì‹œí—˜ì„ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. 6ê°œì›” ê²°ê³¼ëŠ” ì¹˜ë£Œì— ìœ ë¦¬í•©ë‹ˆë‹¤. ì €ìëŠ” ê²°ê³¼ì™€ ê´€ë ¨ ì—†ëŠ” 'ê´€ë¦¬ì  ì´ìœ 'ë¡œ ì¸í•´ ë³€ê²½ì´ ì´ë£¨ì–´ì¡Œë‹¤ê³  ë§í•©ë‹ˆë‹¤.",
        question: "ì´ê²ƒì´ í¸í–¥ í‰ê°€ ìœ„í—˜ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "No concernâ€”administrative changes happen", correct: false },
          { letter: "B", text: "ì„ íƒì  ë³´ê³ ì— ëŒ€í•œ í¸í–¥ ìœ„í—˜ì´ ë†’ìŒ - ë°ì´í„°ë¥¼ ë³¸ í›„ ì‹œì  ë³€ê²½ì´ ì˜ì‹¬ìŠ¤ëŸ½ìŠµë‹ˆë‹¤", correct: true },
          { letter: "C", text: "12ê°œì›” ë°ì´í„°ë„ ë§ˆì°¬ê°€ì§€ë¡œ ìœ„í—˜ì´ ë‚®ìŒ ë³´ê³ í–ˆìŠµë‹ˆë‹¤", correct: false },
          { letter: "D", text: "Unclear riskâ€”we cannot know their true motivation", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! ë¶„ì„ ê³„íšì— ëŒ€í•œ ì‚¬í›„ ë³€ê²½ì€ ì„ íƒì  ë³´ê³ ì— ìœ„í—˜ì´ ë†’ìŠµë‹ˆë‹¤. VIGORì˜ ë°ì´í„° ì°¨ë‹¨ì€ ì„¸ ë²ˆì˜ ì‹¬ì¥ë§ˆë¹„ë¥¼ ìˆ¨ê¸´ 'ë°©ë²•ë¡ ì  ê²°ì •'ì´ì—ˆë‹¤. ë°ì´í„°ê°€ ëˆ„ì ëœ í›„ ì‹œì ì´ ë³€ê²½ë˜ë©´ ìµœì•…ì˜ ìƒí™©ì„ ê°€ì •í•©ë‹ˆë‹¤.",
          incorrect: "ë¨¸í¬ì˜ 'ë°©ë²•ë¡ ì ' ë§ˆê°ì¼ì€ ì¹˜ëª…ì ì¸ ì‹¬ì¥ ë§ˆë¹„ë¥¼ ìˆ¨ê²¼ìŠµë‹ˆë‹¤. ì‚¬í›„ ë¶„ì„ ë³€ê²½ ì‚¬í•­(íŠ¹íˆ ê²°ê³¼ê°€ ì¹˜ë£Œì— ìœ ë¦¬í•œ ê²½ìš°)ì€ ì „í˜•ì ì¸ ì„ íƒì  ë³´ê³ ì…ë‹ˆë‹¤. GRADEì—ì„œëŠ” ì‚¬í›„ ìˆ˜ì •ì— ëŒ€í•œ íšŒì˜ë¡ ì´ í•„ìš”í•©ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ê³µê°œ ë¼ë²¨ ë¬¸ì œ", title: "When Knowing Changes Everything",
        text: "The ASCOT-LLA trial compared atorvastatin to placebo for cardiovascular prevention. The primary endpoint was non-fatal MI plus fatal CHDâ€”<strong>objective outcomes</strong> that shouldn't depend on whether doctors knew which treatment patients received.",
        followup: "But doctors did know. The trial was stopped early when the Data Safety Monitoring Board saw benefit. The problem: some outcomes were adjudicated by committees who were <strong>not blinded</strong> to treatment assignment. Did knowing a patient was on statin affect how borderline MIs were classified? Studies comparing blinded vs. unblinded assessment show systematic differences. Open-label designs can inflate apparent benefits by 10-20% even for 'objective' outcomes. ASCOT-LLA was rated down for risk of bias despite being an RCT."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ‘ï¸", title: "ì‹œë‚˜ë¦¬ì˜¤: ë§¹ê²€ì´ ì•„ë‹Œ í‰ê°€ì",
        xp: 25,
        scenario: "ìˆ˜ìˆ  ì¤‘ì¬ì— ëŒ€í•œ RCTì—ì„œëŠ” 'ì£¼ìš” ì‹¬í˜ˆê´€ ì‚¬ê±´'ì´ 30% ê°ì†Œí–ˆë‹¤ê³  ë³´ê³ í–ˆìŠµë‹ˆë‹¤. ì„ìƒì‹œí—˜ì€ ë°˜ë“œì‹œ ëˆˆê°€ë¦¼ì´ í•´ì œë˜ì—ˆìŠµë‹ˆë‹¤(í™˜ìëŠ” ìˆ˜ìˆ ì„ ë°›ì•˜ëŠ”ì§€ ì•Œê³  ìˆì—ˆìŠµë‹ˆë‹¤). ê²°ê³¼ í‰ê°€ìë„ ëˆˆê°€ë¦¼ì´ í•´ì œë˜ì—ˆìŠµë‹ˆë‹¤. ì‚¬ê±´ì€ ì¹˜ë£Œ í• ë‹¹ì„ ì•Œê³  ìˆëŠ” ìœ„ì›íšŒì—ì„œ íŒê²°ë˜ì—ˆìŠµë‹ˆë‹¤.",
        question: "íƒì§€ í¸í–¥ì— ëŒ€í•œ í¸í–¥ ìœ„í—˜ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Lowâ€”cardiovascular events are objective", correct: false },
          { letter: "B", text: "Highâ€”unblinded assessment of cardiovascular events inflates effects", correct: true },
          { letter: "C", text: "ë¶ˆëª…í™•í•©ë‹ˆë‹¤. ìœ„ì›íšŒì— ëŒ€í•œ ì¶”ê°€ ì •ë³´ê°€ í•„ìš”í•©ë‹ˆë‹¤.", correct: false },
          { letter: "D", text: "Not applicableâ€”surgical trials cannot be blinded", correct: false }
        ],
        feedback: {
          correct: "Correct! Even 'objective' outcomes like MI involve judgment calls (borderline troponins, ECG interpretations). Studies show unblinded assessment inflates effects 10-20%. Outcome assessors should always be blinded when possible, regardless of intervention blinding.",
          incorrect: "Cardiovascular events require interpretationâ€”borderline troponin elevations, ECG changes, symptom classification. Unblinded assessors systematically favor the intervention. Outcome assessment should be blinded even when intervention blinding is impossible."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "ITT ìœ„ë°˜", title: "Roche's Missing Patients",
        text: "In Tamiflu trials, Roche excluded patients from analysis after randomization. Some were excluded for 'protocol violations'â€”but the violations often occurred <strong>after</strong> patients had taken the drug and experienced side effects. Patients who developed complications were retroactively deemed 'protocol violators' and removed.",
        followup: "Intention-to-treat (ITT) analysis exists precisely to prevent this. Once randomized, always analyzedâ€”regardless of what happens afterward. Excluding patients after randomization destroys the balance that randomization created. Roche's selective exclusions removed patients who had adverse outcomes, making Tamiflu appear safer and more effective than it was. The Cochrane review downgraded certainty specifically for these ITT violations."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸšª", title: "ì‹œë‚˜ë¦¬ì˜¤: ë¬´ì‘ìœ„ ë°°ì • í›„ ì œì™¸",
        xp: 25,
        scenario: "A trial randomizes 500 patients per arm. The paper reports results for 420 vs. 380 patients, with 80 and 120 exclusions respectively. Reasons include: 'withdrew consent,' 'lost to follow-up,' and 'protocol deviation.' More patients were excluded from the control arm.",
        question: "What risk of bias concern does this raise?",
        options: [
          { letter: "A", text: "No concernâ€”exclusions happen in every trial", correct: false },
          { letter: "B", text: "High risk of attrition biasâ€”differential exclusions destroy randomization balance", correct: true },
          { letter: "C", text: "Low risk if reasons are documented", correct: false },
          { letter: "D", text: "Unclearâ€”we need to know why controls were excluded more", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! ì°¨ë“± ê°ì†Œ(120ê°œ ëŒ€ 80ê°œ ì œì™¸)ëŠ” ê·¸ë£¹ì´ ë” ì´ìƒ ë¹„êµí•  ìˆ˜ ì—†ìŒì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ê°œì„ ë˜ì§€ ì•Šì€ ëŒ€ì¡°êµ° í™˜ìê°€ íƒˆë½í•  ê°€ëŠ¥ì„±ì´ ë” ë†’ìœ¼ë©´ ë‚˜ë¨¸ì§€ ëŒ€ì¡°êµ°ì€ ì›ë˜ë³´ë‹¤ ë” ê±´ê°•í•´ ë³´ì…ë‹ˆë‹¤. ì´ëŠ” ëª…ë°±í•œ ì¹˜ë£Œ ì´ì ì„ ë¶€í’€ë¦½ë‹ˆë‹¤.",
          incorrect: "ì°¨ë“± ì œì™¸(120 ëŒ€ 80)ëŠ” ë¬´ì‘ìœ„ ë°°ì •ì„ ì¤‘ë‹¨í•©ë‹ˆë‹¤. ë‚˜ë¨¸ì§€ ê·¸ë£¹ì€ ë” ì´ìƒ ê· í˜•ì„ ì´ë£¨ì§€ ì•ŠìŠµë‹ˆë‹¤. ë” ì•„í”ˆ ëŒ€ì¡°êµ° í™˜ìê°€ íƒˆë½í•˜ë©´ ëŒ€ì¡°êµ°ì€ ì¸ìœ„ì ìœ¼ë¡œ ê±´ê°•í•œ ê²ƒì²˜ëŸ¼ ë³´ì…ë‹ˆë‹¤. GRADEì—ì„œëŠ” ìƒë‹¹í•œ ì°¨ë“± ê°ì†Œë¥¼ ìœ„í•´ ë‹¤ìš´ê·¸ë ˆì´ë“œê°€ í•„ìš”í•©ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ë“±ë¡ ê²©ì°¨", title: "ì‚¬ë¼ì§„ ê²°ê³¼",
        text: "A systematic review of trial registration found that <strong>31% of trials</strong> changed their primary outcome between registration and publication. The changes weren't randomâ€”they systematically favored positive results. Outcomes that showed benefit were promoted to primary; outcomes showing no effect were demoted or disappeared.",
        followup: "Selective outcome reporting is invisible without registration comparison. A trial might register five outcomes, find benefit in one, and publish only that one as the 'primary' outcome. The reader sees a positive trial. The reality: 4 of 5 outcomes showed nothing. PROSPERO registration for systematic reviews and ClinicalTrials.gov for trials exist specifically to combat this. When assessing risk of bias, always compare published outcomes to registered protocols."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“‹", title: "Scenario: The Primary Outcome Switch",
        xp: 25,
        scenario: "ê²Œì‹œëœ ì‹œí—˜ì„ ë“±ë¡ê³¼ ë¹„êµí•©ë‹ˆë‹¤. ë“±ë¡ì—ëŠ” 'ì‹¬ì¥í˜ˆê´€ ì‚¬ë§'ì´ 1ì°¨ ì‚¬ë§ìœ¼ë¡œ ê¸°ì¬ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê°„í–‰ë¬¼ì€ 'CV ì‚¬ë§, MI ë˜ëŠ” ë‡Œì¡¸ì¤‘ì˜ ë³µí•©'ì„ ì¼ì°¨ ì§ˆí™˜ìœ¼ë¡œ ë‚˜ì—´í•˜ê³  ì´ë¥¼ ìœ ì˜ë¯¸í•œ ê²ƒìœ¼ë¡œ ë³´ê³ í•©ë‹ˆë‹¤. ì‹¬í˜ˆê´€ ì‚¬ë§ë§Œì€ í‘œì— ë¬»í˜€ì„œ í° ì°¨ì´ë¥¼ ë³´ì´ì§€ ì•ŠìŠµë‹ˆë‹¤.",
        question: "What risk of bias rating is appropriate?",
        options: [
          { letter: "A", text: "Lowâ€”composite endpoints are clinically reasonable", correct: false },
          { letter: "B", text: "Highâ€”this is outcome switching to achieve significance", correct: true },
          { letter: "C", text: "Unclearâ€”the authors may have had good reasons", correct: false },
          { letter: "D", text: "í”„ë¡œí† ì½œì— ë³µí•©ì´ ë¯¸ë¦¬ ì§€ì •ë˜ì–´ ìˆìœ¼ë©´ ë‚®ìŠµë‹ˆë‹¤", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! ì¢ì€ ê²°ê³¼(CV ì‚¬ë§)ì—ì„œ ì¢ì€ ê²°ê³¼ê°€ ì‹¤íŒ¨í•œ ê²ƒì„ í™•ì¸í•œ í›„ ë” ë„“ì€ ë³µí•©(CV ì‚¬ë§/MI/ë‡Œì¡¸ì¤‘)ìœ¼ë¡œ ì „í™˜í•˜ëŠ” ê²ƒì€ êµê³¼ì„œ ê²°ê³¼ ì „í™˜ì…ë‹ˆë‹¤. ì´ë¥¼ ìˆ˜í–‰í•˜ëŠ” ì„ìƒì‹œí—˜ì˜ 31%ëŠ” ì²´ê³„ì ìœ¼ë¡œ ê¸ì •ì ì¸ ê²°ê³¼ë¥¼ ë¶€í’€ë¦½ë‹ˆë‹¤.",
          incorrect: "ì´ê²ƒì´ ê²°ê³¼ ì „í™˜ì…ë‹ˆë‹¤. ë“±ë¡ëœ ê¸°ë³¸ì´ ì‹¤íŒ¨í•˜ì—¬ ë” ê´‘ë²”ìœ„í•œ ë³µí•©ì´ ìŠ¹ê²©ë˜ì—ˆìŠµë‹ˆë‹¤. ë³µí•©ì  ì¤‘ìš”ì„±ì€ ì „ì ìœ¼ë¡œ ëœ ì¤‘ìš”í•œ êµ¬ì„±ìš”ì†Œì— ì˜í•´ ê²°ì •ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ëª¨ë“  ì¶œíŒë¬¼ì„ ë“±ë¡ ë‚´ìš©ê³¼ ë¹„êµí•˜ì„¸ìš”."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Avandia ê°ì‚¬", title: "38,000 Heart Attacks Exposed by One Cardiologist",
        text: "In 2007, Dr. Steven Nissen at the Cleveland Clinic did what regulators hadn't: he pooled all available rosiglitazone (Avandia) data. <strong>42 trials, 27,847 patients</strong>. The FDA had approved Avandia based on surrogate outcomesâ€”it lowered blood sugar beautifully. But Nissen asked a different question: what about hearts?",
        followup: "His meta-analysis revealed the truth: Avandia increased heart attacks by <strong>43%</strong> (OR 1.43, 95% CI 1.03-1.98). GSK had conducted these trials. GSK had the data. But the data on cardiovascular events had been scattered across trials, buried in adverse event tables, never pooled. When Nissen pooled it, the pattern became undeniable. The FDA estimated <strong>83,000 excess heart attacks</strong> between 1999-2007. The bias wasn't in study conductâ€”it was in how results were analyzed and presented. Selective synthesis can be as dangerous as selective reporting."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“‘", title: "ì‹œë‚˜ë¦¬ì˜¤: ë¶„ì‚°ëœ ì•ˆì „ ë°ì´í„°",
        xp: 25,
        scenario: "A drug has been studied in 30 trials for various conditions. Each trial reports a few adverse cardiac events in supplementary tables, but no single trial was powered for cardiac outcomes. A meta-analysis combining cardiac events across all 30 trials shows RR 1.35 (95% CI 1.10-1.65) for heart attacks.",
        question: "How should this post-hoc safety signal affect certainty?",
        options: [
          { letter: "A", text: "Ignore itâ€”trials weren't designed for cardiac outcomes", correct: false },
          { letter: "B", text: "ì§„ì§€í•˜ê²Œ ìƒê°í•˜ì„¸ìš”. í†µí•©ëœ ì´ìƒ ì‚¬ë¡€ëŠ” ì‚¬í›„ ë¶„ì„ì—ì„œë„ ì‹¤ì œ ì‹ í˜¸ë¥¼ ë“œëŸ¬ë‚¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤", correct: true },
          { letter: "C", text: "Dismiss itâ€”meta-analysis of adverse events is unreliable", correct: false },
          { letter: "D", text: "Wait for a dedicated cardiac outcome trial before acting", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! Nissenì˜ Avandia ë¶„ì„ì€ ë¶„ì‚°ëœ ë¶€ì‘ìš©ì„ 'ì‚¬í›„' í†µí•©í•˜ì—¬ 83,000ê±´ì˜ ì´ˆê³¼ ì‹¬ì¥ë§ˆë¹„ë¥¼ ë°í˜€ëƒˆìŠµë‹ˆë‹¤. ë©”íƒ€ ë¶„ì„ì˜ ì‚¬í›„ ì•ˆì „ ì‹ í˜¸ëŠ” ì‹¤ì œì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‚¬ì „ì— ì§€ì •ëœ ì‹¬ì¥ ê²°ê³¼ê°€ ì—†ë‹¤ê³  í•´ì„œ ì‹¬ì¥ ì§ˆí™˜ì´ ë°œìƒí•˜ì§€ ì•Šì•˜ë‹¤ëŠ” ì˜ë¯¸ëŠ” ì•„ë‹™ë‹ˆë‹¤.",
          incorrect: "Avandia ì‚¬ë¡€ëŠ” ë¶€ì‘ìš©ì„ ì‚¬í›„ì— í†µí•©í•˜ì—¬ ì‹¤ì œ í”¼í•´ë¥¼ ë“œëŸ¬ë‚¼ ìˆ˜ ìˆìŒì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ì‹¬ì¥ë§ˆë¹„ 8ë§Œ 3ì²œ ê±´ì´ ëˆ„ì ëœ ìƒíƒœì—ì„œ ì „ë‹´ ì¬íŒì„ ê¸°ë‹¤ë¦¬ëŠ” ê²ƒì€ ë¹„ì–‘ì‹¬ì ì´ì—ˆì„ ê²ƒì´ë‹¤. ë¶€ì‘ìš© ë©”íƒ€ ë¶„ì„ì˜ ì•ˆì „ì„± ì‹ í˜¸ëŠ” ì‹¬ê°í•˜ê²Œ ê³ ë ¤í•  ê°€ì¹˜ê°€ ìˆìŠµë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ENHANCE ì†ì„ìˆ˜", title: "When Merck Hid What They Found",
        text: "2006ë…„ì— MerckëŠ” ì£½ìƒê²½í™”ì¦ì— ëŒ€í•œ Vytorin(ezetimibe + simvastatin)ì˜ ENHANCE ì‹œí—˜ì„ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤. ì´ ì‹œí—˜ì—ì„œëŠ” ì‹¬í˜ˆê´€ ì§ˆí™˜ì˜ ëŒ€ìš© ì§€í‘œì¸ ê²½ë™ë§¥ ë‘ê»˜ë¥¼ ì¸¡ì •í–ˆìŠµë‹ˆë‹¤. ê²°ê³¼ëŠ” 2007ë…„ ì´ˆì— ë°œí‘œë  ì˜ˆì •ì´ì—ˆìŠµë‹ˆë‹¤. ë¨¸í¬ëŠ” 'ì¶”ê°€ ë¶„ì„'",
        followup: "The 'additional analyses' took <strong>two years</strong>. When finally released in 2008, ENHANCE showed <strong>no benefit</strong>â€”Vytorin didn't reduce artery thickness despite lowering LDL cholesterol. During those two years of concealment, Vytorin sales exceeded <strong>$5 billion</strong>. Congressional investigations revealed internal documents showing Merck knew the results were negative in 2006. The delay wasn't for analysisâ€”it was for commercial protection. Publication delay is a form of selective reporting: timing becomes a bias tool."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "â°", title: "ì‹œë‚˜ë¦¬ì˜¤: ì˜ì‹¬ìŠ¤ëŸ¬ìš´ ì§€ì—°",
        xp: 25,
        scenario: "ë§¤ìš° ê¸°ëŒ€ë˜ëŠ” ë¸”ë¡ë²„ìŠ¤í„° ì•½ë¬¼ì— ëŒ€í•œ ì„ìƒì‹œí—˜ ê²°ê³¼ê°€ 18ê°œì›” ì „ì— ë³´ê³ ë  ì˜ˆì •ì´ì—ˆìŠµë‹ˆë‹¤. íšŒì‚¬ëŠ” 'ì§„í–‰ ì¤‘ì¸ ë¶„ì„'ê³¼ 'ë°ì´í„° í’ˆì§ˆ ë¬¸ì œ'ë¥¼ ì–¸ê¸‰í•©ë‹ˆë‹¤. í•œí¸, ì´ ì•½ì€ ë§¤ë…„ ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ë¥¼ ê³„ì† íŒë§¤í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê²½ìŸì‚¬ ì‹œí—˜ì€ ì´ë¯¸ ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹¤.",
        question: "ë³´ê³ ë˜ì§€ ì•Šì€ ê²°ê³¼ì— ëŒ€í•´ ë¬´ì—‡ì„ ì˜ì‹¬í•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Nothingâ€”data quality takes time", correct: false },
          { letter: "B", text: "Likely negative or harmfulâ€”companies delay bad news, not good news", correct: true },
          { letter: "C", text: "Likely positiveâ€”they're waiting for regulatory approval", correct: false },
          { letter: "D", text: "Cannot infer anything from publication timing", correct: false }
        ],
        feedback: {
          correct: "Correct! The ENHANCE delay taught us: companies don't delay good news for two years. Unexplained publication delays, especially for products still generating revenue, are strong evidence of unfavorable results. Consider delayed trials as potentially biased against the intervention.",
          incorrect: "ê²Œì‹œ ì‹œê¸°ì— ëŒ€í•œ ì •ë³´ë¥¼ ì œê³µí•©ë‹ˆë‹¤. ê¸°ì—…ì€ ê¸ì •ì ì¸ ê²°ê³¼(ì£¼ê°€, ë§ˆì¼€íŒ…) ë°œí‘œë¥¼ ê°€ì†í™”í•˜ê³  ë¶€ì •ì ì¸ ê²°ê³¼(ê³„ì† íŒë§¤) ë°œí‘œë¥¼ ì§€ì—°í•©ë‹ˆë‹¤. ë¸”ë¡ë²„ìŠ¤í„° ì•½ë¬¼ì˜ 18ê°œì›” ì§€ì—°ì€ ê²°ê³¼ê°€ ì§€ì†ì ì¸ ì‚¬ìš©ì„ ë’·ë°›ì¹¨í•˜ì§€ ì•ŠëŠ”ë‹¤ëŠ” ê²ƒì„ ê°•ë ¥íˆ ì‹œì‚¬í•©ë‹ˆë‹¤."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Risk of Bias Domains (RCTs)",
        items: [
          "Random sequence generation â€” Was randomization truly random?",
          "Allocation concealment â€” Could anyone predict assignments?",
          "Blinding of participants/personnel â€” Did they know treatment?",
          "Blinding of outcome assessment â€” Did assessors know treatment?",
          "ë¶ˆì™„ì „í•œ ê²°ê³¼ ë°ì´í„° â€” ê°ì†Œê°€ ê· í˜•ì„ ì´ë£¨ê³  ì„¤ëª…ë˜ì—ˆìŠµë‹ˆê¹Œ?",
          "Selective reporting â€” Are registered outcomes all reported?",
          "Other bias â€” Baseline imbalances, early stopping, etc."
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why does GRADE downgrade for open-label outcome assessment even when outcomes seem 'objective'?",
        options: [
          { text: "Open-label trials are always lower quality", correct: false },
          { text: "Even objective outcomes involve judgment calls affected by knowledge of treatment", correct: true },
          { text: "Regulations require blinded assessment", correct: false },
          { text: "ì¦ê±°ì— ê¸°ì´ˆí•œ ê²ƒì´ ì•„ë‹ˆë¼ ë³´ìˆ˜ì ì¸ ê´€ë¡€ì…ë‹ˆë‹¤", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! ê²½ê³„ì„  MI, ë¶ˆí™•ì‹¤í•œ ë‡Œì¡¸ì¤‘ ì¦ìƒ, ë…¼ìŸì˜ ì—¬ì§€ê°€ ìˆëŠ” ECG ë³€í™” ë“± ëª¨ë‘ í•´ì„ì´ í•„ìš”í•©ë‹ˆë‹¤. ì—°êµ¬ì— ë”°ë¥´ë©´ ë§¹ê²€ í•´ì œ í‰ê°€ëŠ” 'í•˜ë“œ' ì—”ë“œí¬ì¸íŠ¸ì— ëŒ€í•´ì„œë„ ì•Œë ¤ì§„ ì¹˜ë£Œë²•ì„ ì²´ê³„ì ìœ¼ë¡œ 10~20%ê¹Œì§€ ì„ í˜¸í•©ë‹ˆë‹¤.",
          incorrect: "ì—°êµ¬ì— ë”°ë¥´ë©´ ê°ê´€ì ì¸ ê²°ê³¼ì— ëŒ€í•´ì„œë„ ë§¹ê²€ í•´ì œ í‰ê°€ì˜ íš¨ê³¼ê°€ ë¶€í’€ë ¤ì§€ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ê²½ê³„ì„  ì‚¬ë¡€ëŠ” ì˜ˆìƒë˜ëŠ” íš¨ê³¼ì— ìœ ë¦¬í•˜ê²Œ í•´ì„ë©ë‹ˆë‹¤. ì´ê²ƒì´ íƒì§€ í¸í–¥ì…ë‹ˆë‹¤."
        }
      }}
    ]
  },
  {
    id: 4, title: "Inconsistency", subtitle: "ì—°êµ¬ê°€ ì¼ì¹˜í•˜ì§€ ì•ŠëŠ” ê²½ìš°", xp: 160,
    slides: [
      { type: "title", theme: "orange-bg", content: { title: "Inconsistency", subtitle: "ë‘ ë²ˆì§¸ ì˜ì—­: ì—°êµ¬ ê²°ê³¼ê°€ ì¼ì¹˜í•˜ì§€ ì•Šì„ ë•Œ ì–´ë–»ê²Œ í•´ì•¼ í•©ë‹ˆê¹Œ?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "ì—°êµ¬ ê²°ê³¼ê°€ ì™œ ë‹¤ë¥¸ì§€, ë³€ë™ì´ ìš°ë ¤ë˜ëŠ” ê²½ìš°ë¥¼ ì´í•´í•©ë‹ˆë‹¤.",
          "ì´ì§ˆì„±ì— ëŒ€í•œ IÂ² ë° tauÂ² í†µê³„ í•´ì„",
          "Distinguish explainable from unexplainable inconsistency",
          "Decide when to downgrade certainty for inconsistency"
        ],
        tip: "Real disagreement between studies tells us something important."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "ë¹„íƒ€ë¯¼ D ëª¨ìˆœ", title: "200ê°œì˜ ì—°êµ¬ê°€ ë™ì˜í•˜ì§€ ì•Šì„ ë•Œ",
        text: "By 2019, over <strong>200 randomized trials</strong> had studied vitamin D supplementation. The results were chaos. Some showed vitamin D prevented cancer (RR 0.77). Others showed no effect (RR 1.02). Some showed harm (RR 1.15). Meta-analyses pooled them all and proclaimed 'statistically significant benefit.' But the IÂ² was <strong>78%</strong>â€”massive heterogeneity that the summary estimate concealed.",
        followup: "The largest trial, VITAL (25,871 participants), finally brought clarity. It showed <strong>no benefit</strong> for cancer or cardiovascular disease. The smaller positive studies had methodological problems: inadequate randomization, post-hoc analyses, selected populations. The pooled estimate had hidden a crucial truth: when studies wildly disagree, the average may represent no one's truth. GRADE requires downgrading for this kind of inconsistency, regardless of what the pooled estimate shows."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“Š", title: "ì‹œë‚˜ë¦¬ì˜¤: ì´ì¢… ë©”íƒ€ ë¶„ì„",
        xp: 25,
        scenario: "A meta-analysis of 15 trials shows pooled benefit (OR 0.75, p<0.001). However, IÂ² = 82%, tauÂ² is large, and the prediction interval crosses 1.0. Six trials show harm, nine show benefit. The authors conclude 'significant benefit with moderate heterogeneity.'",
        question: "How should inconsistency affect the certainty rating?",
        options: [
          { letter: "A", text: "No downgradeâ€”the pooled estimate is statistically significant", correct: false },
          { letter: "B", text: "Downgrade one levelâ€”IÂ² > 75% is substantial heterogeneity", correct: false },
          { letter: "C", text: "Downgrade one or two levelsâ€”prediction interval crossing 1.0 means future studies might show harm", correct: true },
          { letter: "D", text: "Cannot rateâ€”inconsistent evidence is uninterpretable", correct: false }
        ],
        feedback: {
          correct: "Correct! The prediction interval is key. When it crosses the null, we're saying: 'If we did another study, it might show the opposite effect.' That's profound uncertainty. IÂ² = 82% with a prediction interval crossing 1.0 warrants serious downgrading.",
          incorrect: "IÂ² 82%ëŠ” ì‹¬ê°í•œ ì´ì§ˆì„±ì´ì§€ë§Œ ì˜ˆì¸¡ êµ¬ê°„ì´ ë” ë§ì€ ì •ë³´ë¥¼ ì œê³µí•©ë‹ˆë‹¤. 1.0ì„ ë„˜ìœ¼ë©´ í–¥í›„ ì—°êµ¬ì—ì„œ í•´ë¡œì›€ì´ ë‚˜íƒ€ë‚  ìˆ˜ ìˆìŒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì¦‰, í†µí•©ëœ 'í˜œíƒ'ì´ ë‹¤ìŒ í™˜ìì—ê²Œ ì ìš©ë˜ì§€ ì•Šì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•©ë™ ì¶”ì •ì¹˜ì˜ í†µê³„ì  ìœ ì˜ì„±ì€ ì¼ê´€ë˜ì§€ ì•Šì€ ì¦ê±°ë¥¼ êµ¬ì œí•˜ì§€ ëª»í•©ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ë‡Œì¡¸ì¤‘ ë¯¸ìŠ¤í„°ë¦¬", title: "Aspirin's Vanishing Benefit",
        text: "In 1988, the ISIS-2 trial proved aspirin reduced death after heart attack by <strong>23%</strong>. The evidence was bulletproofâ€”17,187 patients, clear benefit, minimal heterogeneity when pooled with similar trials. Aspirin became standard care.",
        followup: "But stroke prevention was different. Meta-analyses of aspirin for primary prevention showed <strong>wildly inconsistent results</strong>. Some trials showed 15% reduction in stroke. Others showed 10% increase. The IÂ² exceeded 60%. The explanation emerged slowly: aspirin prevents <strong>ischemic</strong> stroke but causes <strong>hemorrhagic</strong> stroke. When trials measured 'all stroke,' results depended on the baseline mix of stroke types in each population. The inconsistency wasn't noiseâ€”it was biology. Understanding <em>why</em> studies differ changes interpretation entirely."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ”", title: "ì‹œë‚˜ë¦¬ì˜¤: ì„¤ëª… ê°€ëŠ¥í•œ ë¶ˆì¼ì¹˜",
        xp: 25,
        scenario: "A meta-analysis shows IÂ² = 70%. However, subgroup analysis reveals: trials in high-risk patients show consistent benefit (IÂ² = 15%, OR 0.60), while trials in low-risk patients show consistent null effects (IÂ² = 20%, OR 1.02). The high IÂ² is entirely explained by mixing these populations.",
        question: "ë¶ˆì¼ì¹˜í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Yesâ€”IÂ² = 70% always requires downgrading", correct: false },
          { letter: "B", text: "Noâ€”inconsistency is fully explained by a pre-specified, biologically plausible subgroup", correct: true },
          { letter: "C", text: "Partiallyâ€”downgrade one level despite the explanation", correct: false },
          { letter: "D", text: "Report two separate certainty ratings for each subgroup", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! GRADEëŠ” ì„¤ëª…í•  ìˆ˜ ì—†ëŠ” ì´ì§ˆì„±(ë‹¤ìš´ê·¸ë ˆì´ë“œ)ê³¼ ì‹ ë¢°í•  ìˆ˜ ìˆëŠ” í•˜ìœ„ ê·¸ë£¹ íš¨ê³¼ë¡œ ì™„ì „íˆ ì„¤ëª…ë˜ëŠ” ì´ì§ˆì„±(ë¶ˆì¼ì¹˜ë¡œ ì¸í•œ ë‹¤ìš´ê·¸ë ˆì´ë“œ ì—†ìŒ)ì„ êµ¬ë³„í•©ë‹ˆë‹¤. ì„¤ëª…ì€ ì‚¬í›„ ë°ì´í„° ì¤€ì„¤ì´ ì•„ë‹Œ ì‚¬ì „ì— ì§€ì •ë˜ê³  ìƒë¬¼í•™ì ìœ¼ë¡œ íƒ€ë‹¹í•´ì•¼ í•©ë‹ˆë‹¤.",
          incorrect: "When heterogeneity is fully explained by a pre-specified, credible subgroup effect, the 'inconsistency' actually tells us something useful: treatment works differently in different populations. This informs clinical practice rather than undermining certainty."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "ì•Œë¶€ë¯¼ ì—­ì„¤", title: "28 Trials, Zero Answers",
        text: "Should critically ill patients receive albumin for fluid resuscitation? By 1998, the Cochrane Injuries Group had pooled <strong>28 trials</strong>. Their conclusion: albumin <strong>increases mortality by 68%</strong> (RR 1.68). Headlines screamed. NHS considered banning albumin. The evidence seemed damning.",
        followup: "But look closer at those 28 trials. IÂ² was <strong>0%</strong>â€”no heterogeneity. A different problem lurked: the trials were tiny (many with <50 patients), measured different populations (burns, trauma, surgery), and many were decades old. The <strong>SAFE trial</strong> (6,997 patients, 2004) finally answered the question: albumin was <strong>equivalent to saline</strong>â€”no benefit, no harm. The pooled estimate from 28 small, disparate trials had been an artifact of random variation in underpowered studies, not a real signal. Consistency (low IÂ²) doesn't guarantee truth."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "âš–ï¸", title: "ì‹œë‚˜ë¦¬ì˜¤: ì¼ê´€ë˜ì§€ë§Œ ê´€ë ¨ ì¦ê±°",
        xp: 25,
        scenario: "A meta-analysis pools 12 small trials (total n=400) with IÂ² = 5%â€”very low heterogeneity. The pooled effect is OR 0.50 (dramatic benefit), statistically significant. A colleague argues this deserves HIGH certainty because results are 'beautifully consistent.'",
        question: "What concern should you raise?",
        options: [
          { letter: "A", text: "Noneâ€”low IÂ² means high certainty for inconsistency", correct: false },
          { letter: "B", text: "Low IÂ² in small trials may reflect consistent bias, not consistent truth", correct: true },
          { letter: "C", text: "IÂ² = 5% is too low and suggests publication bias", correct: false },
          { letter: "D", text: "The pooled estimate is too dramatic to be real", correct: false }
        ],
        feedback: {
          correct: "ì˜³ì€! ì¼ê´€ë˜ê³  ê·¹ì ì¸ ê²°ê³¼ê°€ ë‚˜ì˜¤ëŠ” ì†Œê·œëª¨ ì‹¤í—˜ì€ ì˜ì‹¬ì„ ë¶ˆëŸ¬ì¼ìœ¼í‚¬ ê²ƒì…ë‹ˆë‹¤. ê·¸ë“¤ì€ ë™ì¼í•œ í¸ê²¬(ì¶œíŒ í¸ê²¬, ìœ ì‚¬í•œ ê²°í•¨ì´ ìˆëŠ” ë°©ë²•)ì„ ê³µìœ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì•Œë¶€ë¯¼ ë©”íƒ€ ë¶„ì„ì—ì„œëŠ” 28ê°œ ì‹œí—˜ì—ì„œ IÂ²ê°€ 0%ì— ê°€ê¹Œì› ì§€ë§Œ ëŒ€ê·œëª¨ SAFE ì‹œí—˜ì—ì„œëŠ” ë¬´íš¨ íš¨ê³¼ê°€ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì†Œê·œëª¨ ì‹œí—˜ì˜ ì¼ê´€ì„± â‰  ì§„ì‹¤.",
          incorrect: "Low heterogeneity among small, potentially biased trials can be misleading. If all trials share similar biases (publication bias, poor methods), they'll show consistently biased results. The albumin case proves this: IÂ² was low, but the effect was an artifact."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "Understanding IÂ² Thresholds",
        stats: [
          { value: "0-25%", label: "Low heterogeneity" },
          { value: "25-50%", label: "Moderate" },
          { value: "50-75%", label: "Substantial" },
          { value: ">75%", label: "Considerable" }
        ],
        caption: "ê·¸ëŸ¬ë‚˜ IÂ²ë§Œìœ¼ë¡œëŠ” ë‹¤ìš´ê·¸ë ˆì´ë“œë¥¼ ê²°ì •í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì˜ˆì¸¡ êµ¬ê°„ê³¼ ì„ìƒì  ì˜ë¯¸ê°€ ë” ì¤‘ìš”í•©ë‹ˆë‹¤."
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Inconsistency Assessment Checklist",
        items: [
          "Calculate IÂ² and tauÂ² â€” but don't stop there",
          "Examine prediction interval â€” does it cross clinically important thresholds?",
          "ì—°êµ¬ ê°„ ê²¹ì¹˜ëŠ” ì‹ ë¢° êµ¬ê°„ì„ ì°¾ìœ¼ì„¸ìš”",
          "Check if heterogeneity can be explained by credible subgroups",
          "Consider if small trials are driving inconsistency (vs. large trial disagreement)"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "GRADE ë¶ˆì¼ì¹˜ì— ëŒ€í•´ ì˜ˆì¸¡ êµ¬ê°„ì´ IÂ²ë³´ë‹¤ ë” ì¤‘ìš”í•œ ì´ìœ ëŠ” ë¬´ì—‡ì…ë‹ˆê¹Œ? í‰ê°€?",
        options: [
          { text: "Prediction intervals are easier to calculate", correct: false },
          { text: "Prediction intervals tell us what effect a future study might show", correct: true },
          { text: "IÂ² is only valid for large meta-analyses", correct: false },
          { text: "Prediction intervals account for publication bias", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. The prediction interval says: 'The next study from this distribution of effects will probably fall in this range.' If that range includes harm while the pooled estimate shows benefit, we're deeply uncertain about what will happen to the next patient.",
          incorrect: "The prediction interval captures uncertainty about what future studies (or the next patient) might experience. IÂ² tells us whether heterogeneity exists; the prediction interval tells us whether it matters clinically."
        }
      }}
    ]
  },
  {
    id: 5, title: "Indirectness", subtitle: "ì˜ëª»ëœ ì§ˆë¬¸, ì˜ëª»ëœ ëŒ€ë‹µ", xp: 170,
    slides: [
      { type: "title", theme: "purple-bg", content: { title: "Indirectness", subtitle: "ì„¸ ë²ˆì§¸ ì˜ì—­: ì´ ì¦ê±°ê°€ ì‹¤ì œ ì§ˆë¬¸ì— ë‹µí•©ë‹ˆê¹Œ?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Recognize four types of indirectness: population, intervention, comparator, outcome",
          "Understand why surrogate outcomes mislead",
          "Apply indirectness assessment to real scenarios",
          "Decide when evidence is too indirect to trust"
        ],
        tip: "ì˜ëª»ëœ ì§ˆë¬¸ì— ëŒ€í•œ ê°€ì¥ ì¢‹ì€ ì¦ê±°ëŠ” ì—¬ì „íˆ ì˜ëª»ëœ ëŒ€ë‹µì…ë‹ˆë‹¤."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "CAST ì¬ì•™", title: "ë…¼ë¦¬ì  ì¹˜ë£Œë¡œ ì¸í•´ 50,000ëª… ì‚¬ë§",
        text: "After a heart attack, arrhythmias predict death. <strong>Encainide and flecainide</strong> suppressed arrhythmias on ECG beautifullyâ€”85% reduction in premature ventricular contractions. The FDA approved them. Cardiologists prescribed them to hundreds of thousands of post-MI patients. The logic was irresistible: dangerous arrhythmias â†’ sudden death; suppress arrhythmias â†’ prevent death.",
        followup: "The CAST trial was designed to confirm what everyone already 'knew.' Instead, it delivered a verdict that stunned cardiology. Patients on anti-arrhythmic drugs died at <strong>3.6 times the rate</strong> of placebo. The trials were stopped early for harm. An estimated <strong>50,000 Americans died</strong> from drugs that perfectly fixed the surrogate (ECG) while causing the outcome (death). The evidence for arrhythmia suppression was HIGH certaintyâ€”but it was indirect evidence for mortality. That indirectness killed 50,000 people."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“ˆ", title: "ì‹œë‚˜ë¦¬ì˜¤: ì™„ë²½í•œ ëŒ€ë¦¬ì",
        xp: 25,
        scenario: "ìƒˆë¡œìš´ ë‹¹ë‡¨ë³‘ ì•½ë¬¼ì´ ê·¹ì ì¸ HbA1c ê°ì†Œë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤(ìœ„ì•½ ëŒ€ë¹„ 1.5% ê°œì„ ). íšŒì‚¬ëŠ” HbA1cê°€ ì‹¬í˜ˆê´€ ê²°ê³¼ì— ëŒ€í•œ 'ê²€ì¦ëœ ëŒ€ìš©ë¬¼'ì´ê¸° ë•Œë¬¸ì— CV í˜œíƒì˜ í™•ì‹¤ì„±ì€ ì¤‘ê°„ ìˆ˜ì¤€ìœ¼ë¡œ í‰ê°€ë˜ì–´ì•¼ í•œë‹¤ê³  ì£¼ì¥í•©ë‹ˆë‹¤. CV ê²°ê³¼ ì„ìƒì‹œí—˜ì€ ì•„ì§ ì—†ìŠµë‹ˆë‹¤.",
        question: "ì‹¬í˜ˆê´€ í˜œíƒì— ëŒ€í•œ í™•ì‹¤ì„±ì„ ì–´ë–»ê²Œ í‰ê°€í•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "MODERATEâ€”HbA1c is a validated surrogate", correct: false },
          { letter: "B", text: "HIGHâ€”1.5% reduction is clinically meaningful", correct: false },
          { letter: "C", text: "LOW or VERY LOWâ€”downgrade for indirectness (surrogate outcome)", correct: true },
          { letter: "D", text: "Cannot rate until CV trials are conducted", correct: false }
        ],
        feedback: {
          correct: "Correct! ACCORD showed intensive HbA1c lowering <em>increased</em> deaths. Rosiglitazone lowered HbA1c while increasing heart attacks. Surrogate outcomes require downgrading for indirectness, no matter how 'validated' they seem. Patient-important outcomes are required for high certainty.",
          incorrect: "CAST drugs fixed ECGs while tripling deaths. ACCORD lowered HbA1c while increasing mortality. 'Validated surrogates' have repeatedly failed. GRADE requires downgrading one or two levels when only surrogate outcomes are measured."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ê³¨ë°€ë„ ë°°ë°˜", title: "When Stronger Bones Broke More",
        text: "Sodium fluoride increased bone mineral density dramaticallyâ€”<strong>8% improvement per year</strong>. For osteoporosis, this seemed like a miracle. Bone density was the accepted surrogate for fracture risk. Higher density = fewer fractures. The math seemed inescapable.",
        followup: "Then came the trials measuring actual fractures. Sodium fluoride <strong>increased</strong> fracture rates despite improving bone density. The explanation: fluoride created dense but brittle boneâ€”like adding quantity without quality. The surrogate (density) moved in the right direction while the patient-important outcome (fractures) moved in the wrong direction. This case became a landmark in surrogate outcome skepticism."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ¦´", title: "Scenario: The Bone Drug Decision",
        xp: 25,
        scenario: "A new osteoporosis drug shows 4% improvement in bone mineral density at 2 years. The company presents evidence of reduced fractures, but the fracture trials used a different formulation and dose than the one being approved. The FDA asks you to rate certainty of fracture benefit for the approved formulation.",
        question: "What indirectness concern applies?",
        options: [
          { letter: "A", text: "No concernâ€”bone density is a validated surrogate", correct: false },
          { letter: "B", text: "ê°„ì ‘ì  ê°œì… - ë‹¤ì–‘í•œ ì œí˜•/ìš©ëŸ‰ì´ í…ŒìŠ¤íŠ¸ë˜ì—ˆìŠµë‹ˆë‹¤.", correct: true },
          { letter: "C", text: "Indirect for populationâ€”fracture trials may have different patients", correct: false },
          { letter: "D", text: "ê²°ê³¼ì— ëŒ€í•œ ê°„ì ‘ì ì¸ - ê³¨ì ˆì€ ë°œìƒí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. í™˜ìì—ê²Œ ì¤‘ìš”í•¨", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! ê°„ì ‘ì„±ì€ ê°œì…, ëª¨ì§‘ë‹¨, ë¹„êµì ë˜ëŠ” ê²°ê³¼ì— ì ìš©ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ ê³¨ì ˆì— ëŒ€í•´ í…ŒìŠ¤íŠ¸ëœ ì œí˜•/ìš©ëŸ‰ì€ ìŠ¹ì¸ëœ ê²ƒê³¼ ë‹¤ë¦…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë™ë“±í•˜ë‹¤ê³  ê°€ì •í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì´ë¥¼ ìœ„í•´ì„œëŠ” ê°„ì ‘ì ì¸ ê°œì…ì„ ìœ„í•´ í•˜í–¥ ì¡°ì •ì´ í•„ìš”í•©ë‹ˆë‹¤.",
          incorrect: "ê³¨ì ˆ ì¦ê±°ëŠ” ë‹¤ë¥¸ ì œí˜•ê³¼ ìš©ëŸ‰ì—ì„œ ë‚˜ì˜µë‹ˆë‹¤. ìš°ë¦¬ëŠ” X ìš©ëŸ‰ì˜ ì•½ë¬¼ Aì—ì„œ ìš©ëŸ‰ Yì˜ ì•½ë¬¼ Aë¡œ ì¶”ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ê°œì… ê°„ì ‘ì„±ì…ë‹ˆë‹¤. ì¦ê±°ëŠ” ìš°ë¦¬ê°€ ìŠ¹ì¸í•˜ëŠ” ê²ƒì„ ì§ì ‘ í…ŒìŠ¤íŠ¸í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "ë¡œì‹œê¸€ë¦¬íƒ€ì¡´ ê³„ì‚°", title: "FDA's 2.5 Million Patient Gamble",
        text: "In 2007, cardiologist Steven Nissen published a meta-analysis showing rosiglitazone (Avandia) increased heart attacks by <strong>43%</strong>. The drug had been prescribed to millions based on glucose control. But no large outcome trial had ever been required.",
        followup: "The FDA's logic had been: diabetes causes heart disease â†’ better glucose control should prevent it. That's <strong>indirectness</strong>â€”assuming a chain of causation without testing the final link. The FDA estimated rosiglitazone caused <strong>83,000 excess heart attacks</strong> before restrictions were imposed. The European Medicines Agency suspended it entirely. A drug approved on indirect evidence had harmed more patients than it helped."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ’Š", title: "ì‹œë‚˜ë¦¬ì˜¤: ì¼ëŒ€ì¼ ê²©ì°¨",
        xp: 25,
        scenario: "ì•½ë¬¼ Aë¥¼ ë¹„êµí•´ì•¼ í•©ë‹ˆë‹¤. ê·€í•˜ì˜ ì§€ì¹¨ì— ëŒ€í•œ ì•½ B. ì¼ëŒ€ì¼ ì¬íŒì€ ì¡´ì¬í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. 10ë…„ ê°„ê²©ìœ¼ë¡œ ì„œë¡œ ë‹¤ë¥¸ ëª¨ì§‘ë‹¨ì„ ëŒ€ìƒìœ¼ë¡œ ì‹¤ì‹œí•œ ë³„ë„ì˜ ì‹œí—˜ì—ì„œ ì–»ì€ ì•½ë¬¼ A ëŒ€ ìœ„ì•½(RR 0.70) ë° ì•½ë¬¼ B ëŒ€ ìœ„ì•½(RR 0.65).",
        question: "What type of indirectness applies?",
        options: [
          { letter: "A", text: "No indirectnessâ€”we can compare the two placebo-controlled estimates", correct: false },
          { letter: "B", text: "Indirect comparisons require downgradingâ€”different trials break randomization", correct: true },
          { letter: "C", text: "ì§‘ë‹¨ì— ëŒ€í•œ ê°„ì ‘ ë¹„êµë§Œ ê°€ëŠ¥í•˜ë©° ë¹„êµëŠ” ì•„ë‹˜", correct: false },
          { letter: "D", text: "Network meta-analysis solves this indirectness", correct: false }
        ],
        feedback: {
          correct: "Correct! Comparing across trials breaks randomization. Drug A's trial may have sicker patients, different background care, different outcome definitions. The RR difference (0.70 vs. 0.65) may reflect trial differences, not drug differences. GRADE calls this 'indirect comparison' and requires downgrading.",
          incorrect: "ê°„ì ‘ ë¹„êµëŠ” ì§ì ‘ ë¹„êµ ì‹œí—˜ê³¼ ê·¼ë³¸ì ìœ¼ë¡œ ë‹¤ë¦…ë‹ˆë‹¤. ì•½ë¬¼ A ëŒ€ ìœ„ì•½(ì‹œí—˜ 1), ì•½ë¬¼ B ëŒ€ ìœ„ì•½(ì‹œí—˜ 2)ì„ ë¹„êµí•  ë•Œ ì‹œí—˜ ê°„ì˜ ì°¨ì´ëŠ” í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì†Œê°€ ë©ë‹ˆë‹¤. ë„¤íŠ¸ì›Œí¬ ë©”íƒ€ ë¶„ì„ì€ ë„ì›€ì´ ë˜ì§€ë§Œ ì´ëŸ¬í•œ ê°„ì ‘ì ì¸ ë¶€ë¶„ì„ ì œê±°í•˜ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ì˜¤ì…€íƒ€ë¯¸ë¹„ë¥´ ì™¸ì‚½", title: "ì‹¤í—˜ì‹¤ì—ì„œ ì„ìƒê¹Œì§€, ê±°ì§“ë§",
        text: "Tamiflu (oseltamivir) was approved based on trials showing it reduced <strong>symptom duration by 21 hours</strong> in otherwise healthy adults. When pandemic flu threatened, governments extrapolated: if it shortens symptoms, it must prevent complications. If it works in healthy adults, it must work in high-risk patients.",
        followup: "Neither extrapolation was supported. Trials in <strong>high-risk patients</strong> (the ones who actually need protection) showed no benefit. Trials measuring <strong>hospitalizations and complications</strong> (the outcomes that matter) were never conductedâ€”or never published. The Â£473 million UK stockpile was based on indirect evidence: wrong population (healthy, not high-risk), wrong outcome (symptoms, not complications). The Cochrane review downgraded certainty for both types of indirectness."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ¥", title: "ì‹œë‚˜ë¦¬ì˜¤: ì¸êµ¬ ì™¸ì‚½",
        xp: 25,
        scenario: "ì¹˜ë£ŒëŠ” ë…¸ì¸ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ì‹œí—˜ì—ì„œ ì´ì ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ë™ë°˜ì§ˆí™˜ì´ ì—†ëŠ” 18~65ì„¸. ê·€í•˜ì˜ ì§€ì¹¨ì€ ì—¬ëŸ¬ ë™ë°˜ì§ˆí™˜ì´ ìˆëŠ” ë…¸ì¸ ìš”ì–‘ì› ê±°ì£¼ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•©ë‹ˆë‹¤. ì´ ì¹˜ë£Œë²•ì€ ë…¸ì¸ë“¤ì—ê²Œ ë‹¤ë¥´ê²Œ ì‘ìš©í•  ìƒë¬¼í•™ì ìœ¼ë¡œ ê·¸ëŸ´ë“¯í•œ ì´ìœ ê°€ ìˆìŠµë‹ˆë‹¤(ëŒ€ì‚¬ ë³€í™”, ì•½ë¬¼ ìƒí˜¸ ì‘ìš©).",
        question: "ê°„ì ‘ì„±ì„ ì´ìœ ë¡œ ë‹¤ìš´ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Noâ€”age alone doesn't require downgrading", correct: false },
          { letter: "B", text: "Yesâ€”biological reasons for different effects in target population require downgrading", correct: true },
          { letter: "C", text: "Only if the elderly show different baseline risk", correct: false },
          { letter: "D", text: "ëŒ€ì‹  ì›ë˜ ì‹œí—˜ì˜ í•˜ìœ„êµ° ë¶„ì„ì„ ì‚¬ìš©í•˜ì‹­ì‹œì˜¤", correct: false }
        ],
        feedback: {
          correct: "Correct! When there are biological reasons to expect different effects in the target population, downgrade for indirectness. Tamiflu worked in healthy adults but the question was about sick elderly patientsâ€”a population with very different biology. Extrapolation across populations with different biology requires downgrading.",
          incorrect: "Population indirectness applies when the trial population differs meaningfully from the guideline population, especially when there are biological reasons to expect different effects. Elderly with comorbidities may metabolize drugs differently, have drug interactions, and have different risk-benefit profiles."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "í† ë¥´ì„¸íŠ¸ë¼í• ë¹„ê·¹", title: "$800 Million Buried in 82 Days",
        text: "Pfizer's torcetrapib was the most expensive drug development in historyâ€”<strong>$800 million</strong> over 15 years. It dramatically raised HDL cholesterol (the 'good' cholesterol) by 72%. The logic was irresistible: low HDL causes heart disease â†’ raising HDL should prevent it. Phase 2 trials showed perfect surrogate outcomes. Pfizer began building manufacturing plants before Phase 3 completed.",
        followup: "The ILLUMINATE trial enrolled <strong>15,067 patients</strong>. After just 82 days, the Data Safety Monitoring Board stopped the trial. Torcetrapib increased death by <strong>58%</strong> and cardiovascular events by 25%. The drug that perfectly improved HDL was killing patients. Pfizer's stock dropped $21 billion in one day. The entire HDL-raising hypothesisâ€”built on decades of surrogate evidenceâ€”collapsed. No HDL-raising drug has ever prevented cardiovascular events. Surrogate perfection masked clinical catastrophe."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ’”", title: "ì‹œë‚˜ë¦¬ì˜¤: ì™„ë²½í•œ ëŒ€ë¦¬ì",
        xp: 25,
        scenario: "ì‹ ì•½ì€ HDL ì½œë ˆìŠ¤í…Œë¡¤ì„ ì´ì „ ì•½í’ˆë³´ë‹¤ 80%ë‚˜ ì¦ê°€ì‹œí‚µë‹ˆë‹¤. íšŒì‚¬ëŠ” ë‹¤ìŒê³¼ ê°™ì´ ì£¼ì¥í•©ë‹ˆë‹¤: 'ìš°ë¦¬ëŠ” HDLì´ ì‹¬ì¥ë³‘ì„ ì¸ê³¼ì ìœ¼ë¡œ ì˜ˆë°©í•œë‹¤ëŠ” ê²ƒì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ì´ ì•½ì€ ìˆ˜ë°±ë§Œ ëª…ì˜ ìƒëª…ì„ êµ¬í•  ê²ƒì…ë‹ˆë‹¤.' HDL ê°œì„ ë§Œì„ í† ëŒ€ë¡œ ì‹ ì† ìŠ¹ì¸ì„ ìš”ì²­í•©ë‹ˆë‹¤.",
        question: "Based on the torcetrapib experience, what certainty applies to cardiovascular benefit?",
        options: [
          { letter: "A", text: "HIGHâ€”HDL is a validated causal risk factor", correct: false },
          { letter: "B", text: "MODERATEâ€”strong mechanistic support warrants some confidence", correct: false },
          { letter: "C", text: "LOW to VERY LOWâ€”HDL-raising has consistently failed to translate to outcomes", correct: true },
          { letter: "D", text: "Cannot rate until mechanism is fully understood", correct: false }
        ],
        feedback: {
          correct: "Correct! Torcetrapib, dalcetrapib, evacetrapibâ€”every HDL-raising drug has failed to prevent cardiovascular events despite dramatic surrogate improvement. The entire drug class teaches us: manipulating a surrogate doesn't guarantee clinical benefit. Evidence from this class requires serious downgrading for indirectness.",
          incorrect: "ë‹¤ì–‘í•œ HDL ìƒìŠ¹ ì•½ë¬¼ì€ ì‹¬í˜ˆê´€ í˜œíƒ(ë˜ëŠ” ì‹¤ì œ ìœ í•´ì„±) ì—†ì´ ê·¹ì ì¸ ëŒ€ë¦¬ ê°œì„ ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ì´ ì•½ë¬¼ ê³„ì—´ì€ HDL ì¡°ì‘ì´ ê²°ê³¼ë¡œ ì´ì–´ì§€ì§€ ì•ŠëŠ”ë‹¤ëŠ” ê²ƒì„ í™•ì‹¤í•˜ê²Œ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ì•½ë¦¬í•™ì ìœ¼ë¡œ ì¡°ì‘í•˜ë©´ ëŒ€ë¦¬ê´€ê³„ê°€ ìœ ì§€ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ì í˜ˆêµ¬ìƒì„±ì¸ì ì—­ì „", title: "When Better Blood Was Worse",
        text: "ë¹ˆí˜ˆì´ ìˆëŠ” ì•” í™˜ìëŠ” í”¼ë¡œ, ì‡ ì•½, í˜¸í¡ ê³¤ë€ ë“± ë”ì°í•œ ëŠë‚Œì„ ë°›ìŠµë‹ˆë‹¤. ì í˜ˆêµ¬ìƒì„±ì¸ì ìê·¹ì œ(ESA)ëŠ” í—¤ëª¨ê¸€ë¡œë¹ˆì„ ì¦ê°€ì‹œì¼œ í™˜ìì˜ ê¸°ë¶„ì„ ì¢‹ê²Œ ë§Œë“¤ì—ˆìŠµë‹ˆë‹¤. ì‚¶ì˜ ì§ˆì´ í–¥ìƒë˜ì—ˆìŠµë‹ˆë‹¤. FDAëŠ” ì•” ê´€ë ¨ ë¹ˆí˜ˆì— ëŒ€í•œ ESAë¥¼ ìŠ¹ì¸í–ˆìŠµë‹ˆë‹¤. ì¢…ì–‘ ì „ë¬¸ì˜ë“¤ì€ ì´ë¥¼ ê´‘ë²”ìœ„í•˜ê²Œ ì²˜ë°©í–ˆìŠµë‹ˆë‹¤.",
        followup: "Then meta-analyses examining <strong>mortality</strong> emerged. Despite improving hemoglobin (surrogate) and quality of life, ESAs increased <strong>death by 10%</strong> and thromboembolic events by 57%. Patients felt better while dying faster. The FDA added a black box warning. ESA use plummeted. The lesson: even quality-of-life improvements can coexist with mortality harm. Surrogates that patients can feel aren't necessarily safer surrogates."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ©¸", title: "Scenario: The Quality of Life Surrogate",
        xp: 25,
        scenario: "ì¹˜ë£Œë¥¼ í†µí•´ ì¦ìƒ ëŒ€ë¦¬ íš¨ê³¼ê°€ ê·¹ì ìœ¼ë¡œ ê°œì„ ë©ë‹ˆë‹¤. ì¦‰, í™˜ìì˜ ê¸°ë¶„ì´ í›¨ì”¬ ì¢‹ì•„ì§€ê³ , ì—ë„ˆì§€ê°€ í–¥ìƒë˜ë©°, ì¼ìƒ ê¸°ëŠ¥ì´ í–¥ìƒë©ë‹ˆë‹¤. ì‚¶ì˜ ì§ˆ ì ìˆ˜ê°€ 40% í–¥ìƒë©ë‹ˆë‹¤. ì‚¬ë§ë¥  ë°ì´í„°ê°€ ì—†ìŠµë‹ˆë‹¤. íšŒì‚¬ ì¸¡ì€ ì´ê²ƒì´ ë†’ì€ í™•ì‹¤ì„±ì„ ë°›ì•„ì•¼ í•˜ëŠ” 'í™˜ì ì¤‘ì‹¬ ê·¼ê±°'ë¼ê³  ì£¼ì¥í•œë‹¤.",
        question: "What certainty applies to net clinical benefit?",
        options: [
          { letter: "A", text: "HIGHâ€”patient-reported outcomes matter most", correct: false },
          { letter: "B", text: "MODERATEâ€”quality of life is a valid outcome", correct: false },
          { letter: "C", text: "LOWâ€”improved symptoms can coexist with mortality harm; need outcome data", correct: true },
          { letter: "D", text: "íŠ¹ì • ì¡°ê±´ì— ë”°ë¼ ë‹¤ë¥´ë‹¤", correct: false }
        ],
        feedback: {
          correct: "ë§ë‹¤! ESAëŠ” ì‚¶ì˜ ì§ˆì„ í–¥ìƒì‹œí‚¤ëŠ” ë™ì‹œì— ì‚¬ë§ë¥ ì„ 10% ì¦ê°€ì‹œì¼°ìŠµë‹ˆë‹¤. ê¸°ë¶„ì´ ì¢‹ì•„ì§„ë‹¤ëŠ” ê²ƒì´ ê¸°ë¶„ì´ ì¢‹ì•„ì§„ë‹¤ëŠ” ê²ƒê³¼ëŠ” ë‹¤ë¦…ë‹ˆë‹¤. ì¦ìƒ ê°œì„ ì€ ìƒì¡´ì— ëŒ€í•œ í•´ë¡œì›€ì„ ê°€ë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. GRADEì—ì„œëŠ” ì¦ìƒ ê²°ê³¼ê°€ ê¸ì •ì ì´ë”ë¼ë„ ì‚¬ë§ë¥ /ì‹¬ê°í•œ ìœ„í•´ ë°ì´í„°ê°€ ì—†ëŠ” ê²½ìš° ê°„ì ‘ì ì¸ ì´ìœ ë¡œ ë‹¤ìš´ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆë‹¤.",
          incorrect: "ESA ê²½í—˜ì€ í™˜ìê°€ ë” ë¹¨ë¦¬ ì‚¬ë§í•˜ë©´ì„œ ê·¹ì ìœ¼ë¡œ ê¸°ë¶„ì´ ì¢‹ì•„ì§ˆ ìˆ˜ ìˆìŒì„ ì…ì¦í•©ë‹ˆë‹¤. ì‚¶ì˜ ì§ˆ í–¥ìƒì€ í˜„ì‹¤ì ì´ì§€ë§Œ ìˆœ ì´ìµì„ ë³´ì¥í•˜ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ì‚¬ë§ë¥ ê³¼ ì‹¬ê°í•œ ë¶€ì‘ìš© ë°ì´í„°ê°€ ì—†ìœ¼ë©´ ì¦ìƒ ê°œì„ ê³¼ ê´€ê³„ì—†ì´ í™•ì‹¤ì„±ì´ ë‚®ê²Œ ìœ ì§€ë˜ì–´ì•¼ í•©ë‹ˆë‹¤."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Four Types of Indirectness",
        items: [
          "Population â€” Trial patients differ from guideline patients",
          "Intervention â€” Trial intervention differs from recommendation",
          "ë¹„êµ â€” ì‹œí—˜ ë¹„êµëŠ” ì„ìƒ ì§ˆë¬¸ê³¼ ë‹¤ë¦…ë‹ˆë‹¤",
          "Outcome â€” Trial measures surrogates instead of patient-important outcomes"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "ë¶€ì •ë§¥ ì–µì œì— ëŒ€í•œ ì™„ë²½í•œ ì¦ê±°ì—ë„ ë¶ˆêµ¬í•˜ê³  CAST í•­ë¶€ì •ë§¥ì œê°€ 50,000ëª…ì˜ ëª©ìˆ¨ì„ ì•—ì•„ê°„ ì´ìœ ëŠ” ë¬´ì—‡ì…ë‹ˆê¹Œ?",
        options: [
          { text: "ì‹œí—˜ì€ ë‹¤ìŒê³¼ ê°™ìŠµë‹ˆë‹¤. ì‚¬ê¸°ì„±", correct: false },
          { text: "ëŒ€ë¦¬ëª¨(ë¶€ì •ë§¥ ì–µì œ)ê°€ ê²°ê³¼(ì‚¬ë§)ë¥¼ ì˜ˆì¸¡í•˜ì§€ ëª»í–ˆìŠµë‹ˆë‹¤.", correct: true },
          { text: "Doctors used the drugs incorrectly", correct: false },
          { text: "í™˜ì ëª¨ì§‘ë‹¨ì´ ì„ìƒì‹œí—˜ê³¼ ë‹¬ëìŠµë‹ˆë‹¤", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. The evidence for arrhythmia suppression was impeccable. The drugs did exactly what they were supposed to do on ECG. But suppressing arrhythmias didn't prevent deathâ€”it caused it through different mechanisms. This is indirectness for outcome: measuring surrogates instead of patient-important endpoints.",
          incorrect: "The trials were well-conducted. The drugs worked perfectly for their intended purpose (suppressing arrhythmias). The problem was indirectness: arrhythmia suppression (the measured outcome) didn't predict mortality (the outcome that matters). Surrogate outcomes can mislead even when evidence is methodologically perfect."
        }
      }}
    ]
  },
  {
    id: 6, title: "Imprecision", subtitle: "ë°ì´í„°ê°€ ì¶©ë¶„í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤", xp: 150,
    slides: [
      { type: "title", theme: "dark", content: { title: "Imprecision", subtitle: "ë„¤ ë²ˆì§¸ ì˜ì—­: ì¶©ë¶„í•©ë‹ˆê¹Œ? ë°ì´í„°?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand why wide confidence intervals undermine certainty",
          "Apply the 'Optimal Information Size' concept",
          "Recognize when 95% CIs cross clinical decision thresholds",
          "Decide when to downgrade for imprecision"
        ],
        tip: "Statistical significance is not enoughâ€”confidence intervals must be clinically narrow."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "PROWESS Mirage", title: "When 1,690 Deaths Weren't Enough",
        text: "In 2001, Eli Lilly's drotrecogin alfa (Xigris) was approved for severe sepsis based on the PROWESS trial. The trial showed <strong>6.1% absolute mortality reduction</strong>â€”from 30.8% to 24.7%. The FDA approved it despite concerns. Cost: $6,800 per treatment. Lilly projected billions in revenue.",
        followup: "Then came the confidence interval analysis. The 95% CI for mortality reduction ranged from <strong>1.9% to 10.4%</strong>. The benefit might be huge (10.4%) or clinically marginal (1.9%). With a drug this expensive and risky (increased bleeding), that uncertainty mattered. Subsequent trials failed to replicate PROWESS. The ADDRESS trial in less severe sepsis showed <strong>no benefit</strong>. The PROWESS-SHOCK trial confirmed <strong>no mortality benefit</strong> even in severe sepsis. In 2011, Lilly withdrew Xigris worldwide. A decade of use, billions spent, and the imprecision had warned us from the start."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“", title: "Scenario: The Wide Confidence Interval",
        xp: 25,
        scenario: "A trial shows a new treatment reduces mortality from 20% to 14%â€”a 6% absolute reduction (RR 0.70, p=0.04). However, the 95% CI for absolute risk reduction is 0.5% to 11.5%. The lower bound (0.5%) is below your minimum clinically important difference of 2%.",
        question: "ë¶€ì •í™•ì„±ìœ¼ë¡œ ì¸í•´ ë‹¤ìš´ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "ì•„ë‹ˆì˜¤ - ê²°ê³¼ëŠ” í†µê³„ì ìœ¼ë¡œ ìœ ì˜ë¯¸í•©ë‹ˆë‹¤", correct: false },
          { letter: "B", text: "Noâ€”the point estimate shows clinically meaningful benefit", correct: false },
          { letter: "C", text: "Yesâ€”the CI includes clinically unimportant effects", correct: true },
          { letter: "D", text: "ì˜ˆ - CIì—ëŠ” í”¼í•´ê°€ í¬í•¨ë©ë‹ˆë‹¤", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! í†µê³„ì  ìœ ì˜ì„±ì€ ì„ìƒì  ì •í™•ì„±ì„ ë³´ì¥í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì‹¤ì œ íš¨ê³¼ê°€ 0.5%(ìµœì†Œ ì¤‘ìš”í•œ ì°¨ì´ ì•„ë˜)ë§Œí¼ ì‘ì„ ìˆ˜ ìˆë‹¤ë©´ ìì‹  ìˆê²Œ ì¹˜ë£Œë¥¼ ê¶Œì¥í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. CIê°€ nullë¿ë§Œ ì•„ë‹ˆë¼ ì„ìƒ ê²°ì • ì„ê³„ê°’ì„ ì´ˆê³¼í•˜ëŠ” ê²½ìš° GRADEë¥¼ ë‹¤ìš´ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆë‹¤.",
          incorrect: "CIì˜ í•˜í•œ(0.5%)ì´ ì„ìƒì ìœ¼ë¡œ ì¤‘ìš”í•œ ìµœì†Œ ì°¨ì´(2%) ì•„ë˜ë¡œ ë–¨ì–´ì§‘ë‹ˆë‹¤. ì´ëŠ” ì‹¤ì œ íš¨ê³¼ê°€ ì¹˜ë£Œ ë¹„ìš©/ìœ„í—˜ì„ ì •ë‹¹í™”í•˜ê¸°ì—ëŠ” ë„ˆë¬´ ì‘ì„ ìˆ˜ ìˆìŒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. í†µê³„ì  ìœ ì˜ì„±ë§Œìœ¼ë¡œëŠ” ì¶©ë¶„í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. CIëŠ” ë†’ì€ í™•ì‹¤ì„±ì„ ìœ„í•´ ì„ìƒì ìœ¼ë¡œ ì¤‘ìš”í•˜ì§€ ì•Šì€ íš¨ê³¼ë¥¼ ì œì™¸í•´ì•¼ í•©ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ìµœì ì˜ ì •ë³´ í¬ê¸°", title: "Why Sample Size Matters for Certainty",
        text: "Consider a simple thought experiment: You flip a coin 4 times and get 3 heads (75%). Would you bet your house that the coin is biased? Now flip 1,000 times and get 750 heads. Same proportionâ€”but utterly different certainty.",
        followup: "GRADE uses the <strong>Optimal Information Size (OIS)</strong> concept. This asks: 'How many events would a single adequately-powered trial need to reliably detect this effect?' If your meta-analysis has fewer events than the OIS, you're in the position of the person who flipped 4 coinsâ€”the proportion might be right, but you don't have enough data to be confident. For mortality outcomes, OIS is typically <strong>200-400 events</strong>. Many celebrated meta-analyses have far fewer."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ”¢", title: "ì‹œë‚˜ë¦¬ì˜¤: ì†Œê·œëª¨ ë©”íƒ€ ë¶„ì„",
        xp: 25,
        scenario: "A meta-analysis of 8 RCTs (total n=1,200) shows a treatment prevents death with RR 0.65 (95% CI 0.45-0.95). The total number of deaths across all trials is 87. The pooled estimate is statistically significant. Your OIS calculation suggests 300 events would be needed.",
        question: "ë¶€ì •í™•ì„±ìœ¼ë¡œ ì¸í•´ ë‹¤ìš´ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Noâ€”statistical significance means adequate precision", correct: false },
          { letter: "B", text: "Noâ€”8 RCTs provide adequate power through meta-analysis", correct: false },
          { letter: "C", text: "Yesâ€”87 events is well below the OIS of 300", correct: true },
          { letter: "D", text: "CIê°€ êµì°¨í•˜ëŠ” ê²½ìš°ì—ë§Œ 1.0", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! 87ê°œì˜ ì´ë²¤íŠ¸ì™€ 300ê°œì˜ OISëŠ” í•„ìš”í•œ ì •ë³´ê°€ 30% ë¯¸ë§Œì„ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì¶”ì •ì´ ë§ì„ ìˆ˜ë„ ìˆì§€ë§Œ, ìš°ë¦¬ëŠ” ë¬´ì‘ìœ„ ë³€í™”ê°€ ê·¹ì ìœ¼ë¡œ ë³´ì´ì§€ë§Œ ì‹ ë¢°í•  ìˆ˜ ì—†ëŠ” íš¨ê³¼ë¥¼ ìƒì„±í•  ìˆ˜ ìˆëŠ” 'ì‘ì€ í‘œë³¸' ì˜ì—­ì— ìˆìŠµë‹ˆë‹¤. ì´ë²¤íŠ¸ê°€ OISë³´ë‹¤ í›¨ì”¬ ë‚®ì„ ê²½ìš° GRADEë¥¼ ë‹¤ìš´ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆë‹¤.",
          incorrect: "ë©”íƒ€ ë¶„ì„ì€ ë§ˆìˆ ì²˜ëŸ¼ ì •ë³´ë¥¼ ìƒì„±í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ 87ê°œì˜ ì´ë²¤íŠ¸ê°€ í¬í•¨ëœ 8ê°œì˜ ì†Œê·œëª¨ ì‹œí—˜ì€ 300ê°œì˜ ì´ë²¤íŠ¸ê°€ í¬í•¨ëœ ëŒ€ê·œëª¨ ì‹œí—˜ 1ê°œì™€ ê°™ì§€ ì•ŠìŠµë‹ˆë‹¤. í†µê³„ì  ìœ ì˜ì„±ì€ ì·¨ì•½í•  ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤. ì–´ëŠ ìª½ì´ë“  ëª‡ ê°€ì§€ ì‚¬ê±´ìœ¼ë¡œ ì¸í•´ ê²°ë¡ ì´ ë°”ë€” ìˆ˜ ìˆìŠµë‹ˆë‹¤. OISëŠ” ìƒ˜í”Œ ì í•©ì„±ì— ëŒ€í•œ í˜„ì‹¤ ì ê²€ì„ ì œê³µí•©ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "í•˜ì´ë“œë¡ì‹œì—í‹¸ ì „ë¶„ ë°˜ì „", title: "When 10,000 Patients Weren't Enough... Then Were",
        text: "Hydroxyethyl starch (HES) fluids were used for decades in critically ill patients. Early meta-analyses with few events showed possible benefit. Then came the large trials: <strong>6S trial (798 patients)</strong>, <strong>CHEST trial (7,000 patients)</strong>, <strong>CRISTAL trial (2,857 patients)</strong>.",
        followup: "The large trials showed HES <strong>increased mortality and kidney failure</strong>. The earlier 'positive' evidence had been impreciseâ€”confidence intervals that allowed for benefit also allowed for the substantial harm that large trials eventually detected. The European Medicines Agency suspended HES for critical illness. Imprecise evidence had allowed a harmful intervention to persist for years."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "âš ï¸", title: "Scenario: The Borderline Mortality Signal",
        xp: 25,
        scenario: "ë©”íƒ€ ë¶„ì„ì— ë”°ë¥´ë©´ ì¹˜ë£Œ ì‹œ ì‚¬ë§ì— ëŒ€í•œ RRì€ 1.25(95% CI 0.98-1.60)ì…ë‹ˆë‹¤. ê²°ê³¼ëŠ” 'í•´ë¥¼ ë¼ì¹˜ëŠ” ê²½í–¥ì´ ìˆì§€ë§Œ' í†µê³„ì ìœ¼ë¡œ ìœ ì˜ë¯¸í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ëŒ€ì•ˆì´ ì¡´ì¬í•˜ëŠ” ì¹˜ëª…ì ì´ì§€ ì•Šì€ ìƒíƒœì— ëŒ€í•´ ì´ ì¹˜ë£Œë²•ì„ ê¶Œì¥í• ì§€ ì—¬ë¶€ë¥¼ ê°€ì´ë“œë¼ì¸ì—ì„œ ê²°ì •í•´ì•¼ í•©ë‹ˆë‹¤.",
        question: "How should imprecision affect your recommendation?",
        options: [
          { letter: "A", text: "ì¹˜ë£ŒëŠ” ì•ˆì „í•©ë‹ˆë‹¤. CIì—ëŠ” 1.0ì´ í¬í•¨ë©ë‹ˆë‹¤.", correct: false },
          { letter: "B", text: "The treatment is harmfulâ€”point estimate shows 25% increase", correct: false },
          { letter: "C", text: "ìœ„í—˜ì— ëŒ€í•œ ì‹¬ê°í•œ ë¶ˆí™•ì‹¤ì„±â€”ìµœëŒ€ 60%ì˜ ì‚¬ë§ë¥  ì¦ê°€ì™€ ì¼ì¹˜í•˜ëŠ” CI", correct: true },
          { letter: "D", text: "Need more trials before any conclusion", correct: false }
        ],
        feedback: {
          correct: "Correct! The upper bound (1.60) represents a 60% mortality increase. For a non-fatal condition with alternatives, that possibility should drive decision-making. 'Not statistically significant' doesn't mean safeâ€”it means we can't rule out substantial harm. GRADE incorporates the entire CI, not just p-values.",
          incorrect: "CIì˜ ìƒí•œ 1.60ì€ ìš°ë¦¬ê°€ íŒë‹¨í•  ìˆ˜ ì—†ìŒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì‚¬ë§ë¥ ì´ 60% ì¦ê°€í•©ë‹ˆë‹¤. ëŒ€ì•ˆì´ ì¡´ì¬í•˜ëŠ” ì¹˜ëª…ì ì´ì§€ ì•Šì€ ìƒíƒœë¥¼ ë‹¤ë£¨ëŠ” ì¹˜ë£Œì˜ ê²½ìš° ì‹¬ê°í•œ í”¼í•´ì— ëŒ€í•œ ë¶ˆí™•ì‹¤ì„±ì´ ê²°ì •ì„ ì§€ë°°í•´ì•¼ í•©ë‹ˆë‹¤. í†µê³„ì  ë¹„ìœ ì˜ì„± â‰  ì•ˆì „ì„±."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "ì·¨ì•½ì„± ì§€ìˆ˜",
        subtitle: "How stable is statistical significance?",
        text: "The fragility index asks: 'How many patients would need to have had a different outcome to make this result non-significant?' A fragility index of 3 means if just 3 patients had different outcomes, the p-value would cross 0.05. Many published 'significant' findings have fragility indices under 10.",
        highlight: "ì·¨ì•½ì„± ì§€ìˆ˜ê°€ 5ì¸ ì„ìƒì‹œí—˜ì€ ì‚¬ë¬´ì‹¤ ëŒ€ê¸°ì‹¤ì— ì•‰ì•„ ìˆëŠ” í™˜ìë³´ë‹¤ ë” ì ì€ ìˆ˜ì˜ í™˜ìì—ê²Œì„œ 'ìœ ì˜ë¯¸í•œ' ê²°ê³¼ê°€ ë‚˜ì˜¨ë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤."
      }},
      { type: "story", theme: "dark", content: {
        label: "íŠ¸ë¼ë„¥ì‚¼ì‚° ìŠ¹ë¦¬", title: "When Precision Demanded 20,000 Patients",
        text: "Could tranexamic acid (TXA) reduce death from bleeding in trauma? Early trials were suggestive but imprecise. The <strong>CRASH-2 trial</strong> took a different approach: enroll enough patients to get a precise answer.",
        followup: "<strong>20,211 patients</strong> across 274 hospitals in 40 countries. Result: TXA reduced death from bleeding from 5.7% to 4.9%â€”a 0.8% absolute reduction. The 95% CI was <strong>0.3% to 1.3%</strong>. Finally, precision: the entire CI showed clinically meaningful benefit. The WHO added TXA to its Essential Medicines List. The precision wasn't just scientificâ€”it changed global policy because decision-makers could trust the narrow bounds."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "âœ“", title: "Scenario: The Precise But Small Effect",
        xp: 25,
        scenario: "A mega-trial (n=40,000) shows a treatment reduces mortality with RR 0.95 (95% CI 0.91-0.99). The result is statistically significant and the CI is narrow. However, the absolute risk reduction is 0.3% (NNT = 333). Your minimum clinically important difference for this outcome is 0.2%.",
        question: "ë¶€ì •í™•ì„±ìœ¼ë¡œ ì¸í•´ ë‹¤ìš´ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Yesâ€”the effect is too small to matter clinically", correct: false },
          { letter: "B", text: "Noâ€”the narrow CI excludes clinically unimportant effects", correct: true },
          { letter: "C", text: "Yesâ€”NNT of 333 suggests imprecision", correct: false },
          { letter: "D", text: "Cannot determine without knowing the OIS", correct: false }
        ],
        feedback: {
          correct: "Correct! The entire CI (0.91-0.99) lies below 1.0, and the corresponding absolute effects (0.1%-0.5%) are all above your minimum important difference of 0.2%. Small but precise effects that meet the clinical threshold don't require downgrading for imprecision. The issue is clinical judgment about whether the effect justifies intervention.",
          incorrect: "ë¶€ì •í™•ì„±ì€ íš¨ê³¼ í¬ê¸°ê°€ ì•„ë‹ˆë¼ ì‹ ë¢° êµ¬ê°„ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì„ìƒì ìœ¼ë¡œ ì¤‘ìš”í•˜ì§€ ì•Šì€ ê°’ì„ ì œì™¸í•˜ê³  ì‘ì§€ë§Œ ì •í™•í•˜ê²Œ ì¶”ì •ëœ íš¨ê³¼ëŠ” ë¶€ì •í™•í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë‹¨ì§€ ì‘ì„ ë¿ì…ë‹ˆë‹¤. 0.3% ì ˆëŒ€ ê°ì†Œê°€ ì¹˜ë£Œë¥¼ ì •ë‹¹í™”í•˜ëŠ”ì§€ ì—¬ë¶€ëŠ” ì •í™•ì„± ë¬¸ì œê°€ ì•„ë‹ˆë¼ ê°€ì¹˜ íŒë‹¨ì…ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "JUPITER ë…¼ìŸ", title: "When 17,802 Patients Still Weren't Enough",
        text: "The JUPITER trial enrolled <strong>17,802 patients</strong> to test rosuvastatin for primary prevention. After just 1.9 years (planned: 5 years), it was stopped early for 'overwhelming benefit.' Heart attacks were reduced by 54%! Headlines celebrated. Rosuvastatin prescriptions soared.",
        followup: "But critics noticed problems. Only <strong>68 heart attacks</strong> total across both groupsâ€”fragility index of just 4. The wide confidence intervals (0.29-0.73) reflected genuine uncertainty. Early stopping inflates effect sizes by 30% on average. And absolute risk reduction was just <strong>0.35%</strong> over 1.9 yearsâ€”NNT of 286. A 'landmark' trial with thousands of patients still had imprecision concerns because it was stopped before enough events accumulated. Large n doesn't guarantee precision when event rates are low."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "â¹ï¸", title: "ì‹œë‚˜ë¦¬ì˜¤: ì¡°ê¸° ì¤‘ë‹¨ ì‹œí—˜",
        xp: 25,
        scenario: "A large trial (n=10,000) is stopped early after 2 years (planned: 5) for 'overwhelming efficacy.' The treatment shows 50% relative risk reduction. However, only 45 total events occurred, and the original planned stopping boundary was crossed by just 2 events.",
        question: "How should early stopping affect certainty assessment?",
        options: [
          { letter: "A", text: "No concernâ€”large sample size ensures precision", correct: false },
          { letter: "B", text: "ë¶€ì •í™•ì„±ì— ëŒ€í•œ í•˜í–¥ ì¡°ì • - ì¡°ê¸° ì¤‘ë‹¨ì€ íš¨ê³¼ë¥¼ ë¶€í’€ë¦¬ê³  í—ˆì•½í•¨ì„ ì•¼ê¸°í•©ë‹ˆë‹¤. ì—°êµ¬ ê²°ê³¼", correct: true },
          { letter: "C", text: "Upgrade certaintyâ€”stopping early proves the effect is large", correct: false },
          { letter: "D", text: "Neutralâ€”monitoring rules are pre-specified", correct: false }
        ],
        feedback: {
          correct: "Correct! Early stopping typically inflates effect sizes by 30%. With only 45 events and crossing the boundary by 2, this finding is extremely fragile. Large n doesn't help when event rates are lowâ€”you need enough events, not just patients. GRADE recommends downgrading for trials stopped early with few events.",
          incorrect: "ì¡°ê¸° ì¤‘ë‹¨ëœ ì„ìƒì‹œí—˜ì€ ì²´ê³„ì ìœ¼ë¡œ íš¨ê³¼ë¥¼ ê³¼ëŒ€í‰ê°€í–ˆìŠµë‹ˆë‹¤. 45ê°œì˜ ì‚¬ê±´ê³¼ ~2ì˜ ì·¨ì•½ì„± ì§€ìˆ˜ë¡œ ì¸í•´ ë‹¨ 2ëª…ì˜ í™˜ìê°€ ë‹¤ë¥¸ ê²°ê³¼ë¥¼ ë³´ì¸ë‹¤ë©´ 50% ê°ì†ŒëŠ” ì‚¬ë¼ì§ˆ ê²ƒì…ë‹ˆë‹¤. í° í‘œë³¸ì€ ê´€ë ¨ì´ ì—†ìŠµë‹ˆë‹¤. ì •í™•ì„±ì„ ë†’ì´ëŠ” ê²ƒì€ ì´ë²¤íŠ¸ì…ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ISIS-4 ê°•ì˜", title: "58,000ëª…ì˜ í™˜ìê°€ ì§ˆë¬¸ì— ë‹µë³€í–ˆì„ ë•Œ",
        text: "After GISSI-2 suggested magnesium might reduce mortality in heart attack patients, smaller trials showed inconsistent results. The <strong>ISIS-4</strong> trial was designed to end the debate: <strong>58,050 patients</strong>, the largest heart attack trial ever. If magnesium worked, this trial would prove it.",
        followup: "Result: magnesium showed <strong>no benefit</strong> (mortality 7.64% vs. 7.24%, NS). The pooled meta-analysis before ISIS-4 had shown significant benefitâ€”but was driven by small trials with imprecise estimates. When finally tested with adequate precision, the effect vanished. This patternâ€”dramatic effects in small trials, null effects in large trialsâ€”is so common it has a name: 'the winner's curse.' Small trials select for extreme results; large trials reveal reality."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ²", title: "Scenario: Small Trial Meta-Analysis vs. Large Trial",
        xp: 25,
        scenario: "A meta-analysis of 15 small trials (total n=2,000, 180 events) shows significant mortality benefit (RR 0.65, p=0.001). A single large trial (n=15,000, 2,100 events) shows no benefit (RR 0.98, p=0.61). The meta-analysis was published first.",
        question: "ì´ëŸ¬í•œ ìƒì¶©ë˜ëŠ” ê²°ê³¼ì— ì–´ë–»ê²Œ ê°€ì¤‘ì¹˜ë¥¼ ë¶€ì—¬í•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Average themâ€”more trials means more evidence", correct: false },
          { letter: "B", text: "Prefer the meta-analysisâ€”15 trials beat 1 trial", correct: false },
          { letter: "C", text: "ëŒ€ê·œëª¨ ì‹¤í—˜ì„ ì„ í˜¸í•©ë‹ˆë‹¤. 10ë°° ë” ë§ì€ ì´ë²¤íŠ¸ì™€ ì •ë°€ë„", correct: true },
          { letter: "D", text: "í™•ì‹¤í•˜ì§€ ì•Šì€ ì¦ê±° ì„ ì–¸", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! 2,100ê°œì˜ ì´ë²¤íŠ¸ì™€ 180ê°œì˜ ì´ë²¤íŠ¸ëŠ” ëŒ€ê·œëª¨ ì‹œí—˜ì— ìµœëŒ€ 12ë°° ë” ë§ì€ ì •ë³´ê°€ ìˆìŒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì†Œê·œëª¨ ì‹œí—˜ ë©”íƒ€ ë¶„ì„ì€ ì¶œíŒ í¸í–¥ê³¼ ìŠ¹ìì˜ ì €ì£¼ê°€ ë°œìƒí•˜ê¸° ì‰½ìŠµë‹ˆë‹¤. ëŒ€ê·œëª¨ì˜ ì ì ˆí•˜ê²Œ ê²€ì¦ëœ ì‹¤í—˜ì´ ì†Œê·œëª¨ ì‹¤í—˜ì˜ ë©”íƒ€ ë¶„ì„ê³¼ ëª¨ìˆœë˜ëŠ” ê²½ìš° ì¼ë°˜ì ìœ¼ë¡œ ëŒ€ê·œëª¨ ì‹¤í—˜ì—ì„œ ì§„ì‹¤ì´ ë“œëŸ¬ë‚©ë‹ˆë‹¤.",
          incorrect: "ISIS-4 taught this lesson. Small trials showed magnesium benefit; the 58,000-patient trial showed nothing. Events determine precision, not number of trials. Publication bias and random variation create false signals in small trial meta-analyses that large trials correct."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Imprecision Assessment Checklist",
        items: [
          "Does the 95% CI cross clinically important thresholds?",
          "CI êµì°¨ê°€ ì´ìµê³¼ í•´ë¡œì›€ì„ ëª¨ë‘ ì œê³µí•©ë‹ˆê¹Œ?",
          "ì´ ì´ë²¤íŠ¸ ìˆ˜ê°€ ìµœì  ì •ë³´ í¬ê¸°ë³´ë‹¤ ë‚®ìŠµë‹ˆê¹Œ?",
          "í‚¤ì— ëŒ€í•œ ì·¨ì•½ì„± ì§€ìˆ˜ëŠ” ë¬´ì—‡ì…ë‹ˆê¹Œ? ê²°ê³¼ëŠ” ë¬´ì—‡ì…ë‹ˆê¹Œ?",
          "Would the upper or lower bound change clinical decision-making?"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why does GRADE require downgrading when confidence intervals cross 'clinical decision thresholds' even if statistically significant?",
        options: [
          { text: "í†µê³„ì  ê·œì¹™ì€ ì„ì˜ì ì…ë‹ˆë‹¤", correct: false },
          { text: "The true effect might be too small (or too harmful) to justify treatment", correct: true },
          { text: "P-values don't account for sample size", correct: false },
          { text: "Confidence intervals are more accurate than p-values", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "ì •í™•íˆ ê·¸ë ‡ìŠµë‹ˆë‹¤. ì¹˜ë£Œë²•ì´ ì‚¬ë§ë¥ ì„ 'ìƒë‹¹íˆ' ê°ì†Œì‹œí‚¤ì§€ë§Œ CIì— ë¹„ìš©/ìœ„í—˜ì„ ì •ë‹¹í™”í•˜ê¸°ì—ëŠ” ë„ˆë¬´ ì‘ì€ íš¨ê³¼ê°€ í¬í•¨ë˜ê±°ë‚˜ ìƒë‹¹í•œ í”¼í•´ê°€ í¬í•¨ëœ ê²½ìš°ì—ëŠ” í•´ë‹¹ ì¹˜ë£Œë²•ì„ ìì‹ ìˆê²Œ ê¶Œì¥í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. GRADEëŠ” í†µê³„ì  ê´€ë¡€ê°€ ì•„ë‹Œ ì„ìƒì  ê¸°ì¤€ì„ ê¸°ì¤€ìœ¼ë¡œ ì •í™•ì„±ì„ íŒë‹¨í•©ë‹ˆë‹¤.",
          incorrect: "ì„ìƒ ê²°ì •ì„ ë‚´ë¦¬ë ¤ë©´ ì‹¤ì œ íš¨ê³¼ê°€ ì¤‘ìš”í•  ë§Œí¼ í°ì§€ ì•Œì•„ì•¼ í•©ë‹ˆë‹¤. CIê°€ 'ì‚¬ì†Œí•˜ê²Œ ë„ì›€ì´ ë¨'ì—ì„œ 'ì‹¤ì§ˆì ìœ¼ë¡œ ìœ í•´í•¨'ì— ì´ë¥´ëŠ” í†µê³„ì ìœ¼ë¡œ ìœ ì˜ë¯¸í•œ ê²°ê³¼ëŠ” ì¹˜ë£Œì˜ ì§€ì¹¨ì´ ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤. GRADEëŠ” ê²°ì •ì— í•„ìš”í•œ ì„ìƒì  ê¸°ì¤€ì ì„ ì‚¬ìš©í•©ë‹ˆë‹¤."
        }
      }}
    ]
  },
  {
    id: 7, title: "Publication Bias", subtitle: "ë³´ì´ì§€ ì•ŠëŠ” ì¦ê±°", xp: 160,
    slides: [
      { type: "title", theme: "red-bg", content: { title: "Publication Bias", subtitle: "ë‹¤ì„¯ ë²ˆì§¸ ì˜ì—­: ìš°ë¦¬ì—ê²Œ ë„ë‹¬í•˜ì§€ ëª»í•œ ì¦ê±°ëŠ” ë¬´ì—‡ì…ë‹ˆê¹Œ?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "ë¶€ì •ì  ì„ìƒì‹œí—˜ì´ ë¬¸í—Œì—ì„œ ì–´ë–»ê²Œ ì‚¬ë¼ì§€ëŠ”ì§€ ì´í•´í•˜ì‹­ì‹œì˜¤",
          "Interpret funnel plots and their limitations",
          "Recognize when publication bias likely distorts evidence",
          "Decide when to downgrade certainty for publication bias"
        ],
        tip: "ê°€ì¥ ìœ„í—˜í•œ ì¦ê±°ëŠ” ê²°ì½” ë„ë‹¬í•˜ì§€ ëª»í•œ ì¦ê±°ì…ë‹ˆë‹¤. ì°¸ì¡°."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "íŒŒë¡ì„¸í‹´ì˜ ì†ì„ìˆ˜", title: "GlaxoSmithKline's Hidden Children",
        text: "In the early 2000s, GSK marketed paroxetine (Paxil) for adolescent depression. The published evidence looked convincing. Study 329, published in the <em>Journal of the American Academy of Child and Adolescent Psychiatry</em>, reported paroxetine was <strong>'generally well tolerated and effective.'</strong> Thousands of teenagers were prescribed the drug.",
        followup: "Then lawsuits forced GSK to release internal documents. Study 329 had actually shown paroxetine was <strong>no better than placebo</strong> and increased suicidal behavior. GSK had conducted other trialsâ€”also negativeâ€”that were never published. The published paper had been ghost-written by a medical communications company. When all studies were combined, the truth emerged: paroxetine didn't work for teen depression and was dangerous. The published literature had been systematically manipulated. Publication bias wasn't passiveâ€”it was manufactured."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“š", title: "ì‹œë‚˜ë¦¬ì˜¤: ì „ì ìœ¼ë¡œ ê¸ì •ì ì¸ ë¬¸í—Œ",
        xp: 25,
        scenario: "ë©”íƒ€ ë¶„ì„ì—ëŠ” ì—…ê³„ì—ì„œ ìê¸ˆì„ ì§€ì›ë°›ì€ ìƒˆë¡œìš´ í•­ìš°ìš¸ì œì— ëŒ€í•œ 12ê°œì˜ ì‹¤í—˜ì´ í¬í•¨ë˜ì–´ ìˆìœ¼ë©° ëª¨ë‘ í˜œíƒì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ê¹”ë•Œê¸° ê·¸ë¦¼ì€ ëŒ€ì¹­ìœ¼ë¡œ ë‚˜íƒ€ë‚©ë‹ˆë‹¤. í•œ ë™ë£ŒëŠ” FDA ê¸°ë¡ì— ë”°ë¥´ë©´ íšŒì‚¬ê°€ ì•„ì§ ë°œí‘œë˜ì§€ ì•Šì€ 8ê±´ì˜ ì¶”ê°€ ì‹œí—˜ì„ ìˆ˜í–‰í–ˆë‹¤ê³  ë°í˜”ìŠµë‹ˆë‹¤. ê²Œì‹œë˜ì§€ ì•Šì€ ë°ì´í„°ì— ì•¡ì„¸ìŠ¤í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤.",
        question: "ê²Œì‹œ í¸í–¥ìœ¼ë¡œ ì¸í•´ ë‹¤ìš´ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "ì•„ë‹ˆìš”. ê¹”ëŒ€ê¸°í˜• í”Œë¡¯ì´ ëŒ€ì¹­ì…ë‹ˆë‹¤.", correct: false },
          { letter: "B", text: "ì•„ë‹ˆìš”. ì¡´ì¬í•˜ëŠ” ì¦ê±°ë§Œ íŒë‹¨í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤", correct: false },
          { letter: "C", text: "Yesâ€”documented unpublished trials suggest selective reporting", correct: true },
          { letter: "D", text: "ê²°ì •í•˜ê¸° ì „ì— ë°ì´í„°ë¥¼ ìš”ì²­í•˜ì„¸ìš”", correct: false }
        ],
        feedback: {
          correct: "Correct! The funnel plot only shows published studiesâ€”it can't detect missing studies. Knowing that 8 unpublished trials exist is strong evidence of publication bias. Paroxetine's symmetric funnel plot concealed hidden negative trials. GRADE downgrades when there's direct evidence of unpublished studies.",
          incorrect: "ê¹”ë•Œê¸° ë„í‘œëŠ” ê²Œì‹œëœ ë‚´ìš©ë§Œ ë³´ì—¬ì¤ë‹ˆë‹¤. ë¶€ì •ì ì¸ ì‹¤í—˜ì´ íŒŒë¡ì„¸í‹´ê³¼ ê°™ì´ ì²´ê³„ì ìœ¼ë¡œ ì–µì œë˜ë©´ ê²°ì •ì ì¸ ì¦ê±°ë¥¼ ìˆ¨ê¸°ë©´ì„œë„ ê¹”ë•Œê¸°ê°€ ì™„ë²½í•´ ë³´ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë¯¸ë°œí‘œ ì‹œí—˜ì„ ë³´ì—¬ì£¼ëŠ” FDA ê¸°ë¡ì€ ì¶œíŒ í¸í–¥ì˜ ì§ì ‘ì ì¸ ì¦ê±°ì…ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ì˜¤ì…€íƒ€ë¯¸ë¹„ë¥´ ì°¨ë‹¨", title: "Five Years to See the Truth",
        text: "The Cochrane Collaboration spent <strong>five years</strong> fighting Roche for Tamiflu (oseltamivir) data. Published trials showed reduced complications. Governments stockpiled billions of dollars worth of the drug. But Cochrane noticed discrepancies: study reports didn't match clinical study reports.",
        followup: "When Roche finally released the data in 2013, the missing <strong>60% of patient data</strong> revealed the truth. Published trials had reported 'complications' without proper definitions. Unpublished data showed adverse events were underreported. The updated Cochrane review: Tamiflu reduced symptoms by less than a day and had <strong>no proven effect on hospitalization or complications</strong>. Five years. Billions of dollars. And the published literature had been a carefully curated selection."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“Š", title: "ì‹œë‚˜ë¦¬ì˜¤: ë¹„ëŒ€ì¹­ ìœ ì…ê²½ë¡œ",
        xp: 25,
        scenario: "A funnel plot shows clear asymmetryâ€”small studies cluster toward positive effects while negative small studies are absent. Egger's test is statistically significant (p=0.01). The meta-analysis includes 25 trials with a pooled OR of 0.65 (significant benefit).",
        question: "ì´ê²ƒì´ í™•ì‹¤ì„± ë“±ê¸‰ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "No effectâ€”Egger's test has poor specificity", correct: false },
          { letter: "B", text: "Downgrade one levelâ€”asymmetry suggests missing negative small studies", correct: true },
          { letter: "C", text: "ì†Œê·œëª¨ ì—°êµ¬ì™€ ì¬ë¶„ì„", correct: false },
          { letter: "D", text: "Asymmetry could be small-study effects, not publication bias", correct: false }
        ],
        feedback: {
          correct: "Correct! Significant funnel asymmetry with missing negative small studies is classic publication bias. Small negative studies are less likely to be published than small positive ones. Egger's test p=0.01 supports genuine asymmetry. GRADE requires downgrading when funnel asymmetry is clearly present.",
          incorrect: "While asymmetry has multiple causes, missing negative small studies is the most common pattern. The scenario describes classic publication bias: small positive studies published, small negative studies missing. This requires downgrading even if the exact cause is uncertain."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "ë ˆë³µì„¸í‹´ ìŠ¤ìº”ë“¤", title: "74% of Data Hidden",
        text: "Reboxetine, an antidepressant approved in Europe, had <strong>74% of patient data</strong> from clinical trials never published. The published literature showed the drug worked. Regulatory agencies approved it. Doctors prescribed it to thousands of patients.",
        followup: "German researchers obtained the unpublished data through freedom of information requests. When all data was combined, reboxetine was <strong>no better than placebo</strong> and caused more side effects than other antidepressants. The published literatureâ€”based on only 26% of the dataâ€”had created a complete fiction. A drug that didn't work and caused harm had been sold for years because three-quarters of the evidence was invisible."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ—ƒï¸", title: "ì‹œë‚˜ë¦¬ì˜¤: ë“±ë¡ ê³µë°±",
        xp: 25,
        scenario: "í•­ì•”ì œ ì„ìƒì‹œí—˜ì„ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ClinicalTrials.govì— ë”°ë¥´ë©´ 2010ë…„ë¶€í„° 2018ë…„ ì‚¬ì´ì— 15ê°œì˜ ì„ìƒì‹œí—˜ì´ ë“±ë¡ë˜ê³  ì™„ë£Œë˜ì—ˆìŠµë‹ˆë‹¤. ì²´ê³„ì ìœ¼ë¡œ ê²€ìƒ‰í•˜ë©´ ì¶œíŒëœ ë…¼ë¬¸ì´ 9ê°œë§Œ ì°¾ì•„ì§‘ë‹ˆë‹¤. 6ê°œì˜ ë¯¸ì¶œíŒ ì„ìƒì‹œí—˜ì€ ëª¨ë‘ ê²Œì‹œëœ ì„ìƒì‹œí—˜ë³´ë‹¤ ê·œëª¨ê°€ ì‘ì•˜ìŠµë‹ˆë‹¤.",
        question: "ì¶œíŒ í¸ê²¬ì— ëŒ€í•´ ì–´ë–¤ ê²°ë¡ ì„ ë‚´ë ¤ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "í¸í–¥ì´ ì—†ìŠµë‹ˆë‹¤. ê·œëª¨ê°€ ì‘ì€ ì„ìƒì‹œí—˜ì€ ì˜ˆë¹„ ì—°êµ¬ì¸ ê²½ìš°ê°€ ë§ìŠµë‹ˆë‹¤.", correct: false },
          { letter: "B", text: "ë¶ˆë¶„ëª…í•©ë‹ˆë‹¤. ë¯¸ì¶œíŒì˜ ê²°ê³¼ë¥¼ ì•Œ ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì„ìƒì‹œí—˜", correct: false },
          { letter: "C", text: "High likelihood of biasâ€”40% of completed trials unpublished, all smaller ones", correct: true },
          { letter: "D", text: "Request unpublished results before rating", correct: false }
        ],
        feedback: {
          correct: "Correct! 40% unpublished rateâ€”and specifically the smaller trialsâ€”is a red flag. Small trials showing positive results get published; small trials showing nothing often don't. This pattern inflates pooled estimates. GRADE recognizes registry-publication gaps as strong evidence of publication bias.",
          incorrect: "ì™„ì„±ëœ ì„ìƒì‹œí—˜ 15ê°œ ì¤‘ 6ê°œ(40%)ëŠ” ì¶œíŒë˜ì§€ ì•Šì•˜ìœ¼ë©° ëª¨ë‘ ì†Œê·œëª¨ ì—°êµ¬ì˜€ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ë©”íƒ€ ë¶„ì„ì„ ë¶€í’€ë¦¬ëŠ” íŒ¨í„´ì…ë‹ˆë‹¤. ì‘ì€ ë¶€ì •ì ì¸ ì‹œë„ëŠ” ì‚¬ë¼ì§‘ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¯¸ì¶œíŒ ë°ì´í„°ë¥¼ ë¬´í•œì • ê¸°ë‹¤ë¦´ ìˆ˜ëŠ” ì—†ìŠµë‹ˆë‹¤. í¸ê²¬ì´ ì¡´ì¬í•œë‹¤ëŠ” ì ì„ ì¸ì •í•´ì•¼ í•©ë‹ˆë‹¤."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "ìˆ¨ê²¨ì§„ ì¦ê±°ì˜ ê·œëª¨",
        stats: [
          { value: "50%", label: "Trials never published" },
          { value: "74%", label: "ìˆ¨ê²¨ì§„ ë ˆë³µì„¸í‹´ ë°ì´í„°" },
          { value: "60%", label: "ë°œí‘œë˜ì§€ ì•Šì€ íƒ€ë¯¸í”Œë£¨ ë°ì´í„°" },
          { value: "31%", label: "Outcomes switched" }
        ],
        caption: "ì¶œíŒëœ ë¬¸í—Œì€ ì—„ì„ ëœ ì„ íƒì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ì™„ì „í•œ ì¦ê±°."
      }},
      { type: "concept", theme: "dark", content: {
        title: "Why Funnel Plots Aren't Enough",
        subtitle: "ê²€ì¶œí•  ìˆ˜ ì—†ëŠ” ë°œê²¬",
        text: "Funnel plots can only show what's published. They cannot detect:<br>â€¢ Entire drugs that failed in trials and were never developed further<br>â€¢ Studies with outcome switching (positive outcomes published, negative ones hidden)<br>â€¢ Industry studies kept confidential<br>â€¢ Studies published in inaccessible journals",
        highlight: "When publication bias is well-executed, it leaves no visible trace in the published literature."
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Publication Bias Red Flags",
        items: [
          "All or most trials industry-funded",
          "Trial registries show unpublished completed trials",
          "ë¶€ì •ì ì¸ ì†Œê·œëª¨ ì—°êµ¬ì˜ ëˆ„ë½ìœ¼ë¡œ ì¸í•œ ê¹”ë•Œê¸° ë„í‘œ ë¹„ëŒ€ì¹­",
          "Outcomes in publications differ from registered protocols",
          "Large effects in meta-analysis contradicted by single large trial"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "ì²­ì†Œë…„ ìš°ìš¸ì¦ì— ëŒ€í•œ íŒŒë¡ì„¸í‹´ì˜ ì¶œíŒ í¸ê²¬ì´ ìˆ˜ë…„ ë™ì•ˆ ë°œê²¬ë˜ì§€ ì•Šì€ ì´ìœ ëŠ” ë¬´ì—‡ì…ë‹ˆê¹Œ?",
        options: [
          { text: "ì—°êµ¬ëŠ” ë‹¤ìŒê³¼ ê°™ìŠµë‹ˆë‹¤. ì˜ ì§„í–‰ë¨", correct: false },
          { text: "ë¶€ì •ì ì¸ ì‹¤í—˜ì€ ìˆ¨ê²¨ì¡Œê³  ê¸ì •ì ì¸ ì‹¤í—˜ì€ ê²°ê³¼ë¥¼ ì™œê³¡í•˜ê¸° ìœ„í•´ ëŒ€í•„ë¡œ ì‘ì„±ë˜ì—ˆìŠµë‹ˆë‹¤", correct: true },
          { text: "The drug genuinely worked in some patients", correct: false },
          { text: "ê·œì œ ê¸°ê´€ì€ ë°ì´í„°ë¥¼ ê²€í† í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "ì •í™•íˆ. GSKëŠ” ë¶€ì •ì ì¸ ì‹¤í—˜ì„ ìˆ¨ê¸°ê³  ì˜ë£Œ ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ íšŒì‚¬ë¥¼ ê³ ìš©í•˜ì—¬ íŒŒë¡ì„¸í‹´ì´ íš¨ê³¼ì ì´ê²Œ ë³´ì´ë„ë¡ ì—°êµ¬ 329ë¥¼ ì‘ì„±í–ˆìŠµë‹ˆë‹¤. ì¶œíŒ í¸ê²¬ì€ ê³ ì˜ì ì´ê³  ì²´ê³„ì ì´ì—ˆìŠµë‹ˆë‹¤. ì†Œì†¡ìœ¼ë¡œ ì¸í•´ ê³µê°œê°€ ê°•ìš”ëœ ê²½ìš°ì—ë§Œ ë“œëŸ¬ë‚¬ìŠµë‹ˆë‹¤.",
          incorrect: "ê¸°ë§Œì€ ìˆ˜ë™ì ì´ ì•„ë‹ˆë¼ ëŠ¥ë™ì ì´ì—ˆìŠµë‹ˆë‹¤. GSKëŠ” íŒŒë¡ì„¸í‹´ì´ ì‹­ëŒ€ ìš°ìš¸ì¦ê³¼ ìì‚´ í–‰ë™ ì¦ê°€ì— íš¨ê³¼ê°€ ì—†ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì€ ë¶€ì •ì ì¸ ì¬íŒì„ ë¬»ì–´ë‘ê³  ë°œí‘œëœ ì¬íŒì„ í—ˆìœ„ë¡œ í‘œí˜„í–ˆìŠµë‹ˆë‹¤. ê¸°ì¡´ì˜ íƒì§€ ë°©ë²•ì€ ì˜ë„ì ìœ¼ë¡œ ìˆ¨ê²¨ì§„ ê²ƒì„ ì°¾ì„ ìˆ˜ ì—†ì—ˆìŠµë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "í•­ìš°ìš¸ì œ í™˜ìƒ", title: "Turner's 94 Trial Revelation",
        text: "In 2008, Dr. Erick Turner at the FDA did something unprecedented: he compared <strong>74 FDA-registered antidepressant trials</strong> to what was actually published. The FDA had seen all trialsâ€”positive and negative. The literature had seen a carefully curated selection.",
        followup: "The results were damning. Of 38 positive trials, <strong>37 were published</strong>. Of 36 negative or questionable trials, only <strong>3 were published as negative</strong>â€”22 were never published, and 11 were published but 'spun' to appear positive. The published literature showed antidepressants were effective in 94% of trials. The FDA data showed 51%. Effect sizes in publications were <strong>32% larger</strong> than reality. An entire drug class had its efficacy inflated by systematic publication bias."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ’Š", title: "ì‹œë‚˜ë¦¬ì˜¤: ì„ íƒ ë¬¸í—Œ",
        xp: 25,
        scenario: "You're assessing antidepressants for a guideline. The published literature shows 12 of 15 trials are positive. However, you discover FDA databases listing 8 additional completed trials that were never published. The published effect size is d=0.50.",
        question: "í™•ì‹¤ì„± í‰ê°€ë¥¼ ì–´ë–»ê²Œ ì¡°ì •í•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Use only published trialsâ€”unpublished data isn't peer-reviewed", correct: false },
          { letter: "B", text: "Downgrade significantlyâ€”8 unpublished trials likely changes the effect size substantially", correct: true },
          { letter: "C", text: "Assume unpublished trials showed similar results", correct: false },
          { letter: "D", text: "Request unpublished data before making any assessment", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! Turnerì˜ ë¶„ì„ì— ë”°ë¥´ë©´ ë°œí‘œëœ íš¨ê³¼ í¬ê¸°ê°€ 32% ë¶€í’€ë ¤ì§„ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì´ 23ê°œ ì¤‘ 8ê°œì˜ ë¯¸ë°œí‘œ ì‹œí—˜(35% ìˆ¨ê¹€)ì€ íš¨ê³¼ ì¶”ì •ì¹˜ê°€ ìƒë‹¹íˆ í¸í–¥ë˜ì—ˆì„ ê°€ëŠ¥ì„±ì´ ìˆìŒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì¶œíŒ í¸í–¥ì„ í•˜í–¥ ì¡°ì •í•˜ê³  ì‹¤ì œ íš¨ê³¼ëŠ” ì¶œíŒëœ ì¶”ì •ì¹˜ë³´ë‹¤ ì‘ì„ ìˆ˜ ìˆë‹¤ëŠ” ì ì— ìœ ì˜í•˜ì„¸ìš”.",
          incorrect: "í•­ìš°ìš¸ì œ ë¬¸í—Œì—ì„œëŠ” ì¶œíŒë¬¼ì—ì„œ ê¸ì •ì ì¸ ì‹¤í—˜ì´ 94%ì¸ ë°˜ë©´ FDA ë°ì´í„°ì—ì„œëŠ” 51%ì¸ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì¶œíŒë˜ì§€ ì•Šì€ ì„ìƒì‹œí—˜ì€ ì²´ê³„ì ìœ¼ë¡œ ë¶€ì •ì ì…ë‹ˆë‹¤. ì¶œíŒëœ ì‹œí—˜ê³¼ ìœ ì‚¬í•˜ë‹¤ê³  ê°€ì •í•˜ë©´ ì¶œíŒ í¸í–¥ íŒ¨í„´ì— ëŒ€í•œ ìˆ˜ì‹­ ë…„ê°„ì˜ ì¦ê±°ì™€ ëª¨ìˆœë©ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ê¸°ë¡ì ì¸ ì¬ë‚œ", title: "When a Safety Study Hid Safety Signals",
        text: "After Avandia's cardiovascular concerns emerged, GSK designed RECORDâ€”a 'cardiovascular safety study' of rosiglitazone. The study enrolled <strong>4,447 patients</strong> and ran for 5+ years. It was specifically designed to assess cardiovascular safety. The published conclusion: 'Rosiglitazone did not significantly increase cardiovascular risk.'",
        followup: "An FDA re-analysis told a different story. RECORD had serious adjudication problemsâ€”<strong>35% of potential cardiovascular events weren't properly evaluated</strong>. Some patients' events were classified as 'non-cardiac' when records suggested otherwise. The study designed to answer the safety question had been conducted in ways that systematically underdetected the very events it was supposed to measure. The publication bias wasn't in what studies were publishedâ€”it was in how the study itself was designed and analyzed to produce a publishable 'negative' safety finding."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ”", title: "ì‹œë‚˜ë¦¬ì˜¤: 'ì•ˆì‹¬ì„ ì£¼ëŠ”' ì•ˆì „ì„± ì—°êµ¬",
        xp: 25,
        scenario: "A drug with suspected harm has a 'definitive' safety study published showing no increased risk. However, you notice: outcomes were adjudicated by company employees, 30% of potential events were excluded as 'protocol deviations,' and the comparison group had higher baseline risk.",
        question: "ì´ëŸ¬í•œ ë°©ë²•ë¡ ì  íŠ¹ì§•ì´ í•´ì„ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "ë‹¤ìŒì„ ìˆ˜ë½í•˜ì„¸ìš”. ì•ˆì‹¬â€”ì—°êµ¬ëŠ” ì•ˆì „ì„ ìœ„í•´ íŠ¹ë³„íˆ ì„¤ê³„ë˜ì—ˆìŠµë‹ˆë‹¤.", correct: false },
          { letter: "B", text: "Be skepticalâ€”systematic bias in outcome ascertainment can hide real signals", correct: true },
          { letter: "C", text: "Partially reassuredâ€”some bias doesn't eliminate all value", correct: false },
          { letter: "D", text: "ë¬´ì‹œí•˜ê³  ë…ë¦½ì ì¸ ë³µì œë¥¼ ê¸°ë‹¤ë¦½ë‹ˆë‹¤.", correct: false }
        ],
        feedback: {
          correct: "ì˜³ì€! RECORDëŠ” 'ì•ˆì „ ì—°êµ¬'ê°€ í•´ë¥¼ ë¼ì¹˜ì§€ ì•Šë„ë¡ ì„¤ê³„ë  ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ê°€ë¥´ì³ ì£¼ì—ˆìŠµë‹ˆë‹¤. íšŒì‚¬ì˜ íŒê²°, ì„ íƒì  ë°°ì œ ë° ìœ ë¦¬í•œ ë¹„êµëŠ” ì²´ê³„ì ìœ¼ë¡œ ë¶€ì‘ìš©ì„ ê³¼ì†Œí‰ê°€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê¸°ëŠ¥ì„ ê°–ì¶˜ 'ë¶€ì •ì ' ì•ˆì „ì„± ì—°êµ¬ëŠ” ì˜ëª»ëœ í™•ì‹ ì„ ì œê³µí•©ë‹ˆë‹¤.",
          incorrect: "ì˜ì‹¬ë˜ëŠ” ì œí’ˆì— ëŒ€í•´ íšŒì‚¬ê°€ ì„¤ê³„í•˜ê³  íŒê²°í•œ ì•ˆì „ì„± ì—°êµ¬ì—ëŠ” ëª…ë°±í•œ ìƒì¶©ì´ ìˆìŠµë‹ˆë‹¤. RECORDì˜ 35% ë¬´í‰ê°€ ë¹„ìœ¨ì€ ì´ë²¤íŠ¸ê°€ ì œëŒ€ë¡œ ê³„ì‚°ë˜ì§€ ì•Šì•˜ìŒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ìœ„í—˜ì´ ê°ì§€ë˜ì§€ ì•Šë„ë¡ ì„¤ê³„í–ˆë‹¤ë©´ 'ì•ˆì „ì„ ìœ„í•´ ì„¤ê³„ë¨'ì€ ì˜ë¯¸ê°€ ì—†ìŠµë‹ˆë‹¤."
        }
      }}
    ]
  },
  {
    id: 8, title: "Upgrading Factors", subtitle: "When observational evidence earns trust", xp: 140,
    slides: [
      { type: "title", theme: "green-bg", content: { title: "Upgrading Factors", subtitle: "When observation rivals randomization" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand the three GRADE upgrading factors",
          "Learn when large effects can overcome confounding",
          "Recognize dose-response gradients as evidence of causation",
          "Apply 'all plausible confounders' reasoning"
        ],
        tip: "Upgrading is rareâ€”but sometimes observational evidence is unassailable."
      }},
      { type: "story", theme: "green-bg", content: {
        label: "í¡ì—°ì˜ ì¦ê±°", title: "How 30x Risk Silenced Doubt",
        text: "In 1950, Richard Doll and Austin Bradford Hill published their case-control study: smokers had <strong>30 times higher lung cancer rates</strong> than non-smokers. The tobacco industry demanded RCTsâ€”knowing they were impossible. 'Correlation isn't causation,' they insisted. 'Where's the randomized evidence?'",
        followup: "But the effect size spoke for itself. For confounding to explain a 30-fold increase, some unmeasured factor would need to cause both smoking and lung cancer with extraordinary strengthâ€”and be distributed perfectly across populations, generations, and geographies. No such confounder has ever been found. The evidence was upgraded from LOW to HIGH. GRADE recognizes that some effects are too large for confounding to explain."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“ˆ", title: "ì‹œë‚˜ë¦¬ì˜¤: í° íš¨ê³¼",
        xp: 25,
        scenario: "ê´€ì°° ì—°êµ¬ì— ë”°ë¥´ë©´ ìˆ˜ìˆ ì„ í•˜ë©´ ì‚¬ë§ë¥ ì´ 80%ì—ì„œ 10%ë¡œ ê°ì†Œí•©ë‹ˆë‹¤. ìƒëŒ€ ìœ„í—˜ì€ 0.125(ìƒëŒ€ ìœ„í—˜ 87.5%)ì…ë‹ˆë‹¤. ê°ì†Œ). ê·¹ì ìœ¼ë¡œ ê´€ì°°ëœ ì´ì ì„ ê³ ë ¤í•  ë•Œ ë³´ë¥˜ ì²˜ë¦¬ëŠ” ë¹„ìœ¤ë¦¬ì ì´ê¸° ë•Œë¬¸ì— RCTëŠ” ì¡´ì¬í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.",
        question: "í° íš¨ê³¼ë¥¼ ìœ„í•´ ì´ ì¦ê±°ë¥¼ ì—…ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "ì•„ë‹ˆìš”â€”ê´€ì°° ì¦ê±°ë¥¼ ì—…ê·¸ë ˆì´ë“œí•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤", correct: false },
          { letter: "B", text: "Yesâ€”RR 0.125 is so large that confounding alone is implausible", correct: true },
          { letter: "C", text: "ì—°êµ¬ê°€ ë‹¤ìŒê³¼ ê°™ì€ ê²½ìš°ì—ë§Œ ê°€ëŠ¥í•©ë‹ˆë‹¤. ì˜ ì„¤ê³„ëœ", correct: false },
          { letter: "D", text: "Only if dose-response is also present", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 0.125 (or 8-fold relative reduction) is in the range where confounding alone is implausible. No unmeasured confounder could realistically reduce mortality from 80% to 10%. GRADE upgrades for large effects when RR < 0.5 or > 2, with additional upgrading for very large effects (RR < 0.2 or > 5).",
          incorrect: "ì´ë ‡ê²Œ í° íš¨ê³¼ëŠ” ë³¸ì§ˆì ìœ¼ë¡œ RCT ë°©ì§€ì…ë‹ˆë‹¤. 87.5%ì˜ ìƒëŒ€ì  ê°ì†Œë¥¼ ê·¸ëŸ´ë“¯í•˜ê²Œ ì„¤ëª…í•  ìˆ˜ ìˆëŠ” í˜¼ë€ ìš”ì¸ì€ ì—†ìŠµë‹ˆë‹¤. ë‚™í•˜ì‚°ì€ RCTì—ì„œ í…ŒìŠ¤íŠ¸ëœ ì ì´ ì—†ì§€ë§Œ ê·¸ê²ƒì´ ì‘ë™í•œë‹¤ëŠ” ê²ƒì€ ì˜ì‹¬í•  ì—¬ì§€ê°€ ì—†ìŠµë‹ˆë‹¤. íš¨ê³¼ í¬ê¸°ëŠ” ìëª…í•©ë‹ˆë‹¤. GRADEëŠ” ì„¤ëª…í•˜ê¸°ì—ëŠ” ë„ˆë¬´ í° íš¨ê³¼ë¥¼ ì—…ê·¸ë ˆì´ë“œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ì—½ì‚° ë°œê²¬", title: "Neural Tube Defects Prevented",
        text: "1980ë…„ëŒ€ê¹Œì§€ ê´€ì°° ì—°êµ¬ì—ì„œëŠ” ì—½ì‚° ë³´ì¶©ì´ ì²™ì¶” ì´ë¶„ì¦ê³¼ ê°™ì€ ì‹ ê²½ê´€ ê²°ì†(NTD)ì„ ì˜ˆë°©í•œë‹¤ê³  ì œì•ˆí–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ëˆ„ê°€ í™•ì‹ í•  ìˆ˜ ìˆê² ìŠµë‹ˆê¹Œ? í˜¼ë€ì€ í”¼í•  ìˆ˜ ì—†ëŠ” ê²ƒì²˜ëŸ¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ë¹„íƒ€ë¯¼ì„ ì„­ì·¨í•˜ëŠ” ì—¬ì„±ì€ ì—¬ëŸ¬ ë©´ì—ì„œ ë” ê±´ê°•í•  ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤.",
        followup: "Three upgrading factors came together. <strong>Large effect:</strong> Folate reduced NTDs by 70-80%. <strong>Dose-response:</strong> Higher folate levels correlated with lower NTD risk in a clear gradient. <strong>Confounding direction:</strong> Women who take supplements tend to be healthierâ€”which would make folate look beneficial even if it weren't. But folate's effect persisted after adjusting for socioeconomic factors. When an effect survives adjustment for confounders that should bias toward it, the effect is likely real. The MRC RCT eventually confirmed 72% reductionâ€”the observational data had been right."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“‰", title: "ì‹œë‚˜ë¦¬ì˜¤: ìš©ëŸ‰-ë°˜ì‘ ì§ˆë¬¸",
        xp: 25,
        scenario: "A series of cohort studies shows alcohol consumption and liver cirrhosis. Results: 1-2 drinks/day (RR 1.2), 3-4 drinks/day (RR 2.1), 5-6 drinks/day (RR 4.5), 7+ drinks/day (RR 9.3). The gradient is consistent across studies and populations.",
        question: "Does this dose-response pattern support upgrading?",
        options: [
          { letter: "A", text: "ì•„ë‹ˆìš”. ëª¨ë“  íš¨ê³¼ëŠ” ê´€ì°° ì—°êµ¬ì—ì„œ ë‚˜ì˜¨ ê²ƒì…ë‹ˆë‹¤", correct: false },
          { letter: "B", text: "Yesâ€”a consistent dose-response gradient across studies suggests causation", correct: true },
          { letter: "C", text: "Only if RR exceeds 2 at all dose levels", correct: false },
          { letter: "D", text: "Only if confounders show the same gradient", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! ëª…í™•í•œ ìš©ëŸ‰-ë°˜ì‘ êµ¬ë°°(1.2 â†’ 2.1 â†’ 4.5 â†’ 9.3)ëŠ” í˜¼ë™ìœ¼ë¡œ ì„¤ëª…í•˜ê¸° ì–´ë µìŠµë‹ˆë‹¤. í˜¼ë€ìëŠ” ë‹¤ì–‘í•œ ì¸êµ¬ ì§‘ë‹¨ì˜ ëª¨ë“  ìˆ˜ì¤€ì—ì„œ ì•Œì½”ì˜¬ ì„­ì·¨ëŸ‰ì„ ì™„ë²½í•˜ê²Œ ì¶”ì í•´ì•¼ í•©ë‹ˆë‹¤. ì´ ìƒë¬¼í•™ì  ë³€í™”ë„ëŠ” ì¸ê³¼ê´€ê³„ë¥¼ ë’·ë°›ì¹¨í•˜ê³  ì—…ê·¸ë ˆì´ë“œë¥¼ ë³´ì¥í•©ë‹ˆë‹¤.",
          incorrect: "ìš©ëŸ‰-ë°˜ì‘ ê´€ê³„ëŠ” ì¸ê³¼ê´€ê³„ì— ëŒ€í•œ ê°•ë ¥í•œ ì¦ê±°ë¥¼ ì œê³µí•©ë‹ˆë‹¤. ì´ëŸ¬í•œ íŒ¨í„´ì„ ë§Œë“¤ê¸° ìœ„í•´ êµë€ì„ ì¼ìœ¼í‚¤ë ¤ë©´ ëª¨ë“  ì—°êµ¬ì™€ ëª¨ì§‘ë‹¨ì—ì„œ ì¼ë¶€ ì•Œë ¤ì§€ì§€ ì•Šì€ ìš”ì¸ì´ ì•Œì½”ì˜¬ ì„­ì·¨ëŸ‰ì— ì™„ë²½í•œ ë¹„ìœ¨ë¡œ ì¦ê°€í•´ì•¼ í•©ë‹ˆë‹¤. ì´ëŠ” ë¯¿ê¸° ì–´ë ¤ìš´ ì´ì•¼ê¸°ì…ë‹ˆë‹¤. ê²½ì‚¬ë„ê°€ ì¸ê³¼ê´€ê³„ë¥¼ ê°€ë¦¬í‚µë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "green-bg", content: {
        label: "í˜¼ë€ìŠ¤ëŸ¬ìš´ ì—­ì„¤", title: "When Bias Proves the Case",
        text: "ì˜¤í† ë°”ì´ í—¬ë©§ì´ ë¨¸ë¦¬ ë¶€ìƒ ì‚¬ë§ì„ ì¤„ì¸ë‹¤ëŠ” ê´€ì°° ê²°ê³¼ë¥¼ ìƒê°í•´ ë³´ì„¸ìš”. ë¹„í‰ê°€ë“¤ì€ 'ì–´ì©Œë©´ í—¬ë©§ì„ ì“´ ì‚¬ëŒì´ ë” ì¡°ì‹¬ìŠ¤ëŸ¬ìš´ ìš´ì „ìì¼ì§€ë„ ëª¨ë¥¸ë‹¤'ê³  ì£¼ì¥í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ê²ƒì€ í˜¼ë€ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. ì•„ë§ˆë„ ì‚¬ì‹¤ì¼ ê²ƒì…ë‹ˆë‹¤. ì¡°ì‹¬ìŠ¤ëŸ¬ìš´ ìš´ì „ìëŠ” í—¬ë©§ì„ ë” ìì£¼ ì°©ìš©í•  ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤.",
        followup: "But here's the paradox: if cautious driving confounds the relationship, it should bias <em>toward</em> helmets looking beneficial. Cautious drivers have fewer crashes and thus fewer head injuries. If helmets still show dramatic benefit <em>despite</em> this confounding working in their favor, the true effect might be even larger. When all plausible confounders bias in one direction and the effect persists (or is opposite), causation becomes more credible. This 'all plausible confounders' reasoning is GRADE's third upgrading criterion."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ”„", title: "ì‹œë‚˜ë¦¬ì˜¤: í˜¼ë€ìŠ¤ëŸ¬ìš´ ë°©í–¥",
        xp: 25,
        scenario: "ë“±ë¡ ì—°êµ¬ì— ë”°ë¥´ë©´ ìƒˆë¡œìš´ ìˆ˜ìˆ  ê¸°ìˆ ì´ í•©ë³‘ì¦ì„ ì¤„ì´ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤(RR 0.60). ë‹¹ì‹ ì€ í˜¼ë€ìŠ¤ëŸ¬ìš´ ê²ƒìœ¼ë¡œ ì˜ì‹¬ë©ë‹ˆë‹¤. ê±´ê°•í•œ í™˜ìëŠ” ì•„ë§ˆë„ ìƒˆë¡œìš´ ê¸°ìˆ ì„ ë°›ì„ ê²ƒì…ë‹ˆë‹¤. ì–´ì¨Œë“  ê±´ê°•í•œ í™˜ìëŠ” í•©ë³‘ì¦ì´ ë” ì ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í˜¼ë€ì€ ê²°ê³¼ë¥¼ ì´ìµì„ ë‚˜íƒ€ë‚´ëŠ” ë°©í–¥ìœ¼ë¡œ í¸í–¥ì‹œì¼œì•¼ í•©ë‹ˆë‹¤.",
        question: "Does this confounding pattern support or undermine causation?",
        options: [
          { letter: "A", text: "Underminesâ€”confounding invalidates observational studies", correct: false },
          { letter: "B", text: "Supportsâ€”if benefit persists despite confounding that favors treatment, true benefit may exist", correct: true },
          { letter: "C", text: "Neutralâ€”we cannot determine confounding direction", correct: false },
          { letter: "D", text: "Underminesâ€”we need propensity score matching", correct: false }
        ],
        feedback: {
          correct: "Correct! If healthier patients get the new technique AND the technique still shows benefit, the true benefit might be real (or even underestimated). When confounding should bias toward benefit but benefit still appears after adjustment, that's evidence for causation. GRADE upgrades when 'all plausible confounders' would bias in the observed direction.",
          incorrect: "Think about the direction: healthy patient confounding should make the new technique look good. If the technique still shows benefit after adjusting for health status, the true effect is supported. The confounding direction helps interpret the finding."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "ì—…ê·¸ë ˆì´ë“œ ê¸°ì¤€ ìš”ì•½",
        subtitle: "Three paths to higher certainty",
        checkpoints: [
          { day: "LARGE", event: "RR > 2 or < 0.5 (upgrade 1); RR > 5 or < 0.2 (upgrade 2)" },
          { day: "DOSE", event: "Clear gradient between exposure and outcome" },
          { day: "CONFOUND", event: "All plausible confounders would reduce observed effect" }
        ]
      }},
      { type: "story", theme: "dark", content: {
        label: "ê°‘ìƒì„  í­í’", title: "When 96% Survival Speaks for Itself",
        text: "Before propylthiouracil (PTU), thyroid storm had <strong>nearly 100% mortality</strong>. With PTU, mortality dropped to around <strong>4%</strong>. No RCT was ever conductedâ€”it would have required letting patients die in the control arm.",
        followup: "This is the paradigm case for large effect upgrading. A treatment that changes survival from ~0% to ~96% doesn't need an RCT. No confounder could explain turning certain death into reliable survival. The evidence quality was upgraded to HIGH despite being entirely observational. Some effects are simply too dramatic to doubt."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "âš ï¸", title: "ì‹œë‚˜ë¦¬ì˜¤: ì¤‘ê°„ íš¨ê³¼",
        xp: 25,
        scenario: "ì½”í˜¸íŠ¸ ì—°êµ¬ì— ë”°ë¥´ë©´ ìƒí™œ ë°©ì‹ ì¤‘ì¬ê°€ RR 0.75ë¡œ ì‹¬ì¥ë³‘ì„ ì¤„ì´ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. (25% ìƒëŒ€ ê°ì†Œ). ì´ ì—°êµ¬ëŠ” ê·œëª¨ê°€ í¬ê³  ì˜ ì„¤ê³„ë˜ì—ˆìœ¼ë©° ì¼ê´€ëœ ê²°ê³¼ë¥¼ ì œê³µí•©ë‹ˆë‹¤. ë™ë£ŒëŠ” ì´ê²ƒì´ í° íš¨ê³¼ë¥¼ ìœ„í•´ ì—…ê·¸ë ˆì´ë“œí•  ê°€ì¹˜ê°€ ìˆë‹¤ê³  ì£¼ì¥í•©ë‹ˆë‹¤.",
        question: "ì—…ê·¸ë ˆì´ë“œí•´ì•¼ í• ê¹Œìš”?",
        options: [
          { letter: "A", text: "Yesâ€”25% reduction is clinically important", correct: false },
          { letter: "B", text: "Noâ€”RR 0.75 is well within the range confounding can produce", correct: true },
          { letter: "C", text: "Yesâ€”large sample size warrants upgrading", correct: false },
          { letter: "D", text: "Only if dose-response is also present", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 0.75 is exactly the range where confounding thrives. The HRT disaster showed RR 0.50 for heart protectionâ€”entirely due to confounding. Large effect upgrading requires RR > 2 or < 0.5 (some use even stricter thresholds). Clinical importance â‰  causal certainty.",
          incorrect: "RR 0.75 is modest and easily explained by healthy user bias, unmeasured confounders, or selection effects. HRT's observational RR of 0.50 was entirely confounded. Only effects so large that confounding is implausible (RR > 2 or < 0.5) qualify for upgrading."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Upgrading Criteria Checklist",
        items: [
          "Large effect: RR > 2 or < 0.5 (very large: > 5 or < 0.2)",
          "Dose-response: Clear gradient across exposure levels",
          "Confounding: All plausible confounders would reduce the effect",
          "Upgrading is rareâ€”most observational evidence remains LOW",
          "Multiple upgrading factors can be applied if clearly present"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "ì™œ RCTê°€ ì—†ì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  í¡ì—°ê³¼ íì•”ì— ëŒ€í•œ ê´€ì°° ì¦ê±°ê°€ ë†’ì€ í™•ì‹¤ì„±ì„ ë‹¬ì„±í–ˆë‚˜ìš”?",
        options: [
          { text: "ì—°êµ¬ëŠ” ë°©ë²•ë¡ ì ìœ¼ë¡œ ì™„ë²½í–ˆìŠµë‹ˆë‹¤", correct: false },
          { text: "Large effect (30x risk) + dose-response + no plausible confounders could explain it", correct: true },
          { text: "ìƒë¬¼í•™ì  ë©”ì»¤ë‹ˆì¦˜ ì˜ ì´í•´ë¨", correct: false },
          { text: "ë‹¤ì–‘í•œ ì—°êµ¬ ì„¤ê³„ì— ë™ì˜í•¨", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. A 30-fold risk increase is beyond what confounding can explain. The clear dose-response (more cigarettes = more cancer) added evidence. And no unmeasured confounder has ever been found that could explain the effect. All three upgrading criteria were met.",
          incorrect: "The combination was powerful: an effect so large confounding couldn't explain it, a dose-response gradient supporting causation, and the direction of any conceivable confounding wouldn't diminish the finding. All three upgrading factors pushed the evidence to HIGH certainty."
        }
      }}
    ]
  },
  {
    id: 9, title: "Putting It Together", subtitle: "Real guideline decisions", xp: 200,
    slides: [
      { type: "title", theme: "dark", content: { title: "Putting It Together", subtitle: "Applying all five domains to real guideline decisions" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Apply all GRADE domains to complex real-world evidence",
          "ê·¼ê±° ìš”ì•½ êµ¬ì„± ì—°ìŠµ",
          "Make defensible certainty judgments",
          "Translate certainty to recommendation strength"
        ],
        tip: "ì´ ëª¨ë“ˆì€ ì „ì²´ ì‚¬ë¡€ë¥¼ ì œì‹œí•©ë‹ˆë‹¤. ë°°ìš´ ëª¨ë“  ë‚´ìš©ì„ í™œìš©í•˜ê²Œ ë©ë‹ˆë‹¤."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "ì‚¬ë¡€ 1: ìŠ¤íƒ€í‹´ ë…¼ë€", title: "1ì°¨ ì˜ˆë°©ì„ ìœ„í•œ ìŠ¤íƒ€í‹´",
        text: "In 2016, a Lancet review claimed statins for primary prevention were supported by <strong>'overwhelming evidence.'</strong> The meta-analysis showed 25% relative reduction in major vascular events. Industry-funded trials dominated. Patient advocates and independent researchers disagreed vehemently.",
        followup: "Let's assess this systematically. <strong>Risk of bias:</strong> Most trials industry-funded with concerns about selective reporting. <strong>Inconsistency:</strong> Effects varied by baseline riskâ€”benefit clear in high-risk, uncertain in low-risk. <strong>Indirectness:</strong> Many trials included patients with existing disease (secondary prevention). <strong>Imprecision:</strong> For low-risk primary prevention, confidence intervals crossed clinical thresholds. <strong>Publication bias:</strong> Industry sponsorship raised concerns about selective publication."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ’Š", title: "ì‹œë‚˜ë¦¬ì˜¤: ìŠ¤íƒ€í‹´ ì¦ê±° í‰ê°€",
        xp: 30,
        scenario: "For statins in LOW-RISK primary prevention (10-year CVD risk <10%), you have: industry-funded RCTs, some risk of bias concerns, heterogeneous results by risk level, outcomes measured may include secondary prevention patients, and modest absolute benefits (NNT ~200-500 to prevent one event over 5 years).",
        question: "ì–´ë–¤ í™•ì‹¤ì„± ë“±ê¸‰ì´ ê°€ì¥ ì í•©í•œê°€ìš”? ì´ ëª¨ì§‘ë‹¨ì—ì„œ CV ì‚¬ê±´ ê°ì†Œ?",
        options: [
          { letter: "A", text: "ë†’ìŒ - ë©”íƒ€ ë¶„ì„ì´ ê·œëª¨ê°€ í¬ê³  ìƒë‹¹í•œ ì´ì ì„ ë³´ì—¬ì¤ë‹ˆë‹¤.", correct: false },
          { letter: "B", text: "MODERATEâ€”downgrade one level for indirectness (mixed populations)", correct: false },
          { letter: "C", text: "ë‚®ìŒ â€” ì´ íŠ¹ì • ëª¨ì§‘ë‹¨ì— ëŒ€í•œ ê°„ì ‘ì„±ê³¼ ë¶€ì •í™•ì„±ì— ëŒ€í•œ í•˜í–¥ ì¡°ì •", correct: true },
          { letter: "D", text: "VERY LOWâ€”multiple serious concerns across domains", correct: false }
        ],
        feedback: {
          correct: "Correct! For low-risk primary prevention specifically: indirectness (trials mixed with higher-risk patients) and imprecision (modest absolute benefits, NNT 200-500) both warrant downgrading. The certainty differs by populationâ€”what's HIGH for secondary prevention may be LOW for low-risk primary prevention.",
          incorrect: "ì§ˆë¬¸ì€ íŠ¹íˆ ì €ìœ„í—˜ 1ì°¨ ì˜ˆë°©ì— ëŒ€í•´ ë¬»ìŠµë‹ˆë‹¤. ì „ë°˜ì ì¸ ë©”íƒ€ ë¶„ì„ì—ëŠ” ì´ì ì´ ë” ë¶„ëª…í•œ ê³ ìœ„í—˜êµ°ì´ í¬í•¨ë©ë‹ˆë‹¤. ë¬¸ì œì˜ íŠ¹ì • ëª¨ì§‘ë‹¨ì— ëŒ€í•´ì„œëŠ” ê°„ì ‘ì„±ê³¼ ë¶€ì •í™•ì„±ì´ ëª¨ë‘ ì ìš©ë©ë‹ˆë‹¤. GRADEëŠ” ì¸êµ¬ ì§‘ë‹¨ë³„ë¡œ ë‹¤ë¦…ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "ì‚¬ë¡€ 2: í•˜ì´ë“œë¡ì‹œí´ë¡œë¡œí€¸ ì‚¬íƒœ", title: "COVID-19 ë° ì¡°ê¸° í™•ì‹¤ì„±",
        text: "In March 2020, a French study of <strong>36 patients</strong> claimed hydroxychloroquine cleared COVID-19 viral load. The study was open-label, non-randomized, with selective exclusion of patients who died or went to ICU. Despite this, world leaders promoted it and millions of doses were prescribed.",
        followup: "Systematic GRADE assessment would have revealed: <strong>Risk of bias:</strong> CRITICAL (non-randomized, open-label, selective exclusion). <strong>Imprecision:</strong> SERIOUS (36 patients, 6 in treatment arm). <strong>Indirectness:</strong> SERIOUS (viral load, not clinical outcomes). Certainty: <strong>VERY LOW</strong>. Subsequent RCTs (RECOVERY, WHO Solidarity) showed no benefit. The pandemic revealed what happens when certainty assessment is bypassed."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ¦ ", title: "ì‹œë‚˜ë¦¬ì˜¤: ìœ í–‰ë³‘ ì¦ê±° í‰ê°€",
        xp: 30,
        scenario: "ìƒˆë¡œìš´ í˜¸í¡ê¸° ë°”ì´ëŸ¬ìŠ¤ê°€ ë“±ì¥í•©ë‹ˆë‹¤. 80ëª…ì˜ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ë‹¨ì¼ ì„¼í„° ì—°êµ¬(ë¹„ë¬´ì‘ìœ„, ê³µê°œ ë¼ë²¨)ì—ì„œëŠ” ìš©ë„ ë³€ê²½ëœ ì•½ë¬¼ì´ ICU ì…ì›ì„ 25%ì—ì„œ 12%ë¡œ ê°ì†Œì‹œí‚¤ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ê²°ê³¼ëŠ” 'ìœ ë§'í•˜ë‹¤ê³  í™ë³´ë˜ê³  ë§‰ëŒ€í•œ ëŒ€ì¤‘ ìˆ˜ìš”ë¥¼ ì°½ì¶œí•©ë‹ˆë‹¤.",
        question: "ì´ ì¦ê±°ë¥¼ ì–´ë–»ê²Œ í‰ê°€í•˜ê³  ì „ë‹¬í•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "ë³´í†µâ€”íš¨ê³¼ í¬ê¸°ê°€ í¬ê³  ì„ìƒì ìœ¼ë¡œ ì˜ë¯¸ê°€ ìˆìŠµë‹ˆë‹¤", correct: false },
          { letter: "B", text: "ë‚®ìŒâ€”ì‹¬ê°í•œ í•œê³„ê°€ ìˆëŠ” ê´€ì°° ì—°êµ¬", correct: false },
          { letter: "C", text: "VERY LOWâ€”critical risk of bias, serious imprecision; communicate uncertainty clearly", correct: true },
          { letter: "D", text: "Cannot rateâ€”more studies needed before any assessment", correct: false }
        ],
        feedback: {
          correct: "Correct! Non-randomized, open-label, single-center, n=80: VERY LOW certainty. The effect might be real, might be selection bias, might be confounding. Communicating this uncertaintyâ€”not dismissing the evidence, but properly contextualizing itâ€”is essential for informed decision-making.",
          incorrect: "ì´ ì‹œë‚˜ë¦¬ì˜¤ëŠ” ë‹¤ìŒê³¼ ê°™ìŠµë‹ˆë‹¤. í•˜ì´ë“œë¡ì‹œí´ë¡œë¡œí€¸. ì¤‘ëŒ€í•œ ë¹„ëš¤ë¦¼ ìœ„í—˜(ë¹„ë¬´ì‘ìœ„, ê³µê°œ ë¼ë²¨)ê³¼ ì‹¬ê°í•œ ë¶€ì •í™•ì„±(í™˜ì 80ëª…)ìœ¼ë¡œ ì¸í•´ í™•ì‹¤ì„±ì€ ë§¤ìš° ë‚®ìŠµë‹ˆë‹¤. ì´ëŠ” 'ë¬´ì‹œ'í•œë‹¤ëŠ” ì˜ë¯¸ê°€ ì•„ë‹ˆë¼ ë” ë‚˜ì€ ì¦ê±°ë¥¼ ê¸°ë‹¤ë¦¬ë©´ì„œ ì‹¬ê°í•œ ë¶ˆí™•ì‹¤ì„±ì„ ì „ë‹¬í•œë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "green-bg", content: {
        label: "Case 3: The Insulin Pump Victory", title: "When Certainty Builds Slowly",
        text: "ì œ1í˜• ë‹¹ë‡¨ë³‘ì— ëŒ€í•œ ì§€ì†ì ì¸ í”¼í•˜ ì¸ìŠë¦° ì£¼ì…(íŒí”„ ìš”ë²•)ì€ ìˆ˜ì‹­ ë…„ì— ê±¸ì³ ì¦ê±°ë¥¼ ì¶•ì í–ˆìŠµë‹ˆë‹¤. ì´ˆê¸° ì‹œí—˜ì€ ê·œëª¨ê°€ ì‘ì•˜ìŠµë‹ˆë‹¤. ê²°ê³¼ëŠ” ë‹¤ì–‘í–ˆìŠµë‹ˆë‹¤. ë‹¨ í•œ ë²ˆì˜ ì¬íŒë„ í™•ì •ë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ëª¨ìì´í¬ê°€ í•˜ë‚˜ë¡œ í•©ì³ì¡ŒìŠµë‹ˆë‹¤.",
        followup: "By 2010, meta-analyses showed: consistent HbA1c improvement (~0.3%), reduced severe hypoglycemia, improved quality of life. <strong>Risk of bias:</strong> Some concerns but improving over time. <strong>Inconsistency:</strong> Low for HbA1c, moderate for hypoglycemia (likely explainable by patient selection). <strong>Indirectness:</strong> Noneâ€”direct outcomes in target population. <strong>Imprecision:</strong> Resolved with cumulative trials. <strong>Publication bias:</strong> Low concern with trials in multiple settings. Final rating: <strong>MODERATE to HIGH</strong> for HbA1c improvement, with appropriate nuance for other outcomes."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“‹", title: "ì‹œë‚˜ë¦¬ì˜¤: ì§„í™”í•˜ëŠ” ì¦ê±° ê¸°ë°˜",
        xp: 25,
        scenario: "You're updating a guideline. Five years ago, certainty was LOW for a treatment. Since then: 3 new large RCTs with low risk of bias, consistent results (IÂ²=18%), direct population and outcomes, total events now exceed OIS, no evidence of publication bias.",
        question: "What certainty rating is now appropriate?",
        options: [
          { letter: "A", text: "Remains LOWâ€”initial rating shouldn't change dramatically", correct: false },
          { letter: "B", text: "MODERATEâ€”new evidence improves but doesn't transform certainty", correct: false },
          { letter: "C", text: "HIGHâ€”new RCTs with no serious concerns across domains", correct: true },
          { letter: "D", text: "Requires independent replication before upgrading", correct: false }
        ],
        feedback: {
          correct: "Correct! GRADE ratings should evolve as evidence evolves. Starting HIGH (RCTs), no downgrading needed: low risk of bias, consistent (IÂ²=18%), direct outcomes, adequate precision (exceeds OIS), no publication bias concern. The evidence now supports HIGH certainty.",
          incorrect: "GRADEëŠ” ì‚´ì•„ìˆëŠ” í”„ë ˆì„ì›Œí¬ì…ë‹ˆë‹¤. ì¦ê±°ê°€ ì¶•ì ë˜ê³  ì´ì „ ìš°ë ¤ ì‚¬í•­ì´ í•´ê²°ë¨ì— ë”°ë¼ í™•ì‹¤ì„±ì„ ì¬í‰ê°€í•´ì•¼ í•©ë‹ˆë‹¤. ëª¨ë“  ì˜ì—­ì„ ë‹¤ë£¨ëŠ” ì¼ê´€ì ì¸ ê²°ê³¼ë¥¼ ì œê³µí•˜ëŠ” 3ê°œì˜ ëŒ€ê·œëª¨, ë‚®ì€ í¸í–¥ RCTëŠ” í™•ì‹¤ì„±ì„ LOWì—ì„œ HIGHë¡œ ì ˆëŒ€ì ìœ¼ë¡œ ë†’ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Case 4: The Arthroscopy Lesson Revisited", title: "When Guidelines Persist Despite Evidence",
        text: "2008ë…„ê¹Œì§€ 2ê°œì˜ ê°€ì§œ ìˆ˜ìˆ  RCTì—ì„œ ê³¨ê´€ì ˆì—¼ì— ëŒ€í•œ ë¬´ë¦ ê´€ì ˆê²½ ê²€ì‚¬ê°€ ìœ„ì•½ë³´ë‹¤ ë‚˜ì„ ê²ƒì´ ì—†ë‹¤ëŠ” ê²ƒì´ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ê·¼ê±°ëŠ” ì˜ ì„¤ê³„ëœ RCT, ì¼ê´€ëœ ê²°ê³¼, ì§ì ‘ì ì¸ ê²°ê³¼ ë“± ë†’ì€ í™•ì‹¤ì„±ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì§€ì¹¨ì´ ë³€ê²½ë˜ëŠ” ë° ìˆ˜ë…„ì´ ê±¸ë ¸ê³  ì ˆì°¨ëŠ” ê³„ì†ë˜ì—ˆìŠµë‹ˆë‹¤.",
        followup: "This reveals GRADE's limitation: certainty ratings inform decisions but don't make them. Surgeons argued: 'My patients improve.' Patients wanted the procedure. Systems had invested in it. A HIGH certainty of 'no benefit' should have ended the practiceâ€”but implementation requires more than evidence rating. GRADE tells us what the evidence says; behavior change requires understanding why evidence gets ignored."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ”¬", title: "ì‹œë‚˜ë¦¬ì˜¤: ì¦ê±°-ì‹¤ì²œ ê²©ì°¨",
        xp: 25,
        scenario: "ê°€ì´ë“œë¼ì¸ íŒ¨ë„ì€ ì¼ë°˜ì ì¸ ì ˆì°¨ê°€ ìœ„ì•½ë³´ë‹¤ ë‚˜ì„ ê²ƒì´ ì—†ë‹¤ëŠ” ê·¼ê±°ë¥¼ ë†’ì€ í™•ì‹¤ì„±ìœ¼ë¡œ í‰ê°€í•©ë‹ˆë‹¤. ì´ ì ˆì°¨ëŠ” ìˆ˜ìµì„±ì´ ë†’ê³  ê´‘ë²”ìœ„í•˜ê²Œ ìˆ˜í–‰ë˜ë©° í™˜ìë“¤ì€ ë§Œì¡±ê°ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. íŒ¨ë„ íšŒì›ë“¤ì€ ê¶Œì¥ ê°•ë„ì— ëŒ€í•´ ë™ì˜í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.",
        question: "What recommendation strength is appropriate given HIGH certainty of no benefit?",
        options: [
          { letter: "A", text: "Strong recommendation AGAINSTâ€”high certainty of no benefit demands strong action", correct: true },
          { letter: "B", text: "Conditional recommendation againstâ€”patient preferences matter", correct: false },
          { letter: "C", text: "No recommendationâ€”practice patterns should determine guidelines", correct: false },
          { letter: "D", text: "Conditional recommendation forâ€”patients report benefit", correct: false }
        ],
        feedback: {
          correct: "Correct! HIGH certainty that a procedure provides no benefit over placebo justifies a STRONG recommendation against. Patient-reported benefit in unblinded settings is placebo effect. Resource use for ineffective treatments has opportunity costs. High certainty + unfavorable balance = strong recommendation.",
          incorrect: "í™•ì‹¤ì„±ì´ ë†’ê³  ê· í˜•ì´ í™•ì‹¤íˆ ë¶ˆë¦¬í•œ ê²½ìš°(í˜œíƒ ì—†ìŒ, ìˆ˜ìˆ  ìœ„í—˜, ë¹„ìš©) GRADEëŠ” ê°•ë ¥í•œ ê¶Œì¥ ì‚¬í•­ì„ ì§€ì§€í•©ë‹ˆë‹¤. ìœ„ì•½ì— ëŒ€í•œ í™˜ìì˜ ë§Œì¡±ë„ëŠ” ì¹¨ìŠµì  ì‹œìˆ ì˜ ì§€ì†ì ì¸ ì‚¬ìš©ì„ ì •ë‹¹í™”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê°•ë ¥í•œ ì¦ê±°ëŠ” ê°•ë ¥í•œ ê¶Œì¥ ì‚¬í•­ì„ ì´ëŒì–´ë‚´ì•¼ í•©ë‹ˆë‹¤."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "í™•ì‹¤ì„±ì—ì„œ ê¶Œì¥ ì‚¬í•­ìœ¼ë¡œ",
        subtitle: "ì¦ê±°ì˜ ì§ˆì€ ë°©ì •ì‹ì˜ ì¼ë¶€ì¼ ë¿ì…ë‹ˆë‹¤",
        text: "GRADE separates certainty of evidence from strength of recommendations. A recommendation considers:<br><br>â€¢ Certainty of evidence<br>â€¢ Balance of benefits vs. harms<br>â€¢ Patient values and preferences<br>â€¢ Resource use and feasibility",
        highlight: "Even LOW certainty evidence can support a STRONG recommendation (e.g., parachutes) if benefits clearly outweigh harms."
      }},
      { type: "story", theme: "dark", content: {
        label: "ì‚¬ë¡€ 5: ìˆ˜í˜ˆ ê¸°ì¤€ì¹˜", title: "When Less Is More",
        text: "For decades, blood transfusion thresholds were set at hemoglobin <10 g/dLâ€”the '10/30 rule.' The practice seemed logical: more blood should be better for anemic patients. Then came the RCTs.",
        followup: "The TRICC trial (1999) and subsequent studies showed <strong>restrictive transfusion (Hb <7 g/dL)</strong> was as safe or safer than liberal transfusion in most patients. The evidence accumulated: <strong>Risk of bias:</strong> Low in major trials. <strong>Inconsistency:</strong> Low across settings. <strong>Indirectness:</strong> Some subgroups less studied. <strong>Imprecision:</strong> Resolved with multiple trials. <strong>Publication bias:</strong> Unlikely given consistent direction. Certainty: <strong>MODERATE to HIGH</strong> for most populations. Guidelines changed. A practice that had seemed obviously beneficial was actually harmful."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ©¸", title: "ì‹œë‚˜ë¦¬ì˜¤: ì œí•œì ì¸ ì „ëµ",
        xp: 25,
        scenario: "ì—¬ëŸ¬ RCTì—ì„œëŠ” ì œí•œì ì¸ ìˆ˜í˜ˆì´ ììœ  ìˆ˜í˜ˆë§Œí¼ ì•ˆì „í•˜ë©° ì¼ë¶€ í•˜ìœ„ ê·¸ë£¹ì—ì„œëŠ” ì‚¬ë§ë¥ ì´ ë” ë‚®ì€ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ê¸‰ì„± ê´€ìƒë™ë§¥ ì¦í›„êµ° í™˜ìì˜ ê²½ìš° ì„ìƒì ìœ¼ë¡œ ì¤‘ìš”í•œ ì„ê³„ê°’ì„ ë„˜ëŠ” ë„“ì€ ì‹ ë¢° êµ¬ê°„ì„ ê°€ì§„ ë‹¨ í•˜ë‚˜ì˜ ì‘ì€ RCTë§Œ ì¡´ì¬í•©ë‹ˆë‹¤.",
        question: "How should certainty differ between general hospital patients and ACS patients?",
        options: [
          { letter: "A", text: "ë™ì¼í•œ í™•ì‹¤ì„± - ì „ì²´ ì¦ê±°ê°€ ëª¨ë“  í™˜ìì—ê²Œ ì ìš©ë©ë‹ˆë‹¤.", correct: false },
          { letter: "B", text: "ACSì˜ ê²½ìš° ë” ë‚®ìŒ - ë¶€ì •í™•ì„±ê³¼ ê°„ì ‘ì„±ì€ ë³„ë„ì˜ í‰ê°€ê°€ í•„ìš”í•¨", correct: true },
          { letter: "C", text: "ACSì˜ ê²½ìš° ë” ë†’ìŒâ€”ìˆ˜í˜ˆ í•©ë³‘ì¦ìœ¼ë¡œ ì¸í•´ ìƒì„ ê²ƒì´ ë” ë§ìŠµë‹ˆë‹¤", correct: false },
          { letter: "D", text: "ACSë¥¼ í‰ê°€í•  ìˆ˜ ì—†ìŒâ€”ê²°ë¡ ì— ëŒ€í•œ ì¦ê±°ê°€ ë¶€ì¡±í•¨", correct: false }
        ],
        feedback: {
          correct: "ë§ìŠµë‹ˆë‹¤! ACS í™˜ìëŠ” ì„œë¡œ ë‹¤ë¥¸ ë°˜ì‘(ì‹¬ê·¼ ì‚°ì†Œ ìš”êµ¬ëŸ‰)ì— ëŒ€í•œ ìƒë¬¼í•™ì  ì´ìœ ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ ëª¨ì§‘ë‹¨ì—ì„œ í•˜ë‚˜ì˜ ì‘ì€ ë¶€ì •í™•í•œ RCTëŠ” ê°„ì ‘ì„±(ì¼ë°˜ í™˜ìë¡œë¶€í„° ì¶”ì •) ë˜ëŠ” ë¶€ì •í™•ì„±(ì§ì ‘ ACS ì¦ê±°) ëª¨ë‘ ë‚®ì€ í™•ì‹¤ì„±ì„ ë³´ì¥í•œë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. GRADEëŠ” ëª¨ì§‘ë‹¨ë³„ë¡œ ë‹¤ë¦…ë‹ˆë‹¤.",
          incorrect: "GRADEë¥¼ ì‚¬ìš©í•˜ë ¤ë©´ ê° íŠ¹ì • ëª¨ì§‘ë‹¨ì— ëŒ€í•œ í™•ì‹¤ì„±ì„ í‰ê°€í•´ì•¼ í•©ë‹ˆë‹¤. ACS í™˜ìëŠ” ì¼ë°˜ë³‘ì› í™˜ìì™€ ë‹¤ë¥´ê²Œ ë°˜ì‘í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ACS í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ì†Œê·œëª¨ ë¶€ì •í™•í•œ ì„ìƒì‹œí—˜ì€ ë‹¤ë¥¸ ì¸êµ¬ ì§‘ë‹¨ì— ëŒ€í•œ ê´‘ë²”ìœ„í•œ ì¦ê±° ê¸°ë°˜ê³¼ ë™ì¼í•œ í™•ì‹¤ì„±ì„ ì œê³µí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤."
        }
      }},
      { type: "quiz", theme: "dark", content: {
        question: "í•˜ì´ë“œë¡ì‹œí´ë¡œë¡œí€¸ ì½”ë¡œë‚˜19 ê²½í—˜ì—ì„œ ê°€ì¥ ì¤‘ìš”í•œ êµí›ˆì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
        options: [
          { text: "ê´€ì°° ì—°êµ¬ëŠ” í•­ìƒ ì‹ ë¢°í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤", correct: false },
          { text: "Proper GRADE assessment should precede clinical adoption and policy", correct: true },
          { text: "Repurposed drugs don't work for new diseases", correct: false },
          { text: "ë¯¸ë””ì–´ëŠ” ì˜ë£Œì— ëŒ€í•´ ë³´ë„í•´ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤. ì—°êµ¬", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "ì •í™•í•©ë‹ˆë‹¤. ì„ íƒì  ì œì™¸ê°€ í¬í•¨ëœ 36ëª…ì˜ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ë¹„ë¬´ì‘ìœ„ ê³µê°œ ë¼ë²¨ ì—°êµ¬ëŠ” ëª¨ë“  GRADE í‰ê°€ì—ì„œ í™•ì‹¤ì„±ì´ ë§¤ìš° ë‚®ì•˜ìŠµë‹ˆë‹¤. ë„ì… ì „ ì²´ê³„ì ì¸ í™•ì‹¤ì„± í‰ê°€ë¥¼ í†µí•´ ë¹„íš¨ê³¼ì ì¸ ì¹˜ë£Œë²•ì˜ ê´‘ë²”ìœ„í•œ ì‚¬ìš©ì„ ë°©ì§€í•˜ê³  ëŒ€ì¤‘ì˜ ì‹ ë¢°ë¥¼ ìœ ì§€í•  ìˆ˜ ìˆì—ˆì„ ê²ƒì…ë‹ˆë‹¤.",
          incorrect: "êµí›ˆì€ ì†Œê·œëª¨ ì—°êµ¬ê°€ ê°€ì¹˜ê°€ ì—†ë‹¤ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ ì ì ˆí•œ í™•ì‹¤ì„± í‰ê°€ê°€ í•„ìš”í•˜ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì—„ê²©í•œ GRADE í‰ê°€ë¥¼ í†µí•´ ì´ í™•ì‹¤ì„±ì€ ì¦‰ì‹œ ë§¤ìš° ë‚®ìŒìœ¼ë¡œ í‘œì‹œë˜ì—ˆì„ ê²ƒì…ë‹ˆë‹¤. íŠ¹íˆ ì••ë°•ê°ì´ ê°€ì¥ ë†’ì€ ìœ„ê¸° ìƒí™©ì—ì„œëŠ” ì²´ê³„ì ì¸ í‰ê°€ê°€ ì„ìƒ ì±„íƒì— ì•ì„œ ì´ë£¨ì–´ì ¸ì•¼ í•©ë‹ˆë‹¤."
        }
      }}
    ]
  },
  {
    id: 10, title: "Final Assessment", subtitle: "ìˆ™ë‹¬ë„ í…ŒìŠ¤íŠ¸", xp: 250,
    slides: [
      { type: "title", theme: "dark", content: { title: "Final Assessment", subtitle: "Demonstrate your mastery of GRADE certainty assessment" }},
      { type: "concept", theme: "dark", content: {
        title: "ìµœì¢… ê³¼ì œ",
        subtitle: "Apply everything you've learned",
        text: "ì´ ëª¨ë“ˆì—ì„œëŠ” í†µí•© GRADE í‰ê°€ê°€ í•„ìš”í•œ ë³µì¡í•œ ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ì œì‹œí•©ë‹ˆë‹¤. ì—¬ëŸ¬ ì˜ì—­ì„ ë™ì‹œì— ê³ ë ¤í•˜ê³  ë¯¸ë¬˜í•œ íŒë‹¨ì„ ë‚´ë ¤ì•¼ í•©ë‹ˆë‹¤.",
        highlight: "GRADE ë§ˆìŠ¤í„° ë°°ì§€ë¥¼ íšë“í•˜ë ¤ë©´ 80% ì •í™•ë„ë¥¼ ëª©í‘œë¡œ í•˜ì„¸ìš”!"
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“Š", title: "Challenge 1: The New Cancer Drug",
        xp: 35,
        scenario: "A new cancer drug shows median survival improvement from 11 to 14 months in a single industry-funded RCT (n=600). Primary outcome was changed mid-trial from overall survival to progression-free survival. Three of seven pre-specified secondary outcomes were not reported. The survival benefit was a post-hoc analysis.",
        question: "What certainty rating is appropriate for overall survival benefit?",
        options: [
          { letter: "A", text: "HIGHâ€”RCT showing survival benefit", correct: false },
          { letter: "B", text: "MODERATEâ€”single trial but clinically meaningful", correct: false },
          { letter: "C", text: "LOWâ€”downgrade for risk of bias (outcome switching, selective reporting)", correct: true },
          { letter: "D", text: "VERY LOWâ€”multiple serious concerns", correct: false }
        ],
        feedback: {
          correct: "Correct! Key risk of bias concerns: (1) primary outcome changed mid-trial, (2) unreported secondary outcomes, (3) survival benefit was post-hoc. Each suggests selective reporting. Starting HIGH, downgrade one or two levels for serious risk of bias. Industry funding adds concern but isn't sufficient alone for downgrading.",
          incorrect: "The trial shows classic selective reporting: changing primary endpoint, hiding unfavorable secondary outcomes, promoting post-hoc survival analysis. These risk of bias concerns require downgrading even when the finding itself is statistically significant."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ”", title: "ì±Œë¦°ì§€ 2: ë©”íƒ€ ë¶„ì„ í¼ì¦",
        xp: 35,
        scenario: "A meta-analysis of 20 RCTs (n=15,000) shows significant mortality reduction (RR 0.85, 95% CI 0.76-0.95). However: IÂ²=68%, prediction interval 0.62-1.15, funnel plot shows slight asymmetry, 4 trials registered but never published.",
        question: "Which domains require downgrading and by how much?",
        options: [
          { letter: "A", text: "Inconsistency (âˆ’1), publication bias (âˆ’1): HIGH â†’ LOW", correct: true },
          { letter: "B", text: "Imprecision only (âˆ’1): HIGH â†’ MODERATE", correct: false },
          { letter: "C", text: "Inconsistency (âˆ’2): HIGH â†’ LOW", correct: false },
          { letter: "D", text: "Publication bias only (âˆ’1): HIGH â†’ MODERATE", correct: false }
        ],
        feedback: {
          correct: "Correct! Inconsistency: IÂ²=68% with prediction interval crossing 1.0 (could show harm) warrants one downgrade. Publication bias: 4 registered but unpublished trials plus funnel asymmetry warrants one downgrade. Two domains = two downgrades = HIGH â†’ LOW.",
          incorrect: "ì˜ˆì¸¡ êµ¬ê°„(0.62-1.15)ì´ êµì°¨í•©ë‹ˆë‹¤. 1.0 - ë‹¤ìŒ ì—°êµ¬ì—ì„œëŠ” ìœ í•´ì„±ì´ ë‚˜íƒ€ë‚  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‹¬ê°í•œ ë¶ˆì¼ì¹˜ì…ë‹ˆë‹¤. ê¹”ë•Œê¸° ë¹„ëŒ€ì¹­ì„±ê³¼ 4ê°œì˜ ë¯¸ì¶œíŒ ë“±ë¡ ì„ìƒì‹œí—˜ì€ ì¶œíŒ í¸í–¥ì˜ ì§ì ‘ì ì¸ ì¦ê±°ì…ë‹ˆë‹¤. ë‘ ì˜ì—­ ëª¨ë‘ ë‹¤ìš´ê·¸ë ˆì´ë“œê°€ í•„ìš”í•©ë‹ˆë‹¤."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ’‰", title: "ë„ì „ 3: ë°±ì‹  íš¨ëŠ¥",
        xp: 35,
        scenario: "A vaccine trial (n=40,000) shows 95% efficacy against symptomatic disease (RR 0.05, 95% CI 0.03-0.08). Low risk of bias, consistent subgroup results, direct outcome. However, follow-up is only 3 months, and durability of protection is unknown.",
        question: "How should certainty be rated for short-term vs. long-term efficacy?",
        options: [
          { letter: "A", text: "HIGH for bothâ€”large, well-conducted trial", correct: false },
          { letter: "B", text: "HIGH for short-term; VERY LOW for long-term (no data)", correct: false },
          { letter: "C", text: "HIGH for short-term efficacy; LOW for 12-month efficacy (indirect/imprecise)", correct: true },
          { letter: "D", text: "MODERATE for bothâ€”duration uncertainty affects all conclusions", correct: false }
        ],
        feedback: {
          correct: "Correct! Short-term efficacy: large RCT, low bias, precise, direct = HIGH. Long-term efficacy: either indirect (extrapolating from 3 months) or imprecise (no data). GRADE is outcome-specificâ€”different time horizons may have different certainty ratings.",
          incorrect: "GRADEëŠ” íŠ¹ì • ê²°ê³¼ì— ëŒ€í•œ í™•ì‹¤ì„±ì„ í‰ê°€í•©ë‹ˆë‹¤. 3ê°œì›” ë°ì´í„°ëŠ” 3ê°œì›” íš¨ëŠ¥(HIGH)ì„ ì§ì ‘ì ìœ¼ë¡œ ë’·ë°›ì¹¨í•©ë‹ˆë‹¤. 12ê°œì›” íš¨ëŠ¥ì—ëŠ” ì™¸ì‚½ë²•(ê°„ì ‘ì„±)ì´ í•„ìš”í•˜ê±°ë‚˜ ì§ì ‘ì ì¸ ë°ì´í„°ê°€ ì—†ìŠµë‹ˆë‹¤(ë¶€ì •ë°€ì„±). ë™ì¼í•œ ì„ìƒì‹œí—˜ì€ ë‹¤ì–‘í•œ ì§ˆë¬¸ì— ëŒ€í•´ ë‹¤ì–‘í•œ í™•ì‹¤ì„±ì„ ì§€ì›í•©ë‹ˆë‹¤."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "âš–ï¸", title: "ì±Œë¦°ì§€ 4: ê´€ì°° ì—…ê·¸ë ˆì´ë“œ",
        xp: 35,
        scenario: "Cohort studies show a procedure reduces mortality from 95% to 15% (RR 0.16). No RCTs exist because the natural history (95% death) makes randomization unethical. Dose-response is present: earlier intervention shows better outcomes. All plausible confounders would make patients receiving intervention sicker (selection of more severe cases).",
        question: "ì´ ê´€ì°° ì¦ê±°ë¥¼ ì–´ëŠ ìˆ˜ì¤€ê¹Œì§€ ì—…ê·¸ë ˆì´ë“œí•´ì•¼ í•©ë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "No upgradeâ€”observational evidence stays LOW", correct: false },
          { letter: "B", text: "Upgrade to MODERATEâ€”one upgrading factor (large effect)", correct: false },
          { letter: "C", text: "Upgrade to HIGHâ€”all three upgrading factors clearly present", correct: true },
          { letter: "D", text: "Upgrade to MODERATEâ€”observational can never reach HIGH", correct: false }
        ],
        feedback: {
          correct: "Correct! All three upgrading factors: (1) Large effectâ€”RR 0.16 (84% relative reduction from 95% to 15%). (2) Dose-responseâ€”earlier = better. (3) Confounding directionâ€”sicker patients receive intervention, which would bias AGAINST benefit if anything. Multiple upgrading factors can raise observational evidence to HIGH.",
          incorrect: "ì´ëŠ” ì„¸ ê°€ì§€ ì—…ê·¸ë ˆì´ë“œ ê¸°ì¤€ì„ ëª¨ë‘ ì¶©ì¡±í•©ë‹ˆë‹¤. íš¨ê³¼ í¬ê¸°(RR 0.16)ëŠ” ì‚¬ë§ë¥ ì´ 95%~15%ë¡œ ë§¤ìš° í½ë‹ˆë‹¤. ìš©ëŸ‰-ë°˜ì‘ì´ ì¡´ì¬í•¨. ê·¸ë¦¬ê³  êµë€ì€ ê´€ì°°ëœ íš¨ê³¼ì™€ ë°˜ëŒ€ ë°©í–¥ìœ¼ë¡œ ì‹¤í–‰ë©ë‹ˆë‹¤(ì•„í”ˆ í™˜ìê°€ ì‹œìˆ ì„ ë°›ìŠµë‹ˆë‹¤). ëª¨ë“  ê¸°ì¤€ì´ ëª…í™•í•˜ê²Œ ì¶©ì¡±ë˜ë©´ ê´€ì°° ì¦ê±°ëŠ” ë†’ì€ í™•ì‹¤ì„±ì— ë„ë‹¬í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ¯", title: "ë„ì „ 5: ì¢…í•© ê²°ê³¼",
        xp: 35,
        scenario: "An RCT shows significant reduction in 'major adverse cardiovascular events' (MACE: CV death, MI, stroke). However, decomposition reveals: CV death RR 1.02 (95% CI 0.85-1.22), MI RR 0.82 (0.72-0.94), Stroke RR 0.95 (0.80-1.13). The MACE benefit is driven entirely by MI.",
        question: "How should certainty differ for MACE vs. individual components?",
        options: [
          { letter: "A", text: "Same certaintyâ€”MACE is the primary outcome", correct: false },
          { letter: "B", text: "MACE HIGH; CV death/stroke may be rated MODERATE (imprecision)", correct: false },
          { letter: "C", text: "MI HIGH; CV death/stroke LOW (CI includes substantial harm/benefit); MACE MODERATE (driven by MI)", correct: true },
          { letter: "D", text: "ëª¨ë“  êµ¬ì„± ìš”ì†ŒëŠ” ë™ì¼í•˜ê²Œ ì˜ ìˆ˜í–‰ëœ RCTì—ì„œ ë‚˜ì˜µë‹ˆë‹¤.", correct: false }
        ],
        feedback: {
          correct: "Correct! GRADE is outcome-specific. MI evidence is precise (0.72-0.94 excludes 1.0). CV death and stroke CIs are wide and cross 1.0â€”we can't exclude no effect or harm. MACE driven entirely by MI means the composite obscures component-specific uncertainty. Different outcomes warrant different ratings even from the same trial.",
          incorrect: "ë³µí•© ê²°ê³¼ëŠ” êµ¬ì„± ìš”ì†Œë³„ ë¶ˆí™•ì‹¤ì„±ì„ ê°€ë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. RCTëŠ” ëª…í™•í•œ MI ê°ì†Œë¥¼ ë³´ì—¬ì£¼ì§€ë§Œ CV ì‚¬ë§ ë° ë‡Œì¡¸ì¤‘ì— ëŒ€í•œ ë¶ˆí™•ì‹¤ì„±ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. í™˜ìì™€ ì„ìƒì˜ëŠ” ì•½ë¬¼ì´ ì‚¬ë§ì„ ì˜ˆë°©í•˜ëŠ”ì§€ ì•„ë‹ˆë©´ ì¹˜ëª…ì ì´ì§€ ì•Šì€ ì‚¬ê±´ë§Œì„ ì˜ˆë°©í•˜ëŠ”ì§€ ì•Œì•„ì•¼ í•©ë‹ˆë‹¤. GRADEëŠ” ê° ê²°ê³¼ë¥¼ ê°œë³„ì ìœ¼ë¡œ í‰ê°€í•©ë‹ˆë‹¤."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ“‰", title: "ë¬¸ì œ 6: ì·¨ì•½í•œ ê²°ê³¼",
        xp: 35,
        scenario: "A meta-analysis of 5 small RCTs (total n=800, 48 events) shows statistically significant mortality benefit (RR 0.55, 95% CI 0.32-0.95, p=0.03). The fragility index is 2. A single large RCT (n=3,000) is underway.",
        question: "What certainty rating is appropriate while awaiting the large trial?",
        options: [
          { letter: "A", text: "HIGHâ€”statistically significant benefit from RCTs", correct: false },
          { letter: "B", text: "MODERATEâ€”some imprecision but consistent direction", correct: false },
          { letter: "C", text: "LOWâ€”serious imprecision (48 events, fragility index 2, below OIS)", correct: true },
          { letter: "D", text: "í‰ê°€í•  ìˆ˜ ì—†ìŒ - ëŒ€ê·œëª¨ ì‹œí—˜ì„ ê¸°ë‹¤ë¦¼", correct: false }
        ],
        feedback: {
          correct: "Correct! 48 events is far below typical OIS (200-400 for mortality). Fragility index of 2 means 2 different outcomes would flip the result. The CI is wide (0.32-0.95). This is classic imprecision requiring downgrade. We can make provisional conclusions while acknowledging the large trial may change everything.",
          incorrect: "Statistical significance doesn't guarantee precision. The fragility index of 2 means the 'significant' result is extremely unstable. 48 events is grossly underpowered for mortality conclusions. GRADE requires downgrading for imprecisionâ€”we should be honest about uncertainty while awaiting better data."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ§¬", title: "ë¬¸ì œ 7: ëŒ€ë¦¬ ê²°ê³¼",
        xp: 35,
        scenario: "A drug dramatically improves bone mineral density (+8% annually). Observational data suggest each 1% density improvement correlates with 5% fracture reduction. No fracture outcome trials have been conducted. The drug class has previously produced agents where density improved but fractures increased.",
        question: "What certainty applies to fracture prevention?",
        options: [
          { letter: "A", text: "MODERATEâ€”strong surrogate relationship", correct: false },
          { letter: "B", text: "LOWâ€”indirect evidence, but plausible mechanism", correct: false },
          { letter: "C", text: "VERY LOWâ€”serious indirectness (surrogate only) PLUS known discordance in drug class", correct: true },
          { letter: "D", text: "Cannot rate until fracture trials complete", correct: false }
        ],
        feedback: {
          correct: "Correct! Surrogate outcomes require downgrading for indirectness. But here there's added concern: the drug class has precedent for density-fracture discordance (like sodium fluoride). This history of surrogate-outcome discordance in the same class warrants serious downgrading. Starting LOW (observational), downgrade further for known class discordance.",
          incorrect: "ë¶ˆí™”ë‚˜íŠ¸ë¥¨ ì‚¬ë¡€(ë°€ë„ ì¦ê°€, ê³¨ì ˆ)ì€ ëŒ€ë¦¬ ê²°ê³¼ ë¶ˆì¼ì¹˜ê°€ ì•Œë ¤ì§„ ë™ì¼í•œ ì•½ë¬¼ ì¢…ë¥˜ì™€ ì§ì ‘ì ì¸ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. ì•½ë¬¼ í´ë˜ìŠ¤ê°€ ëŒ€ë¦¬ìê°€ ê²°ê³¼ì™€ ë°˜ëŒ€ ë°©í–¥ìœ¼ë¡œ ì›€ì§ì¼ ìˆ˜ ìˆìŒì„ ë³´ì—¬ì£¼ë©´ í•´ë‹¹ í´ë˜ìŠ¤ì˜ ì‹ ì•½ì—ì„œ ì–»ì€ ëŒ€ë¦¬ ë°ì´í„°ëŠ” ë§¤ìš° ë¶ˆí™•ì‹¤í•©ë‹ˆë‹¤."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ğŸ¥", title: "ê³¼ì œ 8: ì‹œìŠ¤í…œ ìˆ˜ì¤€ ì¦ê±°",
        xp: 35,
        scenario: "ê³„ë‹¨í˜• í´ëŸ¬ìŠ¤í„° RCTëŠ” ë³‘ì› í”„ë¡œí† ì½œì´ 30ì¼ ì‚¬ë§ë¥ ì„ ê°ì†Œì‹œí‚¤ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤(OR 0.75, 95% CI 0.62-0.91). 20ê°œ ë³‘ì›ì´ ì°¸ì—¬í–ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ê°œì…ì€ í˜„ì¥ë§ˆë‹¤ ë‹¤ë¥´ê²Œ ì‹œí–‰ë˜ì—ˆê³  ê²°ê³¼ëŠ” ë§¹ê²€ í•´ì œë¡œ í‰ê°€ë˜ì—ˆìœ¼ë©° 5ê°œ ë³‘ì›ì€ ì‹œí—˜ ì¤‘ê°„ì— ì² íšŒë˜ì—ˆìŠµë‹ˆë‹¤.",
        question: "ì–´ë–¤ GRADE ì˜ì—­ì´ ì´ëŸ¬í•œ ë°©ë²•ë¡ ì  íŠ¹ì§•ì˜ ì˜í–¥ì„ ë°›ìŠµë‹ˆê¹Œ?",
        options: [
          { letter: "A", text: "Risk of bias onlyâ€”other domains unaffected", correct: false },
          { letter: "B", text: "Risk of bias (unblinded, attrition) + inconsistency (implementation variation)", correct: true },
          { letter: "C", text: "Imprecision onlyâ€”20 hospitals may be insufficient", correct: false },
          { letter: "D", text: "Indirectnessâ€”cluster trials don't apply to individual patients", correct: false }
        ],
        feedback: {
          correct: "Correct! Risk of bias: unblinded outcome assessment introduces detection bias; 5 hospital withdrawals are attrition bias. Inconsistency: variable implementation across sites may cause heterogeneity (different hospitals implementing different versions). Both domains warrant scrutiny.",
          incorrect: "ë§¹ê²€ í•´ì œ í‰ê°€ ë° ê°ì†Œ(5ê°œ ë³‘ì› ì¤‘í‡´)ëŠ” í¸í–¥ ìš°ë ¤ì˜ ì „í˜•ì ì¸ ìœ„í—˜ì…ë‹ˆë‹¤. ë³€ìˆ˜ êµ¬í˜„ì€ ë¶ˆì¼ì¹˜ ë¬¸ì œì…ë‹ˆë‹¤. ë³‘ì›ì´ ë‹¤ë¥´ê²Œ êµ¬í˜„ë˜ë©´ 'ê°œì…'ì´ ê· ì¼í•˜ì§€ ì•Šê³  êµ¬í˜„ ì¶©ì‹¤ë„ì— ë”°ë¼ ê²°ê³¼ê°€ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "GRADE in Numbers",
        stats: [
          { value: "4", label: "Certainty levels" },
          { value: "5", label: "Downgrading domains" },
          { value: "3", label: "Upgrading factors" },
          { value: "âˆ", label: "Lives protected by rigorous assessment" }
        ],
        caption: "Systematic certainty assessment protects patients from overconfident medicine."
      }},
      { type: "refrain", theme: "black", content: { text: "í™•ì‹¤ì„±ì€ ì–¼ë§ˆë‚˜ ë§ì€ ì¦ê±°ê°€ ì¡´ì¬í•˜ëŠ”ì§€ì— ê´€í•œ ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ì–¼ë§ˆë‚˜ ì‹ ë¢°í•´ì•¼ í•˜ëŠ”ê°€ì˜ ë¬¸ì œì…ë‹ˆë‹¤." }},
      { type: "quiz", theme: "dark", content: {
        question: "GRADEê°€ ì¦ê±° ê¸°ë°˜ ì˜í•™ì— ëŒ€í•´ ì œê³µí•˜ëŠ” ê·¼ë³¸ì ì¸ í†µì°°ë ¥ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
        options: [
          { text: "ëŒ€ê·œëª¨ ì—°êµ¬ëŠ” í•­ìƒ ë” ì¢‹ìŠµë‹ˆë‹¤", correct: false },
          { text: "RCTë§Œì´ ìœ íš¨í•œ ìœ ì¼í•œ ë°©ë²•ì…ë‹ˆë‹¤. ì¦ê±°", correct: false },
          { text: "í™•ì‹¤ì„±ì€ ê° ì˜ì—­ì— ëŒ€í•œ íˆ¬ëª…í•œ ì¶”ë¡ ì„ í†µí•´ ì²´ê³„ì ìœ¼ë¡œ í‰ê°€ë˜ì–´ì•¼ í•©ë‹ˆë‹¤.", correct: true },
          { text: "Meta-analyses provide definitive answers", correct: false }
        ],
        xp: 25,
        feedback: {
          correct: "Exactly. GRADE transforms implicit judgments into explicit, transparent assessments. By systematically considering risk of bias, inconsistency, indirectness, imprecision, and publication biasâ€”and documenting reasoningâ€”GRADE makes certainty assessment reproducible and debatable. This transparency is its core contribution.",
          incorrect: "GRADEì˜ ê·¼ë³¸ì ì¸ ê¸°ì—¬ëŠ” êµ¬ì¡°í™”ëœ íˆ¬ëª…ì„±ì…ë‹ˆë‹¤. ëª¨í˜¸í•œ í’ˆì§ˆ ë¼ë²¨ë³´ë‹¤ëŠ” ëª…ì‹œì ì¸ ì¶”ë¡ ì„ í†µí•´ íŠ¹ì • ì˜ì—­ì— ëŒ€í•œ ì²´ê³„ì ì¸ í‰ê°€ê°€ í•„ìš”í•©ë‹ˆë‹¤. ì´ëŠ” ì¦ê±°ê°€ ì¶•ì ë¨ì— ë”°ë¼ í™•ì‹¤ì„± íŒë‹¨ì„ ì¬í˜„ ê°€ëŠ¥í•˜ê³  ë…¼ìŸ ê°€ëŠ¥í•˜ë©° ê°œì„  ê°€ëŠ¥í•˜ê²Œ ë§Œë“­ë‹ˆë‹¤."
        }
      }}
    ]
  }
];

// ===== NAVIGATION STATE =====
let currentModule = 0;
let currentSlide = 0;
let consecutiveCorrect = gameState.consecutiveCorrect || 0;

// ===== SAVE/LOAD =====
function saveGame() {
  safeSetStorage('gradeGame_v1', gameState);
}

function resetProgress() {
  if (confirm('Reset all progress and achievements?')) {
    gameState = { ...DEFAULT_STATE, answeredQuestions: {}, badges: [], completedModules: [] };
    saveGame();
    currentModule = 0;
    currentSlide = 0;
    renderAll();
  }
}

// ===== COURSE PROGRESS =====
function updateCourseProgress() {
  const totalModules = MODULES.length;
  const completedCount = gameState.completedModules.length;
  const pct = Math.round((completedCount / totalModules) * 100);
  const fillEl = document.getElementById('courseProgressFill');
  const pctEl = document.getElementById('courseProgressPct');
  if (fillEl) fillEl.style.width = pct + '%';
  if (pctEl) pctEl.textContent = pct + '%';
}

// ===== XP & LEVELING =====
function addXP(amount) {
  gameState.xp += amount;
  checkLevelUp();
  saveGame();
  updateStatsDisplay();
  showXPPopup(amount);
}

function checkLevelUp() {
  for (let i = LEVELS.length - 1; i >= 0; i--) {
    if (gameState.xp >= LEVELS[i].xp && gameState.level < LEVELS[i].level) {
      gameState.level = LEVELS[i].level;
      showLevelUp(LEVELS[i]);
      break;
    }
  }
}

function showXPPopup(amount) {
  const popup = document.getElementById('xpPopup');
  document.getElementById('xpAmount').textContent = `+${amount}`;
  popup.classList.add('show');
  setTimeout(() => popup.classList.remove('show'), 1500);
}

function showLevelUp(levelData) {
  triggerConfetti();
}

// ===== BADGES =====
function awardBadge(badgeId) {
  if (gameState.badges.includes(badgeId)) return;
  gameState.badges.push(badgeId);
  saveGame();
  const badge = BADGES.find(b => b.id === badgeId);
  if (badge) showBadgeModal(badge);
  updateBadges();
}

function showBadgeDetails(badgeId) {
  const badge = BADGES.find(b => b.id === badgeId);
  if (badge) showBadgeModal(badge);
}

let _badgeModalTrapHandler = null;

function showBadgeModal(badge) {
  const modal = document.getElementById('badgeModal');
  document.getElementById('badgeModalIcon').textContent = badge.icon;
  document.getElementById('badgeModalTitle').textContent = badge.name;
  document.getElementById('badgeModalDesc').textContent = badge.desc;
  modal.classList.add('show');
  triggerConfetti();

  // Focus trap for accessibility
  const focusableElements = modal.querySelectorAll('button, [tabindex]:not([tabindex="-1"])');
  if (focusableElements.length > 0) {
    focusableElements[0].focus();
  }

  // Remove any previous handler before adding a new one
  if (_badgeModalTrapHandler) {
    modal.removeEventListener('keydown', _badgeModalTrapHandler);
  }

  _badgeModalTrapHandler = function(e) {
    if (e.key === 'Escape') {
      closeBadgeModal();
      return;
    }
    if (e.key === 'Tab') {
      const firstFocusable = focusableElements[0];
      const lastFocusable = focusableElements[focusableElements.length - 1];
      if (e.shiftKey && document.activeElement === firstFocusable) {
        e.preventDefault();
        lastFocusable.focus();
      } else if (!e.shiftKey && document.activeElement === lastFocusable) {
        e.preventDefault();
        firstFocusable.focus();
      }
    }
  };
  modal.addEventListener('keydown', _badgeModalTrapHandler);
}

function closeBadgeModal() {
  const modal = document.getElementById('badgeModal');
  if (_badgeModalTrapHandler) {
    modal.removeEventListener('keydown', _badgeModalTrapHandler);
    _badgeModalTrapHandler = null;
  }
  modal.classList.remove('show');
}

// ===== STREAK =====
function updateStreak() {
  const today = new Date().toDateString();
  if (gameState.lastActive !== today) {
    const yesterday = new Date(Date.now() - 86400000).toDateString();
    if (gameState.lastActive === yesterday) {
      gameState.streak++;
      if (gameState.streak >= 3) awardBadge('streak_3');
      if (gameState.streak >= 7) awardBadge('streak_7');
    } else if (gameState.lastActive) {
      gameState.streak = 1;
    } else {
      gameState.streak = 1;
    }
    gameState.lastActive = today;
    saveGame();
  }
}

// ===== CONFETTI =====
function triggerConfetti() {
  if (window.matchMedia('(prefers-reduced-motion: reduce)').matches) return;
  const container = document.getElementById('confettiContainer');
  const colors = ['#D4AF37', '#22c55e', '#3b82f6', '#f59e0b', '#ef4444', '#7c3aed'];
  for (let i = 0; i < 50; i++) {
    const confetti = document.createElement('div');
    confetti.className = 'confetti';
    confetti.style.left = Math.random() * 100 + '%';
    confetti.style.background = colors[Math.floor(Math.random() * colors.length)];
    confetti.style.animationDelay = Math.random() * 0.5 + 's';
    container.appendChild(confetti);
    setTimeout(() => confetti.remove(), 3500);
  }
}

// ===== COMBO =====
function updateComboDisplay() {
  const comboEl = document.getElementById('comboDisplay');
  const countEl = document.getElementById('comboCount');
  if (consecutiveCorrect >= 2) {
    countEl.textContent = consecutiveCorrect;
    comboEl.classList.add('show');
  } else {
    comboEl.classList.remove('show');
  }
}

// ===== MOBILE SIDEBAR =====
function toggleSidebar() {
  document.querySelector('.sidebar').classList.toggle('open');
  document.getElementById('sidebarOverlay').classList.toggle('show');
  var btn = document.querySelector('.sidebar-toggle, .hamburger, .mobile-menu-btn'); if (btn) btn.setAttribute('aria-expanded', btn.getAttribute('aria-expanded') === 'true' ? 'false' : 'true');
}

// ===== RENDER =====
function renderAll() {
  updateStreak();
  renderSidebar();
  renderSlides();
  updateStatsDisplay();
  updateBadges();
  updateCourseProgress();
}

function updateStatsDisplay() {
  const levelData = LEVELS.find(l => l.level === gameState.level) || LEVELS[0];
  const nextLevel = LEVELS.find(l => l.level === gameState.level + 1);

  document.getElementById('levelIcon').textContent = levelData.icon;
  document.getElementById('levelTitle').textContent = levelData.title;
  document.getElementById('levelNum').textContent = gameState.level;

  const currentXP = gameState.xp - levelData.xp;
  const neededXP = nextLevel ? (nextLevel.xp - levelData.xp) : 500;
  const pct = Math.min(100, (currentXP / neededXP) * 100);

  document.getElementById('xpFill').style.width = pct + '%';
  document.getElementById('xpCurrent').textContent = currentXP;
  document.getElementById('xpNeeded').textContent = neededXP;

  document.getElementById('correctCount').textContent = gameState.correctAnswers;
  document.getElementById('decisionCount').textContent = gameState.decisionsCompleted;
  document.getElementById('gradesCount').textContent = gameState.gradesAssigned || 0;
  document.getElementById('streakCount').textContent = gameState.streak;

  const streakEl = document.getElementById('streakDisplay');
  streakEl.classList.toggle('active', gameState.streak > 0);
}

function updateBadges() {
  const grid = document.getElementById('badgesGrid');
  grid.innerHTML = BADGES.map(b => {
    const earned = gameState.badges.includes(b.id);
    return `<button class="badge-item ${earned ? 'earned' : ''}" type="button" ${earned ? `onclick="showBadgeDetails('${b.id}')"` : ''} aria-label="${b.name}: ${b.desc}" title="${b.name}: ${b.desc}" style="min-width:44px;min-height:44px">${b.icon}</button>`;
  }).join('');
}

function renderSidebar() {
  const list = document.getElementById('moduleList');
  list.innerHTML = MODULES.map((mod, i) => {
    const completed = gameState.completedModules.includes(mod.id);
    const locked = i > 0 && !gameState.completedModules.includes(MODULES[i-1].id);
    const estMins = Math.round(mod.slides.length * 1.5);
    return `
      <div class="module-item ${i === currentModule ? 'active' : ''} ${completed ? 'completed' : ''} ${locked ? 'locked' : ''}"
           onclick="${locked ? '' : `goToModule(${i})`}"
           tabindex="${locked ? -1 : 0}"
           role="button"
           aria-disabled="${locked ? 'true' : 'false'}">
        <div class="module-number">${completed ? 'âœ“' : (locked ? 'ğŸ”’' : mod.id)}</div>
        <div class="module-info">
          <div class="module-title">${mod.title}</div>
          <div class="module-subtitle">${mod.subtitle}</div>
          <div class="module-xp">+${mod.xp} XP</div>
          <div class="module-time">â±ï¸ ~${estMins} min</div>
        </div>
      </div>
    `;
  }).join('');
}

function renderSlides() {
  const container = document.getElementById('slidesContainer');
  container.innerHTML = MODULES.map((mod, mi) => {
    const progressPct = ((currentSlide + 1) / mod.slides.length) * 100;
    return `
    <div class="module-slides ${mi === currentModule ? 'active' : ''}" data-module="${mi}">
      <div class="slide-progress-bar" style="width: ${mi === currentModule ? progressPct : 0}%"></div>
      ${mod.slides.map((slide, si) => renderSlide(slide, si, mi)).join('')}
      <div class="slide-nav">
        <button class="nav-btn" onclick="prevSlide()" ${currentSlide === 0 ? 'disabled' : ''} aria-label="Previous slide">â†</button>
        <div class="nav-center">
          <div class="slide-counter">${currentSlide + 1} / ${mod.slides.length}</div>
          <div class="progress-dots">
            ${mod.slides.map((_, i) => `<button class="progress-dot ${i === currentSlide ? 'active' : ''}" type="button" onclick="goToSlide(${i})" aria-label="Go to slide ${i + 1}" ${i === currentSlide ? 'aria-current="true"' : ''}></button>`).join('')}
          </div>
        </div>
        <button class="nav-btn" onclick="nextSlide()" aria-label="Next slide">â†’</button>
      </div>
      <div class="keyboard-hint" style="position:absolute;bottom:5px;left:50%;transform:translateX(-50%);font-size:0.6rem;opacity:0.4;">â† â†’ arrows or swipe to navigate</div>
    </div>
  `;
  }).join('');
  document.getElementById('currentModule').textContent = MODULES[currentModule].title;
  updateSlideVisibility();
}

function renderSlide(slide, index, moduleIndex) {
  const theme = slide.theme || 'dark';
  let html = `<div class="slide ${theme} ${index === currentSlide ? 'active' : ''}" data-slide="${index}">`;

  switch(slide.type) {
    case 'title':
      html += `<div class="content"><h1 class="title gold animate">${slide.content.title}</h1><p class="subtitle animate delay-1">${slide.content.subtitle}</p></div>`;
      break;

    case 'objectives':
      html += `<div class="content">
        <div class="objectives-box animate">
          <div class="objectives-header">
            <div class="objectives-icon">ğŸ¯</div>
            <div class="objectives-title">Learning Objectives</div>
          </div>
          <ul class="objectives-list">
            ${slide.content.objectives.map(obj => `<li>${obj}</li>`).join('')}
          </ul>
        </div>
        ${slide.content.tip ? `<p class="subtitle animate delay-1" style="font-size:0.85rem;max-width:600px">${slide.content.tip}</p>` : ''}
      </div>`;
      break;

    case 'story':
      html += `<div class="content">
        <article class="story-box ${slide.content.success ? 'success' : ''} animate" role="article">
          <div class="story-label">${slide.content.label}</div>
          ${slide.content.title ? `<h2 class="title gold" style="font-size:1.8rem;margin-bottom:0.75rem">${slide.content.title}</h2>` : ''}
          <p class="story-text">${slide.content.text}</p>
          ${slide.content.followup ? `<p class="story-text" style="margin-top:0.75rem;font-style:italic;opacity:0.9">${slide.content.followup}</p>` : ''}
        </article>
      </div>`;
      break;

    case 'stats':
      html += `<div class="content">
        ${slide.content.title ? `<h2 class="title gold animate">${slide.content.title}</h2>` : ''}
        ${slide.content.subtitle ? `<p class="subtitle animate delay-1">${slide.content.subtitle}</p>` : ''}
        <div class="stats-grid animate delay-2">
          ${slide.content.stats.map(s => `<div class="stat-box"><div class="stat-value gold">${s.value}</div><div class="stat-label">${s.label}</div></div>`).join('')}
        </div>
        ${slide.content.caption ? `<p class="subtitle animate delay-3" style="font-size:0.85rem;margin-top:0.75rem">${slide.content.caption}</p>` : ''}
      </div>`;
      break;

    case 'refrain':
      html += `<div class="content" style="justify-content:center;height:100%"><p class="refrain animate">"${slide.content.text}"</p></div>`;
      break;

    case 'concept':
      html += `<div class="content">
        <h2 class="title ${theme === 'light' ? 'navy' : 'gold'} animate">${slide.content.title}</h2>
        ${slide.content.subtitle ? `<p class="subtitle animate delay-1">${slide.content.subtitle}</p>` : ''}
        ${slide.content.text ? `<div class="card ${theme === 'light' ? '' : 'navy-bg'} animate delay-2"><p class="card-text">${slide.content.text}</p></div>` : ''}
        ${slide.content.highlight ? `<div class="story-box warning animate delay-3"><div class="story-label">Key Insight</div><p class="story-text">${slide.content.highlight}</p></div>` : ''}
        ${slide.content.checkpoints ? `
          <div class="timeline animate delay-2" style="margin-top:0.75rem">
            ${slide.content.checkpoints.map(cp => `
              <div class="timeline-item"><div class="timeline-days">${cp.day}</div><div class="timeline-content"><div class="timeline-title">${cp.event}</div></div></div>
            `).join('')}
          </div>
        ` : ''}
      </div>`;
      break;

    case 'checklist':
      html += `<div class="content">
        <h2 class="title gold animate">${slide.content.title}</h2>
        <div class="checklist animate delay-1">
          ${slide.content.items.map(item => `
            <div class="checklist-item">
              <div class="check-icon">âœ“</div>
              <div class="checklist-text">${item}</div>
            </div>
          `).join('')}
        </div>
      </div>`;
      break;

    case 'decision':
      const did = `dec_${moduleIndex}_${index}`;
      const answered = gameState.answeredQuestions[did];
      html += `<div class="content">
        <div class="decision-tree animate">
          <div class="decision-header">
            <div class="decision-icon">${slide.content.icon}</div>
            <div class="decision-title">${slide.content.title}</div>
            <div class="decision-xp">+${slide.content.xp} XP</div>
          </div>
          <div class="decision-scenario">${slide.content.scenario}</div>
          <div class="decision-question">${slide.content.question}</div>
          <div class="decision-options">
            ${slide.content.options.map(opt => {
              const isSelected = answered === opt.letter;
              const showCorrect = answered && opt.correct;
              const showIncorrect = answered && isSelected && !opt.correct;
              return `
                <div class="decision-option ${isSelected ? 'selected' : ''} ${showCorrect ? 'correct' : ''} ${showIncorrect ? 'incorrect' : ''} ${answered ? 'disabled' : ''}"
                     onclick="answerDecision('${did}', '${opt.letter}', ${opt.correct}, ${slide.content.xp})"
                     tabindex="0"
                     role="button"
                     aria-disabled="${answered ? 'true' : 'false'}">
                  <div class="option-letter">${opt.letter}</div>
                  <div class="option-text">${opt.text}</div>
                </div>
              `;
            }).join('')}
          </div>
          <div class="decision-feedback ${answered ? 'show' : ''} ${answered && slide.content.options.find(o => o.letter === answered)?.correct ? 'correct' : 'incorrect'}" role="alert" aria-live="polite">
            <div class="feedback-title">${answered && slide.content.options.find(o => o.letter === answered)?.correct ? 'âœ“ Correct!' : 'âœ— Not quite'}</div>
            <div class="feedback-text">${answered && slide.content.options.find(o => o.letter === answered)?.correct ? slide.content.feedback.correct : slide.content.feedback.incorrect}</div>
          </div>
        </div>
      </div>`;
      break;

    case 'quiz':
      const qid = `quiz_${moduleIndex}_${index}`;
      const qAnswered = gameState.answeredQuestions[qid];
      html += `<div class="content">
        <div class="quiz-container animate">
          <div class="quiz-question">${slide.content.question}</div>
          <div class="quiz-options">
            ${slide.content.options.map((opt, oi) => {
              const isSelected = qAnswered === oi;
              const showCorrect = qAnswered !== undefined && opt.correct;
              const showIncorrect = qAnswered !== undefined && isSelected && !opt.correct;
              return `
                <div class="quiz-option ${showCorrect ? 'correct' : ''} ${showIncorrect ? 'incorrect' : ''} ${qAnswered !== undefined ? 'disabled' : ''}"
                     onclick="answerQuiz('${qid}', ${oi}, ${opt.correct}, ${slide.content.xp})"
                     tabindex="0"
                     role="button">
                  ${opt.text}
                </div>
              `;
            }).join('')}
          </div>
          <div class="quiz-feedback ${qAnswered !== undefined ? 'show' : ''} ${qAnswered !== undefined && slide.content.options[qAnswered]?.correct ? 'correct' : 'incorrect'}" role="alert" aria-live="polite">
            ${qAnswered !== undefined && slide.content.options[qAnswered]?.correct ? slide.content.feedback.correct : slide.content.feedback.incorrect}
          </div>
        </div>
      </div>`;
      break;
  }

  html += '</div>';
  return html;
}

function updateSlideVisibility() {
  const container = document.querySelector('.module-slides.active');
  if (!container) return;

  container.querySelectorAll('.slide').forEach((slide, i) => {
    slide.classList.toggle('active', i === currentSlide);
  });

  const progressBar = container.querySelector('.slide-progress-bar');
  if (progressBar) {
    const pct = ((currentSlide + 1) / MODULES[currentModule].slides.length) * 100;
    progressBar.style.width = pct + '%';
  }

  container.querySelector('.slide-counter').textContent = `${currentSlide + 1} / ${MODULES[currentModule].slides.length}`;
  container.querySelectorAll('.progress-dot').forEach((dot, i) => {
    dot.classList.toggle('active', i === currentSlide);
  });
  container.querySelector('.nav-btn').disabled = currentSlide === 0;
}

// ===== ANSWERS =====
function answerDecision(did, letter, correct, xp) {
  if (gameState.answeredQuestions[did] !== undefined) return;
  gameState.answeredQuestions[did] = letter;
  gameState.decisionsCompleted++;
  gameState.gradesAssigned = (gameState.gradesAssigned || 0) + 1;

  // Award first_grade badge on first decision
  if (gameState.decisionsCompleted === 1) awardBadge('first_grade');

  if (correct) {
    gameState.correctAnswers++;
    consecutiveCorrect++;
    addXP(xp);
    if (consecutiveCorrect >= 5) awardBadge('perfect_5');
    if (gameState.decisionsCompleted >= 15) awardBadge('decision_maker');
  } else {
    consecutiveCorrect = 0;
  }
  gameState.consecutiveCorrect = consecutiveCorrect;
  saveGame();
  renderSlides();
  updateComboDisplay();
  updateStatsDisplay();
}

function answerQuiz(qid, choice, correct, xp) {
  if (gameState.answeredQuestions[qid] !== undefined) return;
  gameState.answeredQuestions[qid] = choice;

  if (correct) {
    gameState.correctAnswers++;
    consecutiveCorrect++;
    addXP(xp);
    if (consecutiveCorrect >= 5) awardBadge('perfect_5');
  } else {
    consecutiveCorrect = 0;
  }
  gameState.consecutiveCorrect = consecutiveCorrect;
  saveGame();
  renderSlides();
  updateComboDisplay();
}

// ===== NAVIGATION =====
function goToModule(index) {
  if (index > 0 && !gameState.completedModules.includes(MODULES[index-1].id)) return;
  currentModule = index;
  currentSlide = 0;
  renderSlides();
  renderSidebar();
}

function goToSlide(index) {
  currentSlide = index;
  updateSlideVisibility();
}

function nextSlide() {
  const mod = MODULES[currentModule];
  if (currentSlide < mod.slides.length - 1) {
    currentSlide++;
    updateSlideVisibility();
  } else {
    completeModule();
  }
}

function prevSlide() {
  if (currentSlide > 0) {
    currentSlide--;
    updateSlideVisibility();
  }
}

function completeModule() {
  const mod = MODULES[currentModule];
  if (!gameState.completedModules.includes(mod.id)) {
    gameState.completedModules.push(mod.id);
    addXP(mod.xp);

    // Module-specific badges
    if (mod.id === 3) awardBadge('bias_hunter');
    if (mod.id === 4) awardBadge('consistency_king');
    if (mod.id === 5) awardBadge('directness_detective');
    if (mod.id === 6) awardBadge('precision_master');
    if (mod.id === 7) awardBadge('publication_sleuth');
    if (mod.id === 8) awardBadge('upgrader');
    if (mod.id === 10) awardBadge('grade_master');
    if (gameState.completedModules.length === MODULES.length) awardBadge('finisher');

    saveGame();
    triggerConfetti();
    updateCourseProgress();
  }

  if (currentModule < MODULES.length - 1) {
    goToModule(currentModule + 1);
  }
}

// ===== KEYBOARD =====
document.addEventListener('keydown', (e) => {
  const isRoleButton = e.target && e.target.getAttribute && e.target.getAttribute('role') === 'button';
  const isFormControl = e.target && e.target.closest && e.target.closest('button, a, input, textarea, select, [role="radio"], [role="option"]');
  if (isRoleButton || isFormControl) {
    if ((e.key === ' ' || e.key === 'Enter') && isRoleButton) { e.preventDefault(); e.target.click(); }
    return;
  }
  if (e.key === 'Escape') {
    closeBadgeModal();
    document.querySelector('.sidebar').classList.remove('open');
    document.getElementById('sidebarOverlay').classList.remove('show');
    return;
  }
  if (e.key === 'ArrowRight' || e.key === ' ') { e.preventDefault(); nextSlide(); }
  else if (e.key === 'ArrowLeft') { e.preventDefault(); prevSlide(); }
});

// Second keydown handler removed (first handler covers role="button" elements)

// ===== TOUCH =====
let touchStartX = 0;
document.addEventListener('touchstart', (e) => { touchStartX = e.changedTouches[0].screenX; }, { passive: true });
document.addEventListener('touchend', (e) => {
  const diff = touchStartX - e.changedTouches[0].screenX;
  if (Math.abs(diff) > 50) { diff > 0 ? nextSlide() : prevSlide(); }
}, { passive: true });

// ===== INIT =====
renderAll();
</script>
</body>
</html>
